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Abstract
Background
Up to 50% of recurrences of ductal carcinoma in situ (DCIS) of the breast are associated 
with invasive carcinoma but no pathological or molecular features have yet been found to 
predict for the development of invasive disease. For a tumour to invade, it requires the 
formation of new blood vessels. Previous studies have described a vascular rim around 
ducts involved by DCIS raising the possibility that the characteristics of periductal 
vascularisation may be important in determining transformation from in situ to invasive 
disease as well as risk of recurrence.
Hypothesis
I hypothesized that the risk of malignant tranformation (from normal breast to DCIS) and 
of invasive recurrence, following initial diagnosis and treatment of DCIS, is associated 
with the extent and pattern of periductal vascularity. It is likely that the periductal vessels 
are most important in this respect as incipient invasion is most likely to be associated with 
changes in vessels in the immediate vicinity of the tumour cells.
Methodology
I investigated to see whether changes in vasculature are related to the progression of in 
situ to invasive carcinoma and if so, which factors may be important in this change. I 
initially studied vascular density surrounding DCIS with and without invasive cancer and 
its relationship to specific angiogenic factors secreted by the tumour. Periductal vascular 
density and phenotype were determined using morphometry and a panel of anti-endothelial
antibodies (von Willebrand factor [vWF], CD31, CD141 and CD34 ). These were related 
to the presence of invasive carcinoma at initial diagnosis, the histological features of DCIS 
and the risk of recurrence. For each histological section, the number of stained vessels and 
endothelial cells within 100 micrometers of foci of DCIS were counted. Up to 50 foci of 
DCIS on a single slide were scored and the microvessel density (MVD) and endothelial 
cell density (ED) were calculated for each focus. Normal lobules at least 2 mm away were 
used as controls. These studies suggested a change in phenotype and dual fluorescence 
immuno staining for CD34+ and vWF+ vessels was carried out to confirm the change. The 
relationship between Thymidine Phophorylase (TP) expression on sections of pure DCIS 
and periductal vascularity was assessed as it had been previously shown to correlate with 
stromal vascular density. The relationship between stromal (hotspots) and periductal 
vascularity was also evaluated.
Results
Compared to normal lobules, pure DCIS exhibited a greater density of CD34+ and CD31+ 
vessels but a decrease in those that were immuno positive for von Willebrand factor 
(vWF). DCIS associated with invasive carcinoma showed a profile of vascular 
immuno staining similar to that of pure DCIS but there were statistically significantly 
greater numbers of CD34+ and CD141+ vessels and fewer staining for vWF. There was a 
significant negative correlation between vascular density and both the cross-sectional areas 
of the ducts involved and the extent of the necrosis of the tumour they contained. A 
correlation between vascular density and nuclear grade was also noted, being highest in 
the intermediate grade. On dual staining, the number of vessels stained only by CD34 was
significantly higher around DCIS compared to adjacent normal lobules. For TP, although a 
relationship was seen between the H-score and MVD, a relationship with recurrence was 
not identified. Vascularity stained by anti-CD34 around DCIS which recurred was 
statistically significantly higher than those which did not. There was a significant and 
positive correlation between the two types of vascularity (p<0.001) in sections stained 
with anti-vWF antibody, but not anti-CD34.
Conclusions
Blood vessels surrounding DCIS appear to have a different immunophenotype when 
compared with blood vessels surrounding normal breast lobules. Increases in vascular 
density, as detected with the CD34 antibody, correlates with recurrence and the 
development of invasive carcinoma. Recurrent disease does not appear to be related to TP 
expression by DCIS. Periductal MVD appears to be more important than stromal MVD in 
predicting for recurrence in DCIS.
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Abbreviation Full term
5’-DFUR 5 ’ -deoxy- 5 ’ -fluorouridine
5-FU 5-fluorouracil
Anti-CD141 Anti-Thrombomodulin
Anti-vWF/F8/FVin Anti-human von Willebrand factor
BPV Bovine papillomavirus
BSA Bovine Serum Albumen
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ECM Extracellular matrix
ED Endothelial density
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EDTA Ethylenediamine-Tetraacetic Acid
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EM Excision margin
EORTC European organization for research and treatment of cancer
EPWG European Pathologists Working Group
ER Estrogen receptor
FGF Fibroblast growth factor
H&E Haematoxylin and eosin
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HPV Human papillomavirus
HUVECs Human umbilical vein endothelial cells
IGF Insulin-like growth factor
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KDR/flk-1 Endothelial cell specific tyrosine kinase receptors
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MMP Matrix metalloproteinase
MR(I) Magnetic resonance (imaging)
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MVC Microvessel count
MVD Microvessel density
NHSBSP National Flealth Service Breast Screening Programme
OS Overall survival
PA Plasminogen activator
PAI-1 Plasminogen activator inhibitor-1
PCNA Proliferating cell nuclear antigen
PD-ECGF Platelet-derived endothelial cell growth factor
PDGF Platelet derived growth factor
PGE2 Prostaglandin E-2
PR Progesteron receptor
PSA Prostate-specific antigen
Rag Related antigen
RFS Relapse-free survival
RLUH Royal Liverpool University Hospital
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SD Standard deviation
SF Scatter factor
TAM Tumour-associated macrophages
TBS Tris Buffered Saline
TDLU Terminal duct lobular units
TGF Transforming growth factor
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TNP Tumour necrosis factor
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uPA Urokinase plasminogen activator
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor n
VNPI Van Nuys Prognostic index
VPF Vascular permeability factor
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Foreword
It is with great happiness that I am writing this foreword which marks the end of a period 
in which I have devoted all my energy to a single project. The idea of this project arose 
from the description of cancer made by a Persian physician in the seventh century A.D.
''Cancer is an uneven swelling, rough, unseemly, darldsh, painful, and sometimes without
idceration It has Us veins stretched on all sides as the animal, the crab has its feet,
whence it derives its name. ”
Paul of Aegina
The reference to the tumour vascularity is very clear. Angiogenesis (the development of 
new blood vessels from an existing vascular network) is an essential requirement for 
tumour growth and progression. This multi-step process is regulated by a complex 
network of cytokines (including growth factors), enzymes and adhesion molecules. 
Angiogenesis has been shown to have a role in invasive breast cancer. Its importance in 
pre-invasive disease remains to be elucidated.
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Overview of thesis
The introduction of this thesis reviews the histopathology of DCIS and the importance of 
angiogenesis in carcinogenesis. The first part entitled Histopathology o f  DCIS (Chapter 
1) discusses the definition, incidence, local recurrence rates and risk factors for recurrence. 
Different classifications with their respective ability to predict recurrence or reproducibility 
are also discussed. The molecular biology of DCIS is covered briefly.
In the mid-1960 that the contribution of angiogenesis in tumorigenesis was appreciated. 
Most research has focused on invasive cancers or advanced cancers. Angiogenesis-related 
findings in these groups of cancers is reviewed in Chapter 2 entitled Angiogenesis in 
Cancers. The basic principles of the mechanisms of angiogenesis in cancer (including 
angiogenic balance and switch), its relationship with proliferation and malignant 
transformation and the therapeutic implications are also covered.
Recently, there has been a lot of interest in the intensity of angiogenesis as measured by 
microvessel density (MVD). Various types of endothelial markers and different methods 
of assessment of MVD have been used, and these are reviewed in third part of 
Introduction QnïiXlQà Assessment o f Vascularity (Chapter 3). Complimentary methods of 
angiogenesis assessment are also covered.
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With the introduction of screening mammography the frequency with which DCIS is 
detected has increased and the best treatment of DCIS is still controversial. In the UK, the 
Van Nuys classification is not commonly applied to screen-detected DCIS cases which 
have breast conseivative treatment. Chapter 4 (pilot study) addresses different treatments 
and the application of the Van Nuys classification in these patients. In this study, I also 
reviewed all cases of DCIS cases detected in Merseyside.
From the literature reviews and clinical data above, I concluded that the present 
assessment of prognosis for DCIS is inadequate. No pathological or molecular features 
have been found to predict for the development of invasive disease or the risk of 
recurrence. There is a lot of work on angiogenesis in advanced or invasive cancers but 
little is known about the role of angiogenesis in DCIS especially the vascularity around the 
affected ducts.
Chapter 5 highlights my hypothesis that the risk of malignant tranformation and invasive 
recurrence in DCIS is associated with the extent and pattern of periductal vascularity. It is 
likely that the periductal vessels are most important in this respect as incipient invasion is 
most likely to be associated with changes in vessels in the immediate vicinity of the tumour 
cells. I also hypothesized that there is relationship between stromal and periductal 
vascularity in DCIS.
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Section 3 (Chapter 6-8) describes the way I investigated whether changes in vasculature 
are related to the progression of in situ to invasive carcinoma and if so, which factors may 
be important in this change. The features studied included vascular density surrounding 
DCIS with and without invasive cancer and how this relates to the demonstration of 
specific angiogenic factors secreted by the tumour.
The role of angiogenesis in DCIS is investigated in chapters 9 to 12. In the chapter 9, the 
periductal vascularity was compared in pure DCIS and in DCIS associated with invasive 
carcinoma. Rigorous morphometric methodology was used to compare vascularity in 
DCIS with normal breast, and a panel of anti-endothelial antibodies were used to 
determine changes in phenotype as well as numerical changes in vessel density.
Proliferation, differentiation and migration of endothelial cells all play an important role in 
tumour angiogenesis. The relationship between MVD and endothelial cell density (ED) 
has not been evaluated to date. Chapter 9 addresses this and examines changes in ED in 
relation to the progression of in-situ to invasive carcinoma and the correlation between 
MVD and ED.
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MVD increased from low to intermediate grade DCIS but decreased in high grade DCIS. 
There was a significant and negative correlation between MVD and degree of necrosis in 
high grade DCIS. This suggested that periductal angiogenesis increases with tumour 
growth but is unable to cope with most rapidly growing lesions. This suggestion is tested 
in chapter 10 by investigating angiogenesis in pure DCIS in relation to its proliferation 
measured with the anti-Ki67 antibody.
As well as a change in number of vessels with grade, a difference in vessel type was noted. 
There was a significant increase in CD34 positive periductal vessels in DCIS but a 
reduction in those staining for vWF compared with adjacent normal lobules. These 
findings suggest a change in phenotype as well as vascular density. In order to confirm the 
change of phenotype, I examined the relationship between vWF positive and CD34 
positive periductal vessels in pure DCIS as well as adjacent normal lobules by means of 
dual immunostaining for flourescence (chapter 11).
Having determined that both the type and number of vessels are different in normal breast, 
in-situ cancer and invasive cancer, this raised the possibility that changes in vascularity 
may predict the likelihood of recurrence. I therefore compared changes in periductal 
vessels and their characteristics in pure DCIS in patients who did not recur with those who 
developed recurrence either as in-situ or invasive carcinoma. This study is also 
documented in chapter 11.
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The emphasis of my investigations has been on periductal vascularity as it is hypothesized 
that the risk of malignant transformation and recurrence are likely to be associated with 
vascular changes in the immediate vicinity of the tumour foci. However, most of the 
studies in angiogenesis in breast cancer to date have concentrated on stromal vascularity 
and the relationship between these two types of vascular pattern in DCIS has not hitherto 
been investigated. I therefore examined the relationship between stromal and periductal 
vascularity to determine which vascular pattern has a more important bearing on the risk 
of invasive recurrence or development of invasive disease (chapter 12).
The expression of Thymidine Phosphorylase has also been investigated as this has 
previously been shown to correlate with stromal vascular density, and I wished to 
determine whether its expression in DCIS correlates with periductal vascular density. This 
study is outlined in chapter 12.
The results were summarised and conclusions were suggested in chapter 13. Before 
pondering into the future {chapter 15), I reviewed the values of current markers of 
angiogenesis as a prognotic indicator from recent literature in chapter 14.
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Section  1
Chapter 1 
Histopathology of DCIS
Definition
DCIS is defined as a ‘proliferation of epithelial cells with cytological features of 
malignancy within parenchymal structures of the breast .... Distinguished from invasive 
carcinoma by the absence of stromal invasion across the basement membrane’ [National 
Co-ordinationg Committee on Breast Screening Pathology 1995]. It was first described by 
Bloodgood et al [1934]. Lewis and Geschickter et al [1938] described comedo DCIS 
although they failed to distinguish invasive carcinoma from in situ carcinoma. Lobular 
cancerization in DCIS was highlighted by Azzopardi et al [1979]. Page and Dupont et al 
[1982] identified cribriform, micropapillary and other types of non-comedo DCIS as high 
risk factors for the development of ipsilateral invasive breast cancer.
DCIS is no longer thought of as a single disease and is instead recognized as a 
heterogenous group of lesions with a diverse malignant potential. Several sub-types have 
been described to date, which include neuroendocrine, apocrine, clear cell, secretory, 
cystic hypersecretory, mucinous and signet ring sub-types. These subgroups are rare and 
very little is known about their natural histoiy.
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Incidence
Until recently, DCIS was diagnosed relatively infrequently, representing only about 1% of 
all new cases of breast cancer [Nemoto et al 1980]. It was regarded as a single disease 
with a single treatment, which was mastectomy. Most patients presenting with DCIS had 
symptoms -  a palpable mass or nipple discharge. The frequency of detected DCIS has 
increased dramatically since the introduction of mammographie screening, accounting for 
at least 20% of screen-detected breast cancers, compared with about 5% of those in 
symptomatic women in the UK [Badve et al 1998, Fryberg et al 1994].
Natural history
DCIS has been shown to arise within the terminal duct lobular units (TDLU) of the breast 
[Wellings et al 1975, Holland et al 1990a&b, Faverly et al 1994], although the size of 
some of the involved ducts suggest that extralobular ducts are also involved [Rosen et al
1993]. The current belief is that DCIS originates in the terminal ducts and acini of the 
breast, it grows and expands these ducts until at a certain stage in its natural history, it 
develops invasive properties and penetrates the basement membrane.
Autopsy based studies have demonstrated that 15% of young asymptomatic women may 
have DCIS [Nielsen et al 1984 & 87]. It might be argued that DCIS could almost be 
‘normal’ finding, similar in disease frequency to the detection of benign breast disease. 
Critical review of these studies suggests that at least some cases of post-mortem DCIS 
detected in these studies might not meet modern diagnostic criteria. However, the
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incidence of invasive breast cancer in western Caucasian populations is high. The lifetime 
risk of development of invasive breast cancer of l in  8 to l in  12 in North America or 
Europe and this incidence may indeed be consistent with these autopsy findings.
DCIS is nearly always unicentric and recurrences occur almost invariably at the site of 
previous excision [Rosen et al 1980, Baird et al 1990, Schwartz et al 1992, Sneige et al 
1995]. However, DCIS is usually poorly-delineated because of extensive microscopic 
spread along the duct system which makes it difficult to define the precise limits of the 
disease.
The view that DCIS is a single clonal process has been further supported by the 
observation that in 12 cases of DCIS although apparently multifocal, all showed loss of 
heterozygosity at the same chromosome locus implying that the foci of DCIS were derived 
from the same clone [Stratton et al 1995].
The data available on the risk of progression from DCIS to invasive breast cancer is 
limited. This is mainly due to the fact that once DCIS is detected it is excised. Studies that 
provide insight about the natural history of DCIS are those in which patients were initially 
diagnosed as having benign lesions that on subsequent histological review were classified 
as DCIS. These patients received no further treatment after diagnostic biopsy [Farrow et 
al 1970, Page et al 1982 & 95, Rosen et al 1980, Betsill et al 1978, Eusebi et al 1994].
The number of patients in these studies was relatively small (range, 8-25) and most of 
these cases were low-grade non-comedo DCIS with uncertain margins. During the follow-
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up period, ipsilateral invasive breast cancer developed in a significant percentage of these 
women, usually within 10 years of biopsy [Page et al 1982, Rosen et al 1980]. In a more 
recent study [Page et al 1995a], about 40% of low grade DCIS cases treated by 
diagnostic biopsy alone become invasive over a time span of 25-30 years.
These studies show that inadequately treated DCIS is associated with a significant risk for 
the development of subsequent invasive cancer, up to 11-fold higher than the risk 
expected in the general population. These data support the concept of DCIS as an 
anatomical ‘forerunner’ to invasive breast cancer.
There is evidence that not all DCIS progresses to invasive breast cancer. The results of 
autopsy studies suggest that latent DCIS is relatively common, ranging from 0.2 to 18% in 
random autopsy series or series confined to women who died of causes other than breast 
cancer or who were not known to have had breast cancer at the time of death [Bartow et 
al 1987, Nielsen et al 1984 & 87, Alp ers et al 1985, Bhathal et al 1985]. It was estimated 
that no more than one third of all intraductal carcinomas will progress to invasive breast 
cancer [Nielsen et al 1984].
Histological classifications
Histological classifications have been developed in an attempt to predict the likelihood of 
local recurrence and invasive tranformation after initial treatment. DCIS is a 
heterogeneous group of lesions and no single approach will be appropriate for all forms of 
the disease. Therefore, better methods for stratifying DCIS according to risk of recurrence 
have been developed. This in fact has led to a large numbers of new histological
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classifications in recent years. To achieve these objectives, 2 basic requirements have to be 
fulfilled by any prospective histological classification ; 1) it should be able to predict 
clinical outcome such as local recurrence and possibly progression to invasive carcinoma, 
and 2) it should be able to be used reproducibly. Some of the classifications are listed 
below:
Architectural pattern
DCIS is divided solely according to the architectural pattern such as comedo, solid.
cribriform, micropapillary and papillary. Two categories (comedo and non-comedo) can
■be produced by combining some of the groups. The cytological grade of the cells is not 
taken into account.
European Pathologists Working Group
DCIS is divided into three categories according to cytonuclear differentiation and the 
presence or absence of cell polarization. The cytonuclear DCIS classification system used 
by the NHS breast cancer screening programme is derived from this.
Van Nuys
DCIS is divided into three categories according to the presence or absence of comedo 
necrosis and of high nuclear grade cytonuclear differentiation.
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Lagios
DCIS is divided into four categories according to nuclear grade, cytoarchitecture and 
necrosis (I: comedo, II: cribriform/with necrosis. III: cribriform with anaplasia, IV: 
micropapillary). This has subsequently been simplified into three categories by combining 
groups I and II.
Nottingham
DCIS divided into three categories according to the architecture and the presence and 
degree of necrosis.
Ottesen
DCIS is divided into three types according to growth pattern (microfocal, diffuse and 
tumour-forming). Architectural pattern, comedo necrosis and nuclear size are also 
evaluated.
Classifications based on architecture
A number of different morphological patterns are recognized. In the solid type the 
ductules are completely filled by a disorderly proliferation of large epithelial cells with 
abundant cytoplasm, variable nuclear pleomorphism and increased mitoses. A similar 
appearance is seen in the comedo type but in addition there is central necrosis in the lumen 
so that lipid-rich yellow debris is present. The cribriform type is characterized by a 
proliferation of relatively small and regular cells which form a geometric network of 
bridges and trabeculae. The micropapillary type also consists of a proliferation of small
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epithelial cells, which form small papillaiy projections into the lumen. In some cases a 
mixture of one or more patterns may be present.
There are numerous studies which show that there are relationships between DCIS growth 
patterns and clinical characteristics and outcome. DCIS of comedo type is noted to have a 
larger microscopic size, is more likely to be associated with microinvasion and most 
important of all, is more likely to recur after local excision alone [Baird et al 1990, 
Schwartz et al 1992, Fisher ER et al 1995, Patchefsky et al 1989, Poller et al 1994,
Ottesen et al 1992]. Micropapillary types are more extensive [Bellamy et al 1993, 
Patchefsky et al 1989, Lennington et al 1994] and are significantly more likely than other 
patterns to involve multiple quadrants of breast, irrespective of nuclear grade or necrosis 
[Bellamy et al 1993]. Solid DCIS is significantly more often completely excised compared 
to other types of DCIS [Bellamy et al 1993].
It is important to stress that architecture is not independent of cytology. Approximately 
90% of cases of comedo carcinoma are of high nuclear grade which itself shows a 
correlation with microscopic size of tumour, presence of microinvasion, frequency of 
incomplete excision and local recurrence rates after local excision in comparison with 
growth pattern [Bellamy et al 1993, Patchefsky et al 1989]. Although architectural 
classification of DCIS is widely used, two problems arise: First of all, Badve et al [1998] 
failed to establish a relationship between growth patterns and the risk of local recurrence 
after local excision. Secondly, in the presence of heterogenous histological architecture, it 
is difficult for various groups of pathologists to use the classification reproducibly
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[Ottesen et al 1992, Harrison et al 1996]. A relatively low level of consistency was 
achieved by a number of pathologists participating in the UK National scheme when they 
classified DCIS by growth pattern with a kappa statistic value of only 0.23 [Sloane et al 
1994].
Classifications based on nuclear grade (Table 1.1)
In view of the inadequacies of DCIS classification based on growth pattern alone a 
number of newer classifications have been introduced that are primarily based on nuclear 
grade.
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Classifications based on nuclear grade: ability to predict recurrence
Lagios et al [1995] assessed the local recurrence rates of patients a mean of 10 years after 
local excision. The patients with high grade DCIS had the highest risk with a recurrence 
rate of 32% compared with 10% for intermediate grade. None of those with low grade 
DCIS recurred. Similar results were achieved by Silverstein et al [1998b]. Bellamy et al 
[1993] reviewed 130 cases of non-invasive DCIS in women without previous breast 
carcinoma, they found that local recurrence only followed high grade DCIS. Silverstein et 
al [1996] divided 238 patients with DCIS treated with conservation surgery into 3 groups 
: 1— non-high grade DCIS without comedo-type necrosis, 2 -  non-high grade DCIS with 
comedo-type necrosis, 3 -  high-grade DCIS with comedo-type necrosis. There were 31 
local recurrences : 3/80 (3.8%) in group 1, 10/90 (11.1%) in group 2, and 18/68 (26.5%) 
in group 3.
In a study of 141 patients with follow-up of 2 decades, Badve et al [1998] compared the 
ability of 5 different classifications in predicting recurrence after local excision. No 
significant correlation was found between recurrence and growth pattern when a 
traditional architectural-based system was used. A significant correlation was observed 
between histology and recurrence using the Van Nuys classification. A significant 
correlation was also found between nuclear grade as defined by the EPWG and recurrence 
when cell polarization was disregarded, using the classification currently employed by the 
LIK National Health Service and European Commission-funded Breast Screening 
programs. This was attributed to a small number of recurring cases being downgraded as a
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consequence of the presence of cell polarization. These findings strongly support the use 
of nuclear grade to identify cases of DCIS at high risk of recurrence after local excision.
Classifications based on nuclear grade: reproducibility
23 pathologists from 12 different countries examined 33 cases of DCIS using 5 different 
classifications : 1) European Pathologists’ Working Group, EPWG; 2) European Breast 
Screening Group, EBSG; 3) a two tiered classification in which the categories are high 
nuclear grade and other; 4) Van Nuys; 5) a two-category classification based entirely on 
the presence of comedo-necrosis [Sloane et al 1998].The Van Nuys classification gave the 
highest overall Kappa statistic value of 0.42, followed by EPWG (0.37) and EBSG (0.35). 
These values were not particularly high but were better than the 0.23 achieved by up to 
250 pathologists over a 3-year period in the first 6 rounds of the UK National External 
Quality Assessment Scheme using a classification based on architecture alone [Sloane et al 
1994]. The likely explanation for high Kappa value obtained by the Van Nuys system was 
that the three categories do not form a continuous spectrum but are derived from two 
dichotomous decisions : 1) high grade versus other and 2) necrosis versus no necrosis.
In the study of Douglas-Jones et al [1996], a lower percentage of disagreement was found 
using the Van Nuys classification than the EPWG and EBSG systems, where the level of 
agreement was similar. They found the Van Nuys classification the simplest and easiest to 
use and had greatest difficulty in agreeing on growth pattern. Bethwaite et al [1998] 
reported higher levels of consistency using nuclear grade and the Van Nuys system than 
architecture.
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Grade
Low Intermediate High
Breast
Screening
Group
DCIS composed of cells with 
pleomorphic, in-egularly- 
shaped and usually large nuclei 
exliibiting marked variation in 
size, irregular nuclear contour, 
course clu'omatin and 
prominent nucleoli. Mitoses 
are frequent and abnormal 
forms may be seen. May have 
several different growth 
patterns but is often solid with 
central comedo-type necrosis. 
Polarisation of cells is rare.
The nuclei show mild to 
moderate pleomorphism which 
is less than that seen in high 
grade DCIS but they lack the 
monotony of the small cell 
type. The nucleo-cytoplasmic 
ratio is often high and one or 
two nucleoli may be identified. 
The growth pattern may be 
solid, cribriform or 
micropapillary and some 
degree of polarization is 
present.
Composed of monomorphic, 
evenly-spaced cells with 
roughly spherical centrally- 
placed nucleoli. Mitoses are 
few and there is rarely 
individual cell necrosis. The 
architecture is often 
micropapillary and cribriform 
with polarization of cells.
European
Pathologists
Working
Group
The nuclei are very 
pleomorphic with an inegular 
outline and spacing. The 
clrromatin is coarse, clumped 
with prominent nucleoli being 
present. Mitoses are often seen 
and polarisation of cells is 
absent or minimal. Central 
necrosis and individual cell 
necrosis are usually present 
often with associated 
amorphous calcification.
The nuclei show mild to 
moderate pleomoi])hism with 
some variation in size, outline 
and spacing. The clu'omatin is 
fine to coarse and nucleoli are 
evident. Mitoses are 
occasionally present and 
polarisation o f cells is seen. 
Central necrosis is variable but 
individual cell necrosis may be 
focally present. Calcifications 
are amorphous or laminated.
The nuclei are monomorphic 
with uniform size, regular 
outline and spacing. The 
cliromatin is uniform and fine, 
nucleoli are insignificant and 
mitoses are rare. Polarisation 
of cells is marked and central 
necrosis is absent or minimal, 
hidividual cell necrosis is 
absent and calcifications are 
laminated and rarely 
amorphous.
Van Nuys Nuclei with a diameter of 
greater than two red blood 
cells, with vesicular cliromatin 
and one or more nucleoli. 
Comedo necrosis (DCIS with 
central lumina containing 
necrotic debris sunounded by 
large pleomoiphic cells or 
necrotic neoplastic cells witliin 
ducts with other architectural 
patterns eg cribriform or 
micropapillary) is usually 
present but not essential.
Nuclei with low nuclear grade 
(1-1.5 red blood cells in 
diameter witli diffuse 
clu'omatin and inapparent 
nucleoli) or inteiinediate 
nuclear grade (1-2 red blood 
cells in diameter with coarse 
cliromatin and infrequent 
nucleoli) and comedo type 
necrosis. There is no minimum 
requirement for comedo 
necrosis although individual 
necrotic cells are not scored.
Nuclei with low or 
intennediate nuclear grade and 
no comedo necrosis.
Lagios Large nuclei (2 red blood cells 
in diameter) with vesicular 
clu'omatin, 1 or more nucleoli 
and a high mitotic index (2+ 
mitoses/10 hpf). Extensive 
linear coagulative necrosis of 
comedo type is present.
hitennediate nuclei (1-2 red 
blood cells in diameter) with 
coarse cluomatin, infrequent 
nucleoli and an intennediate 
mitotic index (1-2 mitoses/10 
hpf). Punctate necrosis may be 
present.
Small nuclei (1-1.5 red blood 
cells in diameter) with diffuse 
clu'omatin, inapparent nucleoli 
and a low mitotic index (<1 
m itoses/10 hpf). Necrosis is 
absent.
Nottingham Pure comedo subtype showing 
central lumina containing 
necrotic debris surrounded by 
large pleomoiphic viable cells 
in solid masses
DCIS witli necrosis (non-pme 
comedo) are tumours witli 
necrotic neoplastic cells within 
duct lumina but lacking a pure 
comedo pattern and often 
showing a cribrifoiin or 
micropapillary architecture.
DCIS without necrosis show no 
evidence of necrosis or no 
more than one or a few 
necrotic or desquamted cells 
within intraductal lumina. This 
includes the majority of 
classifical cribriform, papillary 
and micropapillary subtypes.
Table LI. Comparison o f DCIS grading classifications.
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Microinvasioii in DCIS
Diagnosis of microinvasion in DCIS is problematic. Histological features resembling 
invasion can be simulated by in situ carcinoma distorted by inflammatory changes and 
fibrosis, Microinvasion has been increasingly diagnosed in the advent of screening 
mammography and is commonly associated with extensive comedo-type DCIS [Silver et al 
1998, Silverstein et al 1997d, Rosen et al 1997].
According to the UK NHSBSP Guidelines on Pathology Reporting in Breast Cancer 
Screening [National Co-ordinating Group for Breast Screening Pathology 1995]; “A 
microinvasive carcinoma is defined as a tumour in which the dominant lesion is DCIS but 
in which there are one or more clearly separate foci of infiltration of nonspecialized 
interlobular or interductal fibrous or adipose tissue, none measuring more than 1 mm 
(about 2 high-power fields) in maximum diameter”. This definition is very restrictive and 
tumours fulfilling the criteria are consequently very rare. If there is sufficient doubt about 
the presence of invasion, the case should be classified as DCIS. Microinvasion is largely 
restricted to high nuclear grade types of DCIS, mainly of comedo type. “Cases of 
apparently pure comedo DCIS should thus be extensively sampled to exclude invasion. 
Microinvasive carcinomas should likewise be extensively sampled in order to exclude the 
possibility of larger invasive foci. Where such foci are found, the lesion should be 
classified as an invasive tumour. Small invasive carcinomas without an in-situ component 
are classified as invasive.”
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The incidence of microinvasion varies according to the size and extent of the DCIS.
Lagios et al [1982] reported a 2% incidence of microinvasion in patients with DCIS 
measuring less than 25 mm, compared with a 29% incidence of microinvasion in index 
lesions larger than 26 mm.
In an attempt to resolve the uncertainty, Prasad et al [1999] recommends the utility of 
double-immunolabelling of cytokeratin and smooth muscle actin. From the clinical point of 
view, microinvasion is seldom associated with axillary nodal metastasis and it has a slight 
poorer prognosis than DCIS [Silver et al 1998, Silverstein et al 1997d, Rosen et al 1997].
Molecular biology of DCIS
Oestrogen receptor (ER): Generally, it is accepted that ER expression is more common 
in low grade and non-comedo DCIS than high grade comedo DCIS. However, the exact
i
frequency of ER expression varies with different studies. Poller et al [1993b] reported ER 
expression in 32% of cases of DCIS. They also established relationships between positive
■ f
expression and non-comedo variants, small cell size, higher proliferation fraction ( S-phase 
fraction ) and lack of c-erbB 2 staining. However, higher proportions of positive 
expression have been reported by other studies [Giri et al 1989, Ronay et al 1990, Pallis et 
al 1992, Bur et al 1992]. Bur et al [1992] found ER expression in 91% of non-comedo 
and 57% of comedo DCIS respectively.
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Progesterone receptor (PR): Progesterone receptor expression has been found 31% to 
73% of cases. [Bobrow et al 1994, Zafrani et al 1994, Pallis et al 1992]. Like ER it 
correlates with low nuclear grade DCIS.
Proliferation fraction: Higher cellular proliferation fractions are related to the high 
nuclear grade DCIS with comedo type necrosis. Cellular proliferation has been assessed by 
Ki 67/MIBI staining of tumour nuclei, S phase estimation using flow cytometric analysis 
of DNA, and by thymidine labelling [Locker et al 1990, Poller et al 1991, Barnes et al 
1991, Kileen et al 1991, Meyer et al 1986].
c-erbB-2 or HER2/neu: c-erbB-2 gene amplification and c-erbB-2 gene protein 
expression is more frequent in high and intermediate nuclear grades of DCIS and those of 
comedo type necrosis [Ramachandra et al 1990, Bobrow et al 1994, Zafrani et al 1994].
Other markers: The p53 protein is more frequently expressed in high nuclear grade DCIS 
with comedo type necrosis [Davidolf et al 1991, Poller et al 1993a, Thorf et al 1992, 
Walker et al 1991]. Loss of heterozygosity was identified at one locus on Chr 17q in the 
vicinity ofBRCA 1 in 10-20% of cases of DCIS examined [Futreal et al 1994]. One study 
showed greater expression of the nm23 gene product in comedo DCIS as compared to 
non-comedo variants [Simpson et al 1994].
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Factors predicting clinical outcome 
Nuclear grade
Numerous studies have shown that high grade DCIS is associated with high recurrence 
rates after local excision alone [Baird et al 1990, Schwartz et al 1992, Solin et al 1993, 
Bellamy et al 1993, Poller et al 1994, Ottesen et al 1992]. High nuclear grade in DCIS is 
also closely correlated with frequency of incomplete excision [Bellamy et al 1993].
Necrosis
The presence comedo type necrosis is correlated with intermediate and high grade DCIS 
which often radiologically contains coarse cast-like calcification. Comedo DCIS tends to 
be have a larger microscopic size, is more likely to be associated with microinvasion and 
has a higher risk of recurrence after local excision alone [Baird e al 1990, Schwartz et al 
1992, Fisher ER et al 1995, Patchefsky et al 1989, Poller et al 1994, Ottesen et al 1992].
Microscopic size
The presence of residual tumour has been shown to be related to DCIS size [Cheng et al 
1997]. Residual DCIS was found in 69% of tumours greater than 25mm compared with 
only 15% of tumours less than 10mm. Tumour size is also predictor of initial margin 
involvement and residual DCIS [Silverstein et al 1994].
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DCIS presenting as a mass (> 1 cm) is associated with a significantly higher incidence of 
occult invasion, multicentricity, axillary lymph node metastatsis, higher local recurrence 
rates, and worse overall and disease-free survival than DCIS incidentally diagnosed on 
screening mammography [Robinson et al 1999, Fonseca et al 1997, Ashikari et al 1971]. 
Unfortunately, accurate determination of the size or extent of the lesion is not always easy.
Microcalcifications on mammography often underestimate the size of the tumour, 
particularly in cases of low-grade (well-differentiated) DCIS, in which substantial areas of 
tumour may not contain microcalcification [Farrow et al 1970, Holland R et al 1990a &
1994]. Holland et al found that in 44% of micropapillaiy tumours, the lesions were more 
than 2 cm larger by histological examination than by mammographie estimate, compared 
with only 12% of the pure comedo subtype [Holland R et al 1990a].
Determination of the lesion size may also be difficult for the pathologist. Macroscopic 
examination of a specimen containing DCIS rarely reveals a grossly evident tumour that 
can be measured. Therefore, the assessment of size of the lesion often must be performed 
on the histological sections. When the lesion is present in a single slide, the greatest 
dimension can be measured and reported. However, in many cases of DCIS, the lesion is 
present on more than one slide. In such cases, accurate determination of the size or extent 
of the lesions is not possible, unless the specimen has been examined in a sequential 
manner [ Silverstein et al 1996].
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Excision margin
Margin width -  the distance between DCIS and the closest inked margin -  confirms the 
completeness of excision. In a series where mastectomy or re-excision was carried out 
after local excision, residual tumour found in 76% of cases with an excision margin of less 
than 1mm, 43% of cases with an excision margin greater than 1mm and in only 5.6% of 
cases with a margin of 10mm or more [Silverstein et al 1997a]. The value of margin width 
has also been confirmed by the group from Nottingham [Sibbering et al 1997], where they 
reported a local recurrence rate of 6% in a group a 48 patients treated with local excision 
alone and with margins greater than 10mm. Fisher [Fisher ER et al 1995] reported an 
adjusted relative risk for local recurrence of 2.3 when margins were involved. Among 
patients with margin widths of 1 to <10mm, there was no statistically significant benefit 
from adjuvant radiotherapy which was only beneficial to those with an excision margin of 
less than 1mm [Silverstein et al 1999].
There are limitations associated with pathological assessment of excision margins. 
Residual tumour may not be present when the excision margins appear involved as tissue 
around the biopsy is destroyed during the operation. Secondly, the technical difficulties of 
assessing margins may lead to false impression of margin involvement due to problems 
such as seepage of ink though the specimen. Furthermore, the exclusion of the involved 
part of the specimen for histological examination can lead to a false impression of 
complete excision, this is more common with ill-defined lesions.
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Van Nuys Prognostic Index
Nuclear grade, the presence of comedo-type necrosis, tumour size, and the excision 
margin are important factors which are able to predict local recurrence in patients with 
DCIS [Silverstein et al 1995a&b, Lagios et al 1989, Silverstein et al 1996, Solin et al 
1993, Bellamy et al 1993]. By using a combination of these factors it enables the clinician 
to select subgroups of patients who do not require radiotherapy after local excision or 
whose recurrence rate is potentially so high, even with breast irradiation, that mastectomy 
is preferable. In the Van Nuys Prognostic Index, scores from 1 to 3 were given for each of 
the three different categories ( size of tumour, excision margin and pathological 
classification ) [Table 7.2], The prognostic index was applied on 333 patients who had 
breast conservation treatment with and without adjuvant irradiation. Patients with low 
scores (3  or 4), showed no difference in local recurrence regardless of whether they had 
had radiotherapy. Patients with intermediate scores ( 5 or 6 or 7 ), showed a significant 
decrease in local recurrence rates with radiotherapy. However, the high scores group ( 8 
or 9 ), the local recurrence rates was very high even with irradiation and therefore they 
should be considered for mastectomy. According to the formulators, it is a numerical 
algorithm based on tumour features which can not be controlled by the patient or clinician. 
It allows clinician to quantify prognostic factors that are measured and to place patients 
into one of three clearly defined categories.
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Score 1 2 3
Size (mm) < or =15 16 to 40 > or =41
Margin width 
(mm)
> or =10 1 to 9 <1
Pathologic
classification
Non high grade 
without necrosis
Non high grade 
with necrosis
High grade with 
or without 
necrosis
Table 1.2, Van Nuys Prognostic Index (using microscopic size, excision margin, 
degree o f necrosis and nuclear grade).
Treatment & local recurrence
Local recurrence is one of the most commonly studied clinical outcomes in DCIS as death 
is rare. The traditional treatment for DCIS was mastectomy with nearly 100% cure rates 
[Sunshine et al 1986, Morrow et al 1997, Silverstein et al 1995a&b], In the early 1980s 
around the same time as breast conservation treatment was popularized for invasive breast 
cancer by Veronesi, breast conservation was also introduced for DCIS. Breast 
conservation treatment for DCIS has now assumed a much greater importance with the 
implementation of the breast screening programmes in the UK as there has been an 
explosion in the number of newly diagnosed cases of DCIS.
Recurrences after mastectomy are almost all invasive carcinoma, and may present initially 
as local failure or distant métastasés. Recurrence is primarily due to unrecognized invasive 
carcinoma present at the time of the initial diagnosis, although incomplete removal of 
breast tissue could allow a new carcinoma to manifest as a local recurrence.
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The local recurrence rate for DCIS is between 10-40%, depending on the length of 
follow-up and type of treatment. [Silverstein et al 1995a&b, Silverstein et al 1996, 
Silverstein et al 1998a, Solin et al 1993, Fisher ER et al 1995]. Silverstein et al [1992] 
looked at the local recurrence rate of patients with DCIS 8 years after treatment. The 
recurrence rates for patients treated by mastectomy, excision with adjuvant radiotherapy 
or excision alone were 0.5%, 16% and 21% respectively. However, the survival rates 
were similar. The major difference between mastectomy and conservative breast surgeiy is 
thus the effect of treatment on local recurrence rates and not patient sumval. This has 
been confirmed in several other studies [Sneige et al 1995, Silverstein et al 1992 & 98a].
Local recurrence after conservative treatment is demoralizing and it causes marked patient 
morbidity. Local excision alone is associated with a high recurrence rate and up to half of 
the recurrences are associated with invasive carcinoma [Silverstein et al 1995a&b and 96, 
Solin et al 1993].
Numerous studies have shown radiotherapy to be beneficial after breast conserving 
treatment, reducing the recurrence rate from 8-45% for excision alone to 4-27% for local 
excision and radiotherapy [Sneige et al 1995]. In the National Surgical Adjuvant Breast 
Project Protocol B-17 [Fisher B et al 1993], the recurrence rate was lower in patients 
treated with local excision with adjuvant radiotherapy as compared with local excision 
alone (15.6% vs 26.2%). A later analysis [ Fisher et al 1999] demonstrated that after 
lumpectomy alone the lowest rates of breast recurrence were observed in patients with
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absent or slight comedo necrosis and margins free of tumour (3 per 100 patient-year); 
when both unfavorable features were present recurrence rates increased to 8.2 per 100 
patient-years. The use of radiotherapy reduced the risk of recurrence in both groups, with 
a 7% absolute decrease in breast recurrences in the favorable group at 8 years. However, 
this trial has been criticized for lacking analysis of different pathological subsets and the 
lack of size measurements in more than 40% of cases [Lagios et al 1993, Page et al 
1995b]. Other problems are the lack of requirement for mammographic-pathological 
correlation or specimen radiography; no uniform guidelines for tissue processing or size 
estimation; and the inappropriate definition of clear excision margin. The margin is defined 
to be clear if no tumour is transected which implies that a few fat cells or collagen fibres 
between the tumour and the inked margin are all that is required to call the margin clear. 
Nevertheless, the study was not designed to find out which subgroups might benefit from 
the adjuvant treatment and by how much and furthermore its findings have been confirmed 
by other studies. Preliminary results from EORTC randomized phase III trial 10853 [Julien 
et al 2000] and UK DCIS Trial [George et al 2000] show that radiotherapy after local 
excision for DCIS, as compared with local excision alone, reduces the overall number of 
both invasive and non-invasive recurrences in the ipsilateral breast.
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The long-term effect of radiotherapy in reducing local recurrence rates is disputed by some 
[Lagios et al 1993]. Radiotherapy is accompanied by considerable side effects such as 
cardiac toxicity, pulmonary fibrosis and radiation fibrosis which changes the texture of the 
breast, makes mammographie follow-up more difficult which can result in delayed 
diagnosis of local recurrence. Nevertheless, approximately half of the recurrences after 
excision and radiation for DCIS are as invasive breast cancer [Solin et al 1994].
The role of tamoxifen in the treatment of DCIS remains undefined. The NSABP B-24 
randomized trial [Fisher B et al 1999] compared the clinical outcome among 1800 women 
with DCIS that were treated with local excision, radiotherapy and either Tamoxifen or 
placebo. The patient characteristics (age, ethnic origin, tumour size, tumour type, methods 
of detection, margin status, presence of comedo necrosis) were similar in two groups of 
women. After a median of 5 years’ follow-up, the incidence of breast tumours was 13.4% 
among the controls and 8.2% In the treatment group ( p-0.0009), a relative reduction of 
nearly 40%. Furthermore, recurrences of DCIS and invasive ductal carcinoma were 
reduced by 30% and >40% respectively. At present, tamoxifen is usually used as adjuvant 
therapy for patients with DCIS in the context of a clinical trial.
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Conclusions
Present classifications are inadequate to predict likelihood of local recurrence and 
malignant transformation because DCIS is a heterogenous group of lesions. The 
prognostic values of current classifications are also inevitably affected by their low 
reproducibility (kappa values). There are also limitations associated with pathological 
assessment of excision margin which is one of the most important factors to predict local 
recurrence. To date, no pathological or molecular features have been found to predict the 
development of invasive disease. Consequently, the best treatment of DCIS still remains 
controversial. If further prognostic markers can be defined they would be important. One 
such potential prognostic marker is angiogenesis. I will review the literature on 
angiogenesis in carcinogenesis in the next section of the introduction.
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Chapter 2 
Angiogenesis in Cancer
Introduction
''Cancer is an uneven swelling, rough, unseemly, darkish, painful, and someiimes without
ulceration It has its veins stretched on all sides as the animal, the crab has its feet,
whence it derives its name. ”
Paul of Aegina
The above description of cancer was made by Paul of Aegina, a Persian physician in the 
seventh century A.D. Although the reference to the tumour vascularity is clear, the 
contribution of angiogenesis in tumorigenesis was not appreciated until the 1960s 
[Harmey et al 1998]. Since the 1980s, there has been a significant escalation in scientific 
research secondary to the discovery of endothelial growth factors, endogenous inhibitors 
and other molecules of the extracellular matrix (ECM). More recently, natural angiogenic 
inhibitors and pharmacological drugs capable of suppressing specific stages of 
neovascularisation have been reported. Measurement of the intra-tumoural microvessel 
density (MVD) has also been found to be an independent prognostic marker.
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Angiogenesis in cancer
For a tumour to grow beyond 1-2 mm^, it needs to develop its own blood supply for the 
supply of oxygen and nutrients as well as excretion of catabolites, by inducing the growth 
of new blood vessels [Folkman et al 1971, Gimbrone et al 1972]. Early tumours are only a 
few cell layers thick [Folkman et al 1992c] and metabolize by the diffusion of oxygen and 
nutrients across the cell layers. This limits tumour size as a tumour cell needing to be 
approximately 100 micrometer from a capillary, this being the upper limit of diffusability 
of macromolecular substances [Tannock et al 1969]. Tumour vascularisation promotes 
survival, growth and metastatic spread of cancer [Folkman et al 1971, Gimbrone et al 
1972, Brem et al 1976, Brooks et al 1994a, Folkman et al 1992a, Srivastava et al 1988, 
Weinstat-Saslow D et al 1994] and the quantification of tumour vascularity by measuring 
the MVD has been reported to be an independent prognostic indicator in carcinomas of 
breast, prostate, lung adenocarcinoma, melanoma, head and neck cancer [Fregene et al 
1993, Gasparini et al 1992 & 93, Hayes et al 1994, Visscher et al 1994, Weldner et al 
1991 &92 & 93, Yamazaki et al 1994, Graham et al 1994].
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Mechanisms of neovascularisation
Neovascularisation is a complex biological process which consists of three stages [Varner
et al 1996] [Fig. 2.1]:
1. Initiation : Angiogenic factors are released by the tumour stimulating endothelial cells 
by interacting with specific cell surface receptors.
2. Invasion and Proliferation : The endothelial cells proliferate and migrate into the 
tumour, This is facilitated by the degradation of the extracellular matrix by proteolytic 
enzymes as well as the interaction between cell surface adhesion molecules and 
adhesion proteins in the matrix.
3. Maturation ; Vessel lumens are formed by differentiation of the endothelial cells, 
facilitated by cell-cell adhesive contacts. The new vessels nourish the tumour and serve 
as conduits for metastasis, the new vessels being immature and ‘leaky’, increasing the 
likelihood of tumour cells entering the general circulation.
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Figure 2.1. Steps in tumour-induced angiogenesis [Varner & Cheresh et al 1996J.
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Regulation of angiogenesis
There are complex interactions between tumour cells, endothelial cells and inflammatoiy 
cells. Secreted pro- and anti- angiogenic factors from the these cells act in an autocrine 
and paracrine manner [de Jong et al 1998a&b, Folkman et al 1996a]. Physiological control 
depends on the balance between these pro- and anti-angiogenic factors as well as a 
response to both oncogene activation and tumour suppressor gene loss [Volpert et al 
1997]. Increased production of inducing factors is necessaiy for neovascularisation but not 
sufficient unless the inhibiting factors are reduced [Folkman et al 1995a&b, Dameron et al 
1994, Hanahan et al 1996].
The angiogenic balance
In terms of the “balance” in normal physiological control, it is the cell phenotype that plays 
the major role, systemic activation of the VEGF receptor KDR/flk-1 selectively triggering 
endothelial cells which express an angiogenic phenotype [Ortega et al 1997].
(a) Role of oncogenes
The role of oncogenes, such as ras and myc, in tumour angiogenesis was first reported by 
Thompson et al [1989]. The oncogenes were able to induce phenotypic changes when 
introduced into 0.1% of the cells used to reconstitute the mouse prostate gland. Myc 
induced hyperplasia while ras induced dysplasia and angiogenesis. Ras and myc together 
induced primarily carcinomas.
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Since, further studies have confirmed this role by examining mutant ras oncogene 
induction or up-regulation of VEGF/VPF in different cells types or systems [Volpert et al 
1997, Rak et al 1995, Grugel et al 1995, Larcher et al 1996, Mazure et al 1996, Aitiser 
et al 1997, Lingen et al 1997, Enholm et al 1997, White et al 1997]. Inactivation of 
tumour suppressor genes, such as the p53 gene, have also been shown to downregulate 
anti-angiogenic factors, such as thrombospondin-1, resulting in increased 
neovascularisation [Dameron et al 1994]. Likewise, levels of thrombospondin-1 are also 
suppressed in the ras oncogene-transformed fibroblast [Zabrenetzky et al 1994, Sheibani 
et al 1996]. Oncogenes also interact under physiological conditions, the expression of 
VEGF/VPF of mutant neu oncogene-transformed NIH 3T3 fibroblasts being upregulated 
by hypoxia [Viloria-Petit et al 1997].
(b) Role of cytokines and inflammatory cells
During tumour progression, the interactions between tumour cells and endothelial cells are 
not static, but in constant flux. In pre-malignant cells, growth is inhibited by endothelial- 
derived cytokines (eg. IL-6, IL-1, TGF-beta). With disease progression, the sensitivity of 
tumour cells to these inhibitors is reduced, lost or “switched” to growth stimulation. At a 
later stage, the “balance” favors angiogenesis and tumorigenesis. These reciprocal 
interactions are mainly evident in melanoma and colorectal carcinoma [Rak et al 1994 & 
96].
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Inflammatory cells (eg. macrophages and neutrophils) influence certain stages of 
angiogenesis especially in hypoxic conditions [Harmey et al 1998, Takahashi et al 1996, 
Sunderkotter et al 1994, Harmey et al 1996, Knighton et al 1983]. It was shown that 
macrophage density is directly proportional to rate of tumour growth [Van Netten et al 
1992]. The inflammatory cells produce substances which induce endothelial cell 
proliferation, migration and differentiation [Polverini et al 1977]. They produce monokines 
and proteases which affect the matrix and alter basement membrane composition 
respectively [Bouck et al 1996]. However, macrophages also produce thrombospondin-1 
(TSP-1) which itself is anti-angiogenic [Bornstein et al 1995]. Angiogenic factors are 
produced and released by activated macrophages in the presence of hypoxia as mentioned 
earlier, altered pH, lactate, pyruvate as well as a variety of cytokines [Sunderkotter et al
1994].
In breast cancer, tumour-associated macrophages (TAM) and neutrophils enhance tumour 
angiogenesis and are associated with a poorer prognosis [Leek et al 1996, Polverini et al 
1989, Mantovani et al 1994, Welch et al 1989]. Leek et al [1996] examined macrophage 
infiltration in invasive breast carcinoma using the Chalkley counting method. They 
reported a significant positive correlation between high vascular grade and increased 
macrophage index. There was a strong relationship between increased macrophage counts 
and reduced relapse-free survival and reduced overall survival. Furthermore, the 
macrophage count was an independent prognostic indicator. Breast cancer cell 
responsiveness to TNF-alpha produced by TAMs play a role in the regulation of TP 
expression by tumour cells and in their metastatic behaviour [Leek et al 1998]. Matrix
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metalloprotease-9 produced by macrophages as well as by other cell types such as 
fibroblasts causes extracellular matrix degradation during tumour angiogenesis [Kurizaki 
et al 1998, Nielsen et al 1997].
In DCIS, two distinct types of inflammatoiy patterns have been described, type I showing 
perivascular clusters of B and T cells; and type II, diffuse clusters of macrophages and T 
cells [Lee AHS et al 1997]. The perivascular pattern is associated with poorer 
differentiation of DCIS. Different patterns of inflammation are associated with different 
patterns of vessels. Inflammatory mast cells have been reported to be involved in the 
regulation of angiogenesis during squamous epithelial carcinogenesis [Coussens et al 
1999]. In hyperplasia and dysplasias, mast cells are conscripted to reorganize stromal 
architecture and hyperactivate angiogenesis, the infiltration of mast cells and activation of 
the matrix metalloproteinase MMP-9/gelatinase B coinciding with the angiogenic switch in 
premalignant skin lesions.
Recently, Leek et al [2000] carried out a study to localize VEGF protein in primaiy breast 
carcinomas and to determine its relationship to focal macrophages infiltration 
(macrophage index). They showed a positive correlation between neoplastic cell VEGF 
expression and macrophage infiltration (index), but not with microvessel density. VEGF 
expression was also inversely associated with EGFR. The author suggested VEGF 
expression may be an important factor in the recruitment of tumour-associated 
macrophages into breast carcinomas and may thus have an additional as well as indirect 
pathway of angiogenic stimulation.
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The angiogenic switch
The theory of “The Angiogenesis Switch” during tumorigenesis was first hypothesized by 
Hanahan and Folkman et al [1996] [Fig. 2.2]. They showed that the “switch” occurs 
before tumour formation in three transgenic mouse models [Fig. 2.3] \
1. Expression of the Tag oncogene in the pancreatic islets and the development of islet 
cell carcinomas. An intermediate stage called the ‘angiogenic islet’ was then identified 
during the malignant transformation of carcinoma in-situ (CIS) into islet cell 
carcinoma. Histologically, there were capillary sprouting and endothelial cell 
proliferation.
2. Expression of the BPV-1 oncogenes in the dermis and the development of 
fibrosarcoma. Angiogenesis was evident in a late preneoplastic stage (aggressive 
fibromatosis) as well as end -stage fibrosarcomas.
3. Expression of the HPV-16 oncogenes in the epidermis and the development of 
squamous cell carcinoma. In the dysplastic stage, there were abundant capillaries 
converging on to the basement membrane separating stroma from dysplastic cells.
The “angiogenic switch” has also been reported in pre-malignant stages of two human 
cancers, breast carcinoma in-situ and cei-vical intraepithélial neoplasia [Hanahan et al 
1996] [Fig. 2.4].
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THE BALANCE HYPOTHESIS FOR THE ANGIOGENIC SWITCH
The switch: 
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Figure 2.2. The balance hypothesis for the angiogenic switch [Hanahan <& Folkman et 
al 1996J.
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Figure 2.3. The angiogenic switch prior to tumour formation in three transgenic 
mouse models of tumorigenesis [Hanahan & Folkman et al 1996].
61
A .
Normal
duct Hyperplasia D ysplasia/CIS
Angiogenic
CIS
Invasive
carcinom a
%
Normal cervical 
squam ous epithelium
(%N( CIN III
vÜt-Xi
Invasive
carcinom a
Figure 2.4. The angiogenic switch can be visualised in neoplastic lesions inferred to be 
progenitor stages to human breast (A) and cenncal cancer (B) [Hanahan & Folkman 
et al 1996!.
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Interaction of endothelial cells with the environment
There are changes in the interaction of endothelial cells with the environment during 
angiogenesis in cancer [Fig. 2.5\
The expression of membrane receptors (tyrosine kinases) is increased. There is a different 
pattern of expressed receptors on stimulation by angiogenic factors, for example, 
receptors for integrins are altered in accordance with the changes that occur to the 
structure and composition of the matrix during angiogenesis [Brooks et al 1996],
The pattern of the ECM is altered by the proteolytic activity of the endothelial cells. At 
the early stage of angiogenesis, there is deposition of type I collagen and fibronectin in the 
ECM, which is followed by deposition of type IV collagen and laminin at the end of the 
process [Brooks et al 1996]. These activities are due to increased levels of MMP/PA and 
decreased levels of TIMP/PAI [Werb et al 1997, DeClerk et al 1997]. Degradation of the 
matrix promotes endothelial cells migration and releases angiogenic factors that are stored 
in the matrix. At the end of the process, the formation of a network of tubular structures is 
dependent on a balance of traction forces, created by the alteration of an elastic matrix by 
the endothelial cells [Sage et al 1994].
At an early stage of angiogenesis, cell junctions between endothelial cells are weakened 
and broken so allowing cell proliferation and migration. During formation of the blood 
vessels, the cell junctions are reformed.
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There are modifications in the interactions with surrounding cells such as pericytes, 
smooth muscle cells and accessory cells. At an early stage of angiogenesis, there is no 
interaction between endothelial cells with these surrounding cells. At a later stage, the 
interaction is mediated by angiopoitin-2 [Lauren et al 1998, Hanahan et al 1997].
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Figure 2.5. Angiogenesis occurs mainly in the capillaries. In response to cytokines 
stimulation, endothelial cells break down the basement membrane, migrates into the 
extravascular space, proliferate, and reorganize to form a neyv vessel [Goldberg & 
Rosen et al 1997].
64
Pro-angiogenic factors 
Vascular endothelial growth factor (VEGF)
VEGF is expressed on a variety of normal cells and is secreted by a number of human 
tumour cell lines [Senger et al 1986]. It increases vascular permeability and is an 
endothelial cell- specific mitogen and angiogenic factor [Ferrara et al 1995, Marine et al 
1996]. It binds exclusively to endothelial cell specific tyrosine kinase receptors, Flt-1 
(VEGFR-1) and KDR (VEGFR-2) [De Veries et al 1992, Terman et al 1992], and it plays 
a role in the paracrine stimulation of angiogenesis.
Production of VEGF can be induced by PDGF [Colville-Nash et al 1997], TGF-beta 
[Pertovaara et al 1994], v-sarc oncogene [Mulkhopadhyay et al 1995], mutated p53 
tumour suppressor gene [Mulkhopadhyay et al 1995], mutated ras oncogene [Rak et al
1995] and hypoxia [Namiki et al 1995]. Production is inhibited by wild-type p53 
[Mulkhopadhyay et al 1995]. VEGF works synergistically with FGF-2 [Pepper et al 
1992]. The activity is potentiated by hypoxic conditions [Minchenkoi et al 1994, Levy et 
al 1995, Grone et al 1995] through the up-regulation of the KDR receptor [Brogi et al
1996].
Structurally, VEGF is homologous with vascular permeability factor (VPF), which itself 
promotes protein extravasation [Dvorak et al 1995]. This process releases fibrin in the 
ECM [Senger et al 1996], which in turn promotes angiogenesis.
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Study by Ferrara et al [1996] emphasize the key role played by VEGF in embryonic 
development. Fleterozygous mutations inactivating the VEGF gene in mice result in 
embryonic lethality between day 11.5 and 12,5. Mutant embiyos revealed dramatic deficits 
in angiogenesis and hematopoiesis as well as in the development of the cardiovascular and 
other systems. These findings indicate that VEGF is a most critical factor in 
vasculogenesis and angiogenesis, as other factors cannot compensate for even reduced 
levels of VEGF.
Acidic fibroblast growth factor (aFGF or FGF-1)
FGF-1 is found mainly in neural tissues [Relf et al 1997] and acts via both autocrine and 
paracrine pathways. It is essential in embryonic development and wound healing and is 
mitogenic for endothelial cells which in turn promotes angiogenesis [Folkman et al 1987, 
Thompson et al 1988, Klagsburn et al 1989, Thomas et al 1987], FGF-1 is expressed in a 
variety of tumours [Relf et al 1997] but is believed to be suppressed by the angiogenesis 
suppressor gene which itself is downregulated during carcinogenesis [Folkman et al 
1995b], It has to be released into the ECM to bind with receptors to be angiogenic, 
however, it is usually confined to the cell of origin as it lacks the signal sequence for 
secretion [Mulkhopadhyay et al 1995].
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Basic fibroblast growth factor (bFGF or FGF-2)
FGF-2 , an endothelial mitogen [Schweigerer et al 1987], is produced and released by 
capillary endothelial cells. It has been isolated in a variey of normal and tumour cells 
[Asahara et al 1995]. It acts in an autocrine and paracrine manner. It also acts 
synergistically with VEGF [Mulkhopadhyay et al 1995]. Like FGF-1, it has to be released 
to be angiogenic and yet is usually confined to the cell of origin in the absence of the 
secretory signal peptide [Mulkhopadhyay et al 1995]. It has been shown that angiogenesis 
is associated with a switch in the ability to secrete FGF-2 from cells during carcinogenesis 
in a fibrosarcoma model [Kandel et al 1991].
The administration of FGF-2 increases vascularity and promotes tumour growth [Gross et 
al 1993]. The binding of FGF-2 can be blocked by suramin [Danesi et al 1993], and the 
blockade of its receptor can suppress tumour growth [Hori et al 1991].
Platelet-derived endothelial cell growth factor (PD-ECGF)
PDECGF is structurally homologous to thymidine phosphorylase [Furukawa et al 1987].
It is produced by platelets [Miyazono et al 1987] and vascular smooth muscle cells [Usuki 
et al 1989], and acts as an endothelial mitogen. It has a role in endothelial cell migration 
[Risau et al 1992] and differentiation [Klagsburn et al 1991] as well as during the blood 
clotting cascade.
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Its expression in human breast cancer cells has been shown to correlate with microvessel 
density [Fajardo et al 1992, Folkman et al 1996, Fox et al 1996]. TP expression is 260- 
fold higher in invasive bladder cancer [O’Brien et al 1995] and 27-fold higher in invasive 
breast carcinoma than normal tissue [Patterson et al 1995]. In ovarian carcinoma, areas of 
increased expression of TP have been associated with high blood velocity as measured by 
colour Doppler imaging [Reynolds et al 1994].
In most normal organs, TP is most highly expressed in resident tissue macrophages, and 
may be part of a mechanism controlling angiogenesis in response to injury [Fox et al
1995]. TP is not a classic type of pro-angiogenic factor in tumours as it is thought to exert 
its angiogenic effects via the metabolites of its enzymatic activity [Moghaddam and 
Bicknell et al 1992]. DNA released from dying cells and engulfed in apoptotic nuclei may 
be degraded to thymidine, which can freely enter cells, including tumour cells and TAMs, 
which then metabolize thymidine via TP to angiogenically active metabolites such as 
deoxyribose-1-phosphate. TP also catalyses the phosphorolytic cleavage of the 
chemotherapeutic pro-drug 5 ’-deoxy-5’-fluorouridine (5’-DFUR) to its therapeutically 
active form 5-fluorouracil (5-FU) [Patterson et al 1995], and it is thought that resistance 
to 5’-DFUR therapy may be due to low TP activity in some tumours.
Expression of TP in tumour cells can be modulated by hypoxia [Shweiki et al 1992] and 
up-regulated by tumour necrosis factor-alpha, interleukin-1 and interferon-gama, and basic 
fibroblast growth factor [Ho et al 1990, Eda et al 1993], It is suggested that tumours 
might directly regulate TP expression through autocrine and paracrine pathways and that
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cytokines might also recruit macrophages rich in TP that may themselves, also, through 
paracrine loops, augment tumour cell TP.
On immunohistochemical examination, the location of TP expression varies. In bladder 
[Mitutani et al 1997] and lung cancers [Giatromanoraki et al 1997, Koukourakis et al
1997], TP expression was observed mainly in cancer cells. By contrast, however, it was 
observed mainly in the infiltrating cells around the stroma of gastric [Takebayashi et al
1996] and colorectal cancer [Takahashi et al 1996]. Nagaoka et al [1998] showed both 
breast cancer cells and normal or benign breast epithethelial cells expressed TP, and that 
expression tended to be more intense in the former [Fig. 2.6\. TP has been shown to be 
prognostic indicator in colorectal, gastric and breast cancers [Takebayashi et al 1996, 
Takahashi et al 1996, Nagaoka et al 1998].
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Figure 2.6. TP expression in breast carcinomas. DCIS lesions negative (A), and 
positive (B) for TP. (C) Invasive ductal carcinoma with higher TP expression at the 
invading border [Goldberg & Rosen et al 1997].
Transforming growth factor beta (TGF-beta)
TGF-beta is produced by macrophages and platelets. It is chemotactic to macrophages, 
angiogenic in vivo and promotes wound healing [Thompson et al 1991, Roberts et al 
1986, Sporn et al 1987, Shah et al 1995, Pierce et al 1992]. It also upregulates the 
production of matrix and integrin during angiogenesis, acting in a biphasic manner, low 
levels having a stimulatory effect and high levels an inhibitory effect. [Pepper et al 1993].
Epidermal growth factor (EGF)
EGF is a mitogenic and angiogenic growth factor. It is produced by tumour-associated 
macrophages in breast carcinoma [O’Sullivan et al 1993].
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Iiitegrins
The integrin family consists of 15 alpha and 8 beta subunits that are expressed in over 20 
different alpha/beta heterodimeric combinations on cell surfaces. Integrins bind to 
extracellular matrix proteins or cell-surface immunoglobin family molecules through short 
peptide sequences in the ligands. Combinations of different integrins on cell surfaces allow 
cells to recognize and respond to different extracellular matrix proteins. Integrins faciliate 
cellular adhesion to and migration on the ECM proteins [Cheresh et al 1993, Hynes et al 
1992] as well as regulate cellular entry into and withdrawal from the cell cycle [Dike et al 
1988, Guadagnow et al 1993, Varner et al 1995]. Prevention of integrin-ligand interaction 
suppresses cellular growth and induces apoptotic cell death [Varner et al 1995, Meredith 
et al 1993, Montgomery et al 1994].
The migration of endothelial cells into a tumour requires adhesion to proteins of the 
extracellular matrix, including thrombospondin, vitronectin, fibronectin, laminin and 
collagen [Montgomery et al 1994, Brooks et al 1994b, Good et al 1990]. Laminin is 
implicated in angiogenesis as the deposition of matrix by newly forming capillaries appears 
to be critical in angiogenesis. Adhesion molecules, of the seleetin family and their ligands 
sialyl Lewis X/A have been implicated in the differentiation phase of angiogenic lumen 
formation [Bischoff et al 1995, Nguyen et al 1993] and inhibition of the molecules by 
monoclonal antibodies has been shown to decrease angiogenesis [Folkman et al 1995b].
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Integrin alpha5beta3 is a receptor for a wide variety of extracellular matrix proteins. It is 
the most ‘promiscuous’ member of the integrin family, mediating cellular adhesion to 
vitronectin, fibronectin, fibrinogen, laminin, collagen, von Willebrand factor, osteopontin, 
and other molecules [Cheresh et al 1987 & 93, Leavesley et al 1992]. It is strongly 
expressed on cytokine-activated endothelial or smooth muscle cells explaining its intense 
expression on blood vessels in granulation tissue and tumours [Montgomery et al 1994, 
Brooks et al 1994b, Enenstein et al 1994, Sepp et al 1994]. The expression is upregulated 
by bFGF, TNF-alpha and human tumours in vitro and during wound healing in vivo 
[Montgomery et al 1994, Brooks et al 1994b]. Alpha5beta3 has angiogenic and anti- 
apoptotic effects by suppressing wild-type p53 activity and increasing the bcl2/bax ratio 
[Naylor et al 1993]. Antagonists of integrin alpha5beta3 not only suppress angiogenesis in 
vitro without affecting adjacent blood vessels, but also induce tumour regression up to five 
fold [Brooks et al 1994b],
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Tumour necrosis factor alpha (TNF-alpha)
TNF-alpha is produced by tumour-associated macrophages, especially in breast and 
ovarian carcinoma [Pusztai et al 1994, Scanned et al 1993] and its expression is up- 
regulated by hypoxia [Niedbala et al 1991]. It activates endothelial proteases [Fajardo et al 
1992], induces granulocyte-macrophage colony stimulating factor production, increases 
adherence of endothelial cells, and has a role in the blood clotting cascade. It also acts in a 
dose-dependant manner being angiogenic at low concentrations and vice versa [Leek et al 
1994].
Interleukin-8 (IL-8)
ÏL-8 was first detected in lung tumour from which extracts were shown to be angiogenic 
in the rabbit cornea angiogenesis assays [Smith et al 1994] and inhibited by anti-IL-8 
antibodies [Smith et al 1994]. Recombinant human IL-8 has been reported to stimulate 
new blood vessel formation in a rabbit cornea assay [Strieter et al 1992].
Endotoxin
Endotoxin, an angiogenic factor, is found in the cell wall of most Gram-negative as well as 
some Gram-positive bacteria, It up-regulates the production of VEGF, bFGF, TGF-beta, 
TNF, IL-1, IL-6 and other molecules [Mattsby-Baltzer et al 1994, Watson et al 1994, Li 
WWet a l  1991].
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Anti-angiogenic factors 
Thrombospondin (TSP)
Thrombospondin, a matrix-bound glycoprotein, is found in endothelial cells, epithelial 
cells, fibroblasts, smooth muscle cells, monocytes, macrophages and other cell populations 
[Raugi et al 1982]. It is a potent anti-angiogenic factor, controlling the motility, 
adhesiveness and proteolytic activity of endothelial cells [Bussolino et al 1997]. During 
carcinogenesis, the levels of TSP are downregulated [Folkman et al 1992b, Rastinejad et 
al 1989, Bouck et al 1990]. Angiogenesis is regulated by wild-type p53 through 
upregulation of TSP, inactivation of the gene resulting in decreased levels of TSP 
[Rastinejad et al 1989]. In inflammation, TSP potentiates the angiogenic effect of bFGF 
and endotoxin [BenEzra et al 1993]. Recently, it was shown that in vivo transfection of 
human breast cancer cells with DNA encoding TSP-1 resulted in a decreased micro vessel 
density [Weinstat-Saslow DL et al 1994].
Angiostatin
Angiostatin is a fragment of plasminogen, which itself is not anti-angiogenic [O’Reilly et al
1994] which suppresses endothelial cell proliferation and tumour growth. It is produced 
during the development of solid tumours and has been found to suppress growth of 
métastasés [O’Reilly et al 1994]. Systemic administration of angiostatin has been shown to 
cause tumour regression in a variety of animal models [O’Reilly et al 1996].
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Ëiidostatin
Endostatin is a fragment of collagen XVII and acts in a similar way to angiostatin. It 
blocks endothelial cell proliferation, matrix remodeling and the activity of collagenase. 
Recombinant endostatin has been shown to inhibit angiogenesis, suppressing growth of 
primary and secondaiy tumours [O’Reilly et al 1997]. In treated tumours, angiostatin 
appears to increase apoptosis but not the proliferation of the lesions [O’Reilly et al 1994].
Angiogenesis in breast carcinoma
To date, there is evidence that breast carcinoma is angiogenesis-dependent:
Indirect evidence (experimental studies)
Brem et al [1977] assessed the angiogenic response induced in the rabbit iris by the 
transplantation of xenografts of normal, hyperplastic and chemically-induced neoplastic 
mammary tissues. They showed that angiogenesis preceded the transforamation of 
mammary hyperplasia to carcinoma. Using a similar experimental model, Jensen et al 
[1982] showed that angiogenesis is involved in human breast cancer transformation and 
progression. The angiogenic activity of normal breast tissues from cancerous breasts was 
twice that of non-cancerous ones. Studies by McLesky et al [1993] and Costa et al [1994] 
demonstrated that fibroblastic growth factors (FGF) 3 and 4 induce angiogenesis followed 
by rapid tumour growth and metastasis in human breast cancer cell lines. Zhang et al 
[1995] reported that human breast carcinoma cells transfected with vascular endothelial 
growth factor (VEGF) show high vascularity and growth.
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Overall, the above studies demonstrate that different peptides induce angiogenesis and 
facilitate progression and metastasis in vivo.
Indirect evidence (clinical studies)
Using a rabbit iris assay, Brem et al [1978] demonstrated that angiogenesis is a potentially 
useful marker of preneoplastic lesions and that it is associated with most human breast 
cancers. An iris angiogenic response was recorded in 30% of tissue fragments from 
biopsies of human hyperplastic breast lobules compared with 65% of those from invasive 
breast carcinoma. They also found that the frequency of transformation was higher in the 
subgroup of hyperplastic lesions with angiogenic activity. By examining the histological 
sections of breast cancer stained with a specific endothelial marker, Weidner et al [1991] 
showed that it is possible to observe in situ carcinomas in the prevascular and vascular 
phase.
In another study, Guinerbretiere et al [1994] suggested that the risk of women with 
fibrocystic disease developing invasive breast carcinoma increases with the degree of 
vascularisation within the lesion. Hildenbrand et al [1995] found a significant association 
between urokinase plasminogen activator (uPA) levels and intratumoural vascularisation in 
breast cancers. McCulloch et al [1995] demonstrated that the extent of tumour cells 
shedding into effluent venous blood during breast cancer surgeiy are associated with the 
microvessel count of primary tumour, confirming preclinical studies indicating that 
angiogenesis facilitates métastasés [1994].
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Direct evidence (experimental studies)
Studies have shown that inhibition of angiogenesis can cause regression of human breast 
cancer in animal models. Weinstat-Saslow et al [1994] transfected TSP-1 complementary 
DNA into a metastatic human breast cancer cell line. The genetic modulation inhibited 
angiogenesis in vivo along with a reduction of tumour growth and metastasis compared 
with untreated controls. Brooks et al [1995] reported that systemic treatment with an 
antibody (LM609) against the alphaVbeta3 integrin reduced angiogenesis and tumour 
growth in a severe combined immunodeficient (SCID) mouse/human chimera bearing 
subcutaneous transplant of human breast cancer. Folkman et al [1996] administered 
angiostatin to nude mice bearing diverse solid human tumours. They demonstrated an 
induced tumour regression through inhibition of angiogenesis and prolonged tumour 
dormancy.
In conclusion, the current evidence suggests that angiogenesis is necessary, but not 
sufficient alone, for breast cancer growth, and that inhibition of angiogenesis is a potential 
therapeutic modality along with conventional anticancer therapies.
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Angiogenesis and DCIS
With the advent of screening mammography, the reported incidence of DCIS has 
increased significantly. However, despite the importance of various pathological features, 
the prognosis for individual patients cannot be accurately predicted and the optimal 
treatment for DCIS remains unresolved. Breast conservation with or without adjuvant 
radiotherapy is associated with a significant risk of recurrence, of which 50% will be 
invasive carcinoma [Silverstein et al 1995a&b & 96, Solin et al 1993 & 94 & 96]. Several 
studies have studied neovascularisation and in-situ breast cancer.
Guidi et al [1994] reported two types of vascular pattern, a diffuse pattern (Pattern I) and 
a dense vascular rim around the involved ducts (pattern II) [Fig. 2.7], This finding was 
confirmed by Engels et al [1997a], who proposed two angiogenic pathways to account for 
these morphological findings: Pattern II is thought to result from angiogenic factors being 
secreted by tumour cells (autocrine pathway) and Pattern I to be mediated via the 
recruitment of accessory cells, releasing proangiogenic factors themselves (paracrine 
pathway). Engels et al [1997b] in another study, showed a significant correlation between 
Thymidine Phosphroylase (TP) and the presence of the type II vascular pattern, although 
there was no correlation between the vascular patterns or expression of TP with relapse- 
free survival. Sales et al [1999] reported that there was a significant association between 
MVD, histological features and nuclear area in both DCIS and ductal hyperplastic 
epithelial lesions. The two types of angiogenic patterns were again identified, a type II 
vascular pattern also being seen in hyperplasia.
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The association between vascularity and inflammation in DCIS has been studied by Lee 
AHS et al [1997]. They found the Type I pattern was associated with perivascular clusters 
of inflammatory cells while pattern II was associated with difflase inflammation, supporting 
the hypothesis that vascular patterns result from paracrine or autocrine factors released by 
the DCIS/inflammatory cells. More recently, they have also reported that the vascular 
pattern I in DCIS is associated with TP expression in the perivascular inflammatory cells 
and tumour cells [Lee AHS et al 1999].
Vaitola et al [1999] examined the role of VEGFR-3 and its ligand VEGF-C in DCIS. They 
noted that VEGFR-3 was prominent in vessels adjacent to the basal lamina of affected 
ducts and its ligand was localized in the cytoplasm of the tumour cells. These results 
suggest that the role of VEGF-C involves modifying the permeabilities of both blood and 
lymphatic vessels.
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High levels o f  expression o f  VEGF mRNA and its receptor mRNA have been found in 
both tumour cells and microvessel endothelial cells [Brown et al 1995]. Guidi et al [1994] 
showed that there was a significant correlation between a high K i-Sl proliferation index 
and high microvessel counts [Solin et al 1994] as well as VEGF expression [Morales et al
1995]. Parham et al [1992] also reported increased levels o f  TGF-alpha expression in 
DCIS.
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Figure 2.7. Different vessel patterns in DCIS. (A) Distant rim and (B) dense rim of 
microvessels around a DCIS duct close to the basement membrane. (C) High vascular 
density between DCIS lesions. All vessels are stained with anti-vWF antibodies 
[Goldberg & Rosen et al 1997].
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Angiogenesis and hormonal control
Oestrogen added to human umbilical vein endothelial cells (HUVECs) grown in an 
oestrogen-free medium culture cause an increase in endothelial cell proliferation, cell 
attachment to laminin and enhances the ability of HUVECs to organize into tubular 
networks, these are all features that are important in angiogenesis [Morales et al 1995]. 
Oestrogen may also have a role in preservation of endothelial cells by inhibiting apoptosis 
[Sypridopoulos et al 1997], the apoptosis caused by TNF-alpha on cultures of HUVECs 
being reversed by the addition of oestrogen.
Partial oestrogen antagonists including Tamoxifen, and pure antagonists ICI 164, 384 and 
ICI 182, 780 have been shown to inhibit angiogenesis in the chick egg chorio-allantoic 
membrane [Gagliardi et al 1993]. It has also been shown that the growth of porcine 
pulmonary artery endothelial cells is stimulated by bFGF and VEGF, and inhibited by 
Tamoxifen [Gagliardi et al 1995], suggesting that the anti-angiogenic effect of anti- 
oestrogens is mediated through direct inhibition of growth factor stimulated endothelial 
cell growth. Male rats treated with Tamoxifen injected with VEGF-impregnated matrigel 
show a reduction in gel MVD, suggesting that tamoxifen affects VEGF-mediated 
angiogenesis [McNamara et al 1998]. Angiogenesis is also decreased in ovariectomized 
mice in the presence of bFGF, suggesting that the angiogenic effects of bFGF are 
promoted by oestrogen [Morales et al 1995]. Therefore, as well as enhancing the action of 
angiogenic factors, oestrogen receptors may mediate the control of angiogenesis 
[Sypridopoulos et al 1997].
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Angiogenesis and therapeutic implications
The understanding that tumour growth is angiogenesis dependent has led to the 
development of agents directed towards the tumour vasculature [Table 2 J \  These have 
yielded striking successes in experimental models, which if translated into the clinical 
setting may have a substantial effect on patient survival.
Neutralising angiogenesis promoters
This treatment interferes with pro-angiogenic factors produced by tumours. Reported 
models include;- targeting vascular endothelial growth factor with a monoclonal antibody 
[Kim et al 1993], viral delivery of dominant negative receptors to VEGF and preventing 
the release of active fibroblast growth factor 2 from the extracellular matrix by eradicating 
a binding protein necessai*y for its release [Czubayko et al 1997].
Endogenous angiogenesis inhibitors
The angiogenic stimulus produced by tumours can be countered by means of endogenous 
inhibitory proteins. This can be carried out either by direct supply of angiogenic inhibitors 
such as angiostatin and endostatin [O’Reilly et al 1994 & 96 & 97] or by gene transfer of 
DNA coding for angiogenic inhibitors such as angiostatin and platelet factor 4.
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Endothelial cell targets
Specific markers for tumour endothelial cells can be used to direct a toxin or antibody to 
the tumour vasculature causing tumour infarction by inducing coagulation. The possible 
targets are VEGF-receptor complexes, Endoglin and intergrin alphaSbetaS, The latter is 
expressed only on proliferating vessels in healing wounds and in tumours. The antibody 
promotes tumour regression by inducing endothelial cell apoptosis [Brooks et al 1994a],
Synthetic angiogenic inhibitors
This approach inhibits tumour angiogenesis with drugs that specifically prevent endothelial 
division. These medications can act synergistically with conventional cytotoxic treatment 
and with “hypoxia activated” cytotoxic dmgs.
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Mechanisms Target Theranv
Block of proteolytic 
pathways in extracellular 
matrix
Metalloproteinases Metalloproteinase inhibitors
Block of adhesion molecules Betal, alphaVbeta3, 
alphaVbetaS integrins
Neutralising antibodies
Block of endothelial cell 
migration
In vitro tests for cell 
migration
Linomide
Block of proliferating 
endothelial cells
Activated endothelium Specific growth inhibitors
Block of angiogenic peptides VEGF, bFGF, etc. Growth factor inhibitors, 
neutralising antibodies
Gene therapy TSP-1, angiostatin & 
platelet-factor 4
Transfection of tumour cells 
with gene encoding 
angiogenic inhibitors
Table 2,1. Anti-angiogenic therapy: possible targets and mechanisms o f  action 
[Gasparini et al 1996].
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Conclusions
There have been many studies of the process of angiogenesis in carcinoma but most, not 
surprisingly, have focused on invasive disease. Some, however, have investigated DCIS of 
the breast or other precursor breast lesions [Lee AHS et al 1997&99, Guidi et al 
1994&97, Engles et al I997a&b, Sales et al 1999, Vaitola et al 1999, Brown et al 1995] 
where 2 patterns have been described: diffuse stromal vascularity and a vascular rim 
around the involved ducts. Several studies have shown that various pre-malignant lesions 
of the breast can induce angiogenesis in animal experimental systems and in the human 
breast [Lichtenbeld et al 1998, Gimbrone et al 1976, Brem et al 1977, Maiorana et al 
1978, Stmm et al 1983, Heffelfinger et al 1996]. Little work has been done in 
angiogenesis in DCIS of the breast but there are tantalizing glimpses suggesting that this 
may be important. The mechanisms involved in the angiogenesis in invasive disease may be 
applicable to this pre-invasive breast pathology.
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Chapter 3 
Assessment of Vascularity
Microvessel density/ hotspots
Weidner et al [1991] introduced a method of identifying hotspots (areas with high vascular 
density) in breast carcinoma. The rationale is that there is an active relationship between 
the tumour and the endothelial cells in these hotspots. The functionality of endothelial cell 
in terms of proliferation, differentiation and migration plays an important role in tumour 
angiogenesis. MVD is believed to reflect the intensity of tumour angiogenesis as well as 
carrying useful insights on the functionality of the endothelial cells.
The method first involved selecting the appropriate blocks for further study by scanning 
sections stained with haemotoxylin and eosin. The blocks selected were then 
immunostained with an endothelial marker (eg, anti-factor VIII antibody) and the hotspots 
were identified by analyzing the section on low magnification (lO-lOOx) [Fig. 3J],  The 
hotspots were usually localized around the peripheral tumour margin. The counting was 
carried out at a higher magnification with a proposed field size of 0.74 mm2. A countable 
micro vessel included any stained endothelial cell or cell cluster clearly separated from 
adjacent microvessels, tumour cells and other connective tissue components. A lumen or 
the presence of red blood cells was not required. Single cell sprouts and larger vessels 
were included. In cases where clusters give the impression of being part of one vessel 
these were counted as separate micro vessels. The following studies have all used hotspot 
counting to assess MVD.
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mFigure 3.1. Breast carcinoma with microvessels highlighted with anti-vWF antibodies. 
(Left) Two foci of invasive carcinoma are shown (open arrows). Microvessels are 
represented by dark clusters, which stand out from carcinoma cells and connective 
tissue. (Right) Carcinoma with high angiogenesis. Solid arrows indicate representative 
microvessels [Weidner & Folkman et al 1996].
MVD and its relationship to angiogenic factors
Li et al [1994] measured bFGF in the cerebrospinal fluids o f children with various brain 
tumours and correlated increasing fluid levels with greater MVD and increased risk o f  
recurrence. In gliomas and meningiomas, there was an association between VEGF mRNA 
expression and MVD [Samoto et al 1995]. Similar findings have been seen with renal and 
cervical tumours. In human renal cell carcinomas grafted into a murine model, Berger et al
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[1995] reported a correlation between MVD and VEGF mRNA expression. Dobbs et al 
[1997] showed a correlation between MVD and VEGF expression in CIN and SCC of the 
ceiwix. Furthermore, there were significant increases in MVD and VEGF expression from 
the progression from normal cervix through CIN I to CIN III to invasive SCC.
The degree of VEGF mRNA and Thymidine Phosphorylase expression in perivascular 
inflammation were significantly associated with MVD in DCIS [Guidi et al 1997, Lee et al 
1999]. Toi et al [1995a] reported a significant correlation between MVD and VEGF as 
well as PdECGF expression in invasive ductal carcinoma, A similar association between 
MVD and VEGF expression was also shown in early stage breast cancers [Toi et al 
1995b]. Multivariate analysis confirmed that the former had an independent predictive 
value for relapse-free survival (RFS), whereas VEGF expression had a similar predictive 
value when univariate analysis was performed. These studies suggest that MVD provides 
important information on the degree and functionality of the tumour vasculature, as well 
as quantifying the vascular morphology.
MVP and iiPA/PAI-1 & MMP levels
Urokinase plasminogen activator (uPA) is an extracellular proteolytic enzyme which is 
produced by endothelial, tumour and inflammatory cells. The migration of endothelial cells 
is facilitated by the secretion of collagenases, urokinases, and plasminogen activator 
[Pepper et al 1987, Fox et al 1993, Moscatelli et al 1981]. The degradative enzymes 
facilitate the spread of tumour cells into and through the adjacent fibrin-gel matrix and 
connective tissue stroma. Both uPA and plasminogen activator inhibitor-1 (PAI-1) have
independent prognostic values in breast cancer [Janicke et al 1993]. There was a 
correlation between MVD and the uPA/PAI-1 levels and pro MMP-9 in human breast 
cancer tissues [Hildebrand et al 1995, Kurizaki et al 1998]. These extracellular proteolytic 
enzymes activity may contribute to tumour cell invasion and métastasés to distant sites. 
Since activated endothelial cells produce uP A, this represents part of the reciprocal 
paracrine interaction between tumour and host cells. A higher MVD might represent a 
more extensive intercellular interaction at the interface between tumour and host.
MVD and tumour cell shedding
McCulloch et al [1995] investigated the relationship between the risk of tumour cell 
shedding and MVD of operable breast cancer in 16 patients. Before, during and one day 
after the operation, blood samples obtained via a central venous catheter which was fixed 
in the ipsilateral proximal subclavian vein. The samples were cytospun and then stained 
with appropriate cytokeratin antibodies that would detect any epithelial cells. Circulating 
cells were found in 1 patient before, 6 during, and none after operation. The results 
suggested that the risk of tumour cell shedding was related to MVD.
MVP and iiitratiimoral tissue plasma volume
The tumour plasma volume can be assessed by means of magnetic resonance imaging 
(MRI) with the injection of contrast medium [Van Dijke et al 1996]. It was noted that the 
estimated plasma volume had an exponential relationship with the MVD. This study, along 
with other related literature mentioned earlier, strongly support the idea that MVD is a 
reliable measure of tumour angiogenesis.
89
MVD and prognostic values
Even though Brem et al [1972] were among the first to put forward the idea that there 
might be a correlation between MVD and the tumour grade and invasive characteristics, it 
was Srivastava et al [1988] who provided experimental evidence that there was a 
relationship between the tumour vascularity and the risk of metastasis in human solid 
tumours by studying cutaneous melanoma. The latter studied the vascularity of 20 
intermediate-thickness skin melanomas. Micro vessels were stained with Ulex eiiropaeus~l 
agglutinin conjugated with peroxidase, and the stained histology sections analysed with a 
semiautomatic image analysis system. The 10 patients who developed métastasés had a 
vascular area at the tumour base that was more than twice that seen in the 10 cases 
without métastasés. Patient characteristics, Breslow’s tumour thickness and Clark’s level 
of invasion were similar in the two groups.
A number of studies have shown that MVD is associated with tumour aggressiveness 
(including the risk of metastasis) and patient survival. The associations have been shown in 
patients with melanoma [Srivastava et al 1986&88, Smolle et al 1989, Fallowfield et al 
1991, Barnhill et al 1993, Vacca et al 1993, Graham et al 1993], central nervous system 
tumours [Li et al 1994], multiple myeloma [Vacca et al 1994], head and neck squamous­
cell carcinomas [Mikami et al 1993, Gasparini et al 1993, Albo et al 1994, Williams et al 
1994], non-small-cell lung carcinomas [Macchiarini et al 1992&94, Yamazaki et al 1994, 
Yuan et al 1995], breast carcinomas [Weidner et al 1991&92, Bosari et al 1992, Horak et 
al 1992, Gasparini et al 1994a&b, Gasparini et al 1995a&b, Obermair et al 1994a&b],
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gastrointestinal carcinomas [Saclarides et al 1994, Maeda et al 1995], transitional-cell 
carcinoma of the bladder [Jaeger et al 1995, Bochner et al 1995], testicular germ-cell 
malignancies [Olivarez et al 1994], prostate carcinoma [Weidner et al 1993, Fregene et al 
1993, Brawer et al 1994, Vesalainen et al 1994], cei*vical squamous cell carcinoma 
[Wiggins et ai 1995] and ovarian carcinoma [Hollingsworth et al 1995]. In some of the 
above studies, MVD was shown to have independent prognostic value, confirmed by 
multivariate analysis.
MVD also has a place in predicting the response or resistance to treatment and to 
outcome or survival after adjuvant treatment. Kohno et al [1993] reported that cervical 
carcinomas with high vascularity were more responsive to hypertensive intra-arterial 
chemotherapy. Zatterstrom et al [1995] noticed that head and neck squamous-cell 
carcinomas with a higher vascular count were more responsive to radiotherapy. 
Jacquemier et al [1998] investigated the prognostic value of tumour vascularity in patients 
with breast carcinoma undergoing conventional adjuvant chemotherapy. The study 
showed that the chemotherapy did not reduce the high prognostic value of microvessel 
count (MVC) and suggested that MVC may predict the degree of resistance to 
chemotherapy. Gasparini et al [1996] showed that MVD added significant prognostic 
information to ER status in predicting the outcome after adjuvant Tamoxifen treatment in 
node positive breast cancer patients. The authors found that the outcome for those 
patients with high MVD was poor after therapy, irrespective of the ER status.
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Endothelial markers
Vascular endothelial cells have an important role in coagulation, inflammation, immunity, 
regulation of vascular tone and in a wide variety of synthetic and metabolic functions. 
Endothelial cells also have a pivotal role in immunological diseases, angiogenesis in 
tumours, transplantation rejection, atherogenesis and placentation [Fajardo et al 1989].
The endothelial cells of microvessels can be identified using immunohistochemical 
methods. There are two major categories of endothelial markers; pan-endothelial cell 
markers or those that only stain proliferating endothelium [Table 3.1 &3. 2]. Both might 
also stain pericytes and other constituents of the basal lamina. In comparison with the 
activated endothelial cell-specific antibodies, the pan-endothelial cell-specific antibodies 
might not represent the dynamic angiogenic capacity of a tumour. The corresponding 
antigens of the former endothelial markers are usually lost during the tissue fixation or 
paraffin embedding, at the expense of the sensitivity of the antibodies.
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Antibody Sensitivity Snecificity Lymohatic
Anti-CD31 Small/large vessels, 
equal staining in 
normal & tumour 
tissue
Non-specific in 
cryostat section
No
UEA As above Low Yes
Anti-CD34 As above High Proportion
PAL-E As above High Proportion
BMA120-BW200 As above High ?
EN-4 Small/large vessels, 
restricted distribution 
pattern
Stromal staining, 
infiltrate cell staining, 
occasional tumour 
staining
?
Anti-8-Rag Large vessels: 
sensitive, capillaries: 
variable & focal, P 
Ab more sensitive
M Ab: High 
P Ab: Stromal 
staining
Proportion
Anti-CD36 Intense staining of 
small vessels -  
variable/weak
Monocyte and 
platelet staining
7
Table 3.1. Endothelial cell-specific antibodies [Vermeulen et al 1996a].
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Antibody Sensitivity Snecificity Lymnhatic
TEC-11 >80% of tumour 
vessels
Weak staining : 
Normal endothelial 
cells, stromal cell
?
E9 Small vessels: 
positive 
Large vessels: 
negative
Weak staining: 
Normal tissue vessels 
in skin, mucosa, 
tonsils
?
EN 7/44 Small vessels in 
tumour, 
inflammation, 
immune reaction
Staining in normal 
tissues in colon, 
placenta capillaries
?
4 A ll Tissue vessels in 
tumour, inflammation
Staining in normal 
tissues in lymph 
nodes, tonsils, vessels 
in synovial tissue
?
H4/18 Delayed 
hypersensitivity in 
Hodgkin’s lymphoma 
lymph node vessels
Negative in normal 
tissue
?
FB5 Most of the small 
tumour vessels
Negative in normal 
tissue
?
Table 3.2. Activated endothelial cell-specific antibodies [Vermeulen et al 1996a].
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Common endothelial markers 
vWF
vWF antigen is involved in platelet aggregation and adhesion [Vermeulen et al 1996a]. 
vWF is found in endothelial cells of arterioles, capillaries, and venules of several tissues, it 
is also found in high endothelial venules of lymphoid tissue and liver sinusoids, but it is 
absent in glomemlar capillaries, and splenic sinusoids express it only weakly [Turner et al 
1987]. F8-Rag is also found in platelets, megakaryocytes, mast cells and the mesangial 
region of renal glomeruli [Parums et al 1990].
F8-Rag has been established as one of the markers of endothelial cells [Throgeirsson et al 
1978], along with the Weibel-Palade body, associated with secretion of vWF [Gimbrone et 
al 1974, Jaffe et al 1973]. Antibodies against the antigen are highly specific, providing very 
high contrast between microvessels and other tissue components, and are also highly- 
reproducible. They stain the large vessels strongly and small vessels weakly [Vermeulen et 
al 1996a].
It has been shown that their staining is absent on part of the capillary endothelium in 
tumour tissues [Vermeulen et al 1995a] such as proliferating spindle cells lining the slits in 
the lesions of Kaposi’s sarcoma and angiosarcoma [Vermeulen et al 1995a]. It was 
suggested that in some pathological conditions, the endothelial cells do not contain 
sufficient F8-Rag to be demonstrable [Burgdorf et al 1981]. This could also be due to the 
tumour dedifferentiation, leakage through a defective cell membrane, or increased
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turnover rate [Burgdorf et al 1981]. Furthermore, the marker also stains a proportion of 
lymphatic vessels [Burgdorf et al 1981].
Siitonen et al [1995] reported that this marker is the most sensitive of the commonly used 
antibodies. However, it has been reported to show lack of specificity, sensitivity, and 
reproducibility by others, particularly when using polyclonal preparations [Little et al 
1986, Millard et al 1987], It is also claimed that F8-Rag is a less reliable marker of 
malignant endothelial cells and less specific for endothelial cells of cardiovascular origin 
[Parums et al 1990].
CD31
CD31 has a role in platelet adhesion, in inflammation and wound healing [Parums et al 
1990]. Its antibody is a sensitive pan-endothelial cell markers and doesn’t stain lymphatic 
vessels. It stains large and small vessels in either normal or tumour tissue equally 
[Vermeulen et al 1996a]. The marker also stains occasional plasma cells and 
megakaryocytes in formalin fixed sections. This can be due to the fact that endothelial cells 
contain several proteins, mainly glyproteins, which are antigenically related to proteins 
isolated from platelet membranes [Borsum et al 1987],
Horak et al [1992], Toi et al [1993] and Giatromanolaki et al [1997] showed that anti- 
CD31 antibody is more sensitive than anti-F8-Rag. The latter also reported that anti-CD31 
is more sensitive for highlighting small, immature microvessels or single endothelial cells.
A recent study showed that it has a weaker endothelial staining than anti-F8-Rag antibody
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[Martin et al 1997a], Horak et al [1992] reported that anti-CD31 is more sensitive than 
anti-CD34. In angiosarcoma, Parums et al [1990] showed that CD31 gave clear, strong 
staining compared with F8 or UEA-1 , particularly in areas of necrosis and haemorrhage.
Despite this fact the antibody has been recommended in the proposed standard method for 
intratumoral microvessel density assessment [Vermeulen et al 1996a], there are two major 
drawbacks to this marker. Firstly, it strongly cross-reacts with plasma cells [De Young et 
al 1993, Longacre et al 1994] which can significantly obscure the microvessels in tumours 
in the presence of inflammation. Secondly, the antigen is frequently lost in fixation in the 
presence of acetic acid. The latter drawback can be solved by means of microwave antigen 
retrieval [Vermeulen et al 1996a],
CD34
CD34 is a cell surface glycoprotein (cell adhesion molecule) that is selectively expressed 
within the human hematopoietic system on stem and progenitor cells, and in early blood 
vessels. It has a role in leukocyte adhesion and endothelial cell migration in 
neovascularisation [Fina et al 1990].
The antigen is a 105-120kDa single chain transmembrane protein which is expressed on 
most haematopoietic colony-forming cells from human bone marrow, including unipotent 
and multipotent progenitors [Civin et al 1984&89&90]. CD34 appears to be expressed at 
highest levels on the earliest progenitors, and to decrease progressively with maturation 
[Civin et al 1989], It is a stage-specific leukocyte differentiation antigen, which is present
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on B lymphoid progenitor cells [Civin et al 1989, Loken et al 1989]. The antigen is 
encoded by a gene located on chromosome 1 [Molgaard et al 1989].
Anti"CD34 antibody is an IgGl antibody and can be raised by injecting mice with 
endothelial cell membranes obtained as vesicles from human placenta by injecting a 
chemical vesicant N-methyl maleimide [Watt et al 1987]. The antibody detects the 
formalin resistant epitope on the endothelial cells lining all types of vessels. The antibody 
(clone QBEnd/10) is a class II [ defined from the sensitivity of the corresponding CD34 
epitopes to degradation to enzymes ] monoclonal antibody that recognizes a CD34 
epitope which is resistant to neuraminidase, and sensitive to glycoprotease and 
chymopapain [Sutherland et al 1992]. In addition, the data accumulated by Fina et al 
[1990], indicates that the binding of the CD34 antibody to vascular endothelium is to the 
CD34 gene product, and not to cross-reactive epitopes.
The anti-CD34 antibody is a sensitive endothelial marker which stains small and large 
vessels in normal and tumour tissue equally [Vermeulen et al 1996a]. This marker also 
highlights perivascular stromal cells and a proportion of lymphatic vessels [Vermeulen et 
al 1996a]. According to a recent study by Martin et al [1997a], the marker is more 
sensitive, more reproducible and gives consistently higher vessel counts than anti-F8-Rag 
or anti-CD31 antibodies.
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other endothelial markers 
Thrombomodulin (TM)
Thrombomodulin (TM) is an endothelial cell-associated protein (cell-surface receptor) that 
functions as a potent natural anticoagulant through its cofactor role in the thrombin- 
catalyzed activation of human protein C [Bourin et al 1988, Preissner et al 1990]. It 
converts thrombin from a pro-coagulant protease to an anticoagulant and inhibits the 
activity of thrombin [Bourin et al 1988, Preissner et al 1990]. It is widely distributed in 
normal human tissues, such as endothelial cells of blood vessels, lymph vessels and 
syncytiotrophoblasts in placenta [Maruyama et al 1985]. It was recently reported by 
Calneck et al [1998] that the TM-dependent anticoagulant activity is regulated by VEGF, 
a pro-angiogenic factor.
TM has been shown to be a specific and a highly sensitive marker for angiosarcoma in 
comparison with F8-Rag or UEA-I [Yonezawa et al 1987]. It had been reported that the 
decreased TM expression could be associated with métastasés of tumour cells [Tesuka et 
al 1995, Suehiro et al 1995, Collins et al 1992]. In a study by Kim et al [1997], low 
expression of TM in invasive breast carcinoma was significantly associated with a high 
relapse rate. The authors proposed that TM might have a role in cancer invasion and 
metastasis as well as could have prognostic values.
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Ulex europeus agglutinin I (UEA-I)
Ulex europeus agglutinin I (UEA-I) is a lectin that reacts with alpha-L-fucose in a variety 
of cell types [Holthofer et al 1982]. It is a pan-endothelial marker which stains small and 
large vessels in normal as well as tumour tissue [Vermeulen et al 1996a]. It also stains 
lymphatic vessels. It is limited by its low specificity and reproducibility [Ordonez et al 
1984]. UEA-1 shows variable staining of angiosarcoma cells [Miettenen et al 1983] and is 
not specific for endothelial cells, binding to squamous cell carcinomas and synovial 
sarcomas [Allés et al 1988] as well as to neoplasm arising from colonic epithelium 
[Yonezawa et al 1983]. It is a less reliable marker for malignant endothelial cells and may 
be less specific for endothelial cells of cardiovascular origin [Parums et al 1990].
It has been claimed that it is a more sensitive marker than F8-Rag and works well in 
paraffin wax sections [Miettenen et al 1983]. Stephenson et al [1986] reported that it is a 
more reliable endothelial marker of vascular endothelium in follicular carcinoma of the 
thyroid than F8. Furthermore, according to Yonezawa et al [1987], UEA-I is more 
sensitive for benign vascular tumours than thrombomodulin or F8,
Mab E9
This monoclonal antibody was developed by Wang et al [1993&94]. It was raised against 
proliferating endothelial cells of human umbilical vein origin. The antibody is very sensitive 
to small intratumoral vessels of all tumours, vessels in regenerating or inflamed tissues, 
and vessels in fetal organs [Vermeulen et al 1996a]. It is highly specific with only weak 
staining in normal tissue vessels [Vermeulen et al 1996a]. The drawback for this new
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marker is that most of the corresponding antigen is lost during tissue fixation and paraffin 
embedding [Vermeulen et al 1996a]. E9 and another new marker, TEC-II, are both 
directed at endoglin (CD 105) which resembles the TGFbeta type III receptor, and 
antibodies directed at members of the cell adhesion molecule family integrins [Weidner et 
al 1991], which might react more specifically to the fraction of endothelial cells affected by 
the angiogenic drive of the tumour/host.
Kumar et al [1999] using anti-CD 105 and anti-CD34 antibodies in the assessment of 
microvessel density in breast cancers found that vessel counts using anti-CD 105 
antibodies, but not anti-CD34 antibodies, showed a significant correlation with overall or 
disease-free survival. Multivariate analysis also confirmed that microvessel density using 
anti-CD 105 antibodies was an independent prognostic factor.
Tie2
Tie2 is a monoclonal antibody against the endothelial Tie receptor tyrosine kinase [Salven 
et al 1996, Peters et al 1998]. So far, it has been used in the assessment of breast cancer 
angiogenesis with favorable results. Several authors proposed that it is an antigenic marker 
for evaluation of tumour angiogenesis [Salven et al 1996, Peters et al 1998].
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Potential pitfalls in assessment of microvessel density (Weidiier’s method)
MVD has been shown to be an independent prognostic factor for disease-free or overall 
survival in a variety of solid tumours. However, conflicting results have been produced by 
a number of studies. The discrepancies can be due to performance of different endothelial 
markers (antibodies) for immunostaining and the lack of consistency in the methodology 
for vessel counting, selecting sections of representative tumour block and selecting ‘hot­
spots’. Furthermore, conflicting results can be secondary to inaccurate staging, inadequate 
patient follow-up, biased case selection and inappropriate statistical data analysis.
Selection of a representative block is very precarious in the presence of heterogeneity 
between different blocks from the same tumour. De Jong et al [1995] showed a high 
average coefficient of variation of 24% if more than one tissue block was assessed as 
compared to 15% when only counts within one section of one block were made. They 
proposed that single sections should be taken from multiple blocks and each should be 
scanned to localize the ‘hot-spots’. However, Martin [Martin et al 1997b] assessed MVD 
in sections from each end and one from the centre of the tumour. They reported that 
vessel counts among blocks varied by less than 20% in 14 out of 20 cases (70%). The 
results were similar to those shown by Van Hoef et al [1993], De Jong et al [1995] and 
Bo sari et al [1992]. Martin [Martin et al 1997b] suggested that a tumours’ angiogenic 
potential can be assessed on one histological section making this technique suitable for 
clinical practice.
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Ideally, proper scanning at low magnification for ‘hot-spots’ requires low background 
staining and a highly specific and intense labeling of endothelial cells. Most of the current 
antibodies (endothelial markers) are not able to fulfill this requirement. This makes the 
training and experience of the investigator extremely important. Barbareschi et al [1995] 
reported that only the counts of experienced investigators were significantly associated 
with relapse-free survival in both univariate and multivariate analysis. In a case-control 
study by Vermeulen et al [1995b], the prognostic value of MVD in a sample set of node­
negative breast cancer patients was shown. For experienced investigators, a cut off point 
could be identified for which a significantly different distribution of MVD for an 
unfavorable versus a favorable outcome group was present. This was not obseiwed for 
inexperienced investigators. When the counts of two experienced investigators were 
compared according to their median, agreement was reached in 76% of cases. Axelsson et 
al [1995] reported a agreement ratio of 73%.
In early studies of MVD as a prognostic indicator, the histological sections were scanned 
at low magnification (x40 and xlOO) for ‘hot-spots’. These were more likely to be found 
at the margins of the tumour (‘leading edge’), only one x200 microscopic field was then 
assessed for microvessel density. In subsequent studies, between 1 and 5 ‘hot-spots’ were 
counted and MVD recorded either as the highest count [Weidner et al 1991, Horak et al 
1992, Gasparini et al 1994a] or as the mean of three, four or five fields [Bosari et al 1992, 
Toi et al 1993, Van Hoef et al 1993, Hall et al 1992, Miliaras et al 1995, Ogawa et al 
1990]. The rationale is that the intratumoral vessel density is heterogeneous and the blood 
vessel invasion (systemic dissemination) of tumour cells is more likely to occur in the areas
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of highest vessel density [Horak et al 1992], The question is : What is the optimum 
number o f ‘hot-spots’ considered to be desirable? Martin et al [1997a] assessed the 
current methodology by scanning for ten hot-spots at low magnification followed by 
point-counting stained vessels at x200 magnification. The apparent ‘hot-spot’ selected at 
low magnification often did not contain the highest MVD at high magnification. The first 
count was the highest in only 20% of cases. As for the apparent highest five fields, the 
highest count was only found in 65% of cases. The authors suggested that counting ten 
fields reduced the chance of missing the most vascular area as well as shortening the 
training period for prospective investigators.
Weidner et al [1991] suggested an optimum field size of 0.74mm2 at high magnification in 
order to count the labeled microvessels. However, a wide range of magnification and 
related field sizes have been applied with conflicting results in the assessment of MVD. 
These range from 0.12 to 1.00 mm2. A small area at higher magnification tends to allow 
the identification of more single endothelial cell sprouts. Vermeulen et al [1996b] reported 
a 2-fold higher MVD at magnification x400 than at magnification x200 in breast cancer 
sections. An area larger or smaller than the ‘hot-spot’ will result in loss of information. 
Weidner et al [1991] showed that as counting area decreased from an optimal size of 0.74 
mm2, statistical power for predicting outcome diminished. The deviation from the 
Weidner procedure is likely to be one of the contributing factors why Hall et al [1992], 
Van Hoeff et al [1993], Axelsson et al [1995] and others failed to show the prognostic 
value of MVD in solid tumours.
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Regarding the definition of microvessel at high magnification, strict application of 
objective criteria is likely to result in low inter-obsei*ver variability when analyzing ‘hot­
spots’ [Vermeulen et al 1996b], Hall et al [1992] believed that a lumen was necessary for 
definition of a vessel and that single cells were frequently not of vascular origin, which 
may partly explain why they failed to relate the MVD to metastasis in breast carcinoma.
Other methods of MVD assessment 
MVD grading
This is a semi-quantitative grading system which is rather subjective and requires a long 
period of training to achieve comparable results between different obsei*vers. The method 
is time-efficient but unlikely to be suitable for multi-centre trials involving MVD 
assessment. It was reported that there is a relationship between MVD grading and 
quantitative MVD [Guidi et al 1994]. Weidner et al [1992] showed that both quantitative 
and semi-quantitative MVD scores were significantly related to the RFS and OS in breast 
cancer patients.
By means of anti-CD34 antibodies on 836 patients, Hansen et al [2000a] showed vascular 
grade was significantly associated with axillary node involvement, tumour size, malignancy 
grade, oestrogen receptor status and histological type. In univariate analysis, vascular 
grade significantly predicted recurrence free survival and overall survival for all patients, 
node-negative patients and node-positive patients. Cox multivariate regression analysis 
showed that vascular grading contributed independent prognostic value in all patients.
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Clialkley counting
This method was developed by Fox et al [1995], It involves scanning the histological 
section at low magnification for ‘hot-spots’. At high magnification (x200-250), an 
eyepiece graticule containing 25 randomly-positioned dots is rotated so that the maximum 
number of dots are on or within the vessels of the ‘hot-spots’. Then, the dots are counted. 
Fox et al [1995] showed that there is a significant correlation between MVD assessment 
according to the Weidner method and Chalkley point counting. It was also reported that 
this method had independent prognostic value in breast [Hansen et al 2000a] and 
transitional bladder carcinoma [Dickinson et al 1994]. Gasparini et al [1996] found the 
Chalkey score was the strongest significant independent predictor of outcome as well as 
being useful for studies of angiogenesis between multicentres. Even though the selection 
for ‘hot-spots’ remains subjective, no decision is needed on whether adjacent stained 
stmctures are separate microvessels or otherwise.
Hansen et al [1998] showed that the Chalkey method has less observer variation in 
comparison with other MVD methods and suggested that the former may be superior from 
a methodological point of view. The same author [Hansen et al 2000b] also showed a 
significant correlation between high Chalkey counts and axillary lymph node metastasis, 
large tumour size, high histological malignancy grade, and histological type. A high 
Chalkey count showed a lower probability of recurrence-free survival and overall survival.
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Multiparametric computerised image analysis systems (CIAS)
The advantage of this system is that it is able to measure the number of vessels within a 
certain dimension range, the vessel lumen area, the vessel lumen perimeter and the 
percentage of immunostained area per microscopic field. The main drawback is the 
heterogeneity of microvessel morphology such as size, length and anastomoses; and the 
locoregional differences in immuno staining intensity.
In a study involving node-negative ductal carcinoma patients, Barbareschi et al [1995] 
showed that MVD measured by experienced investigators and the microvessel area -  
consisting of the endothelial cells plus the vessel lumen, measured by CIAS, were 
independently associated with RFS. This suggested that the prognostic value of 
microvessel area is less dependent on the experience of identifying ‘hot-spots’. In breast 
carcinoma, Dickinson & Fox et al [1994] found a significant correlation between manual 
Chalkey counting and microvessel area, microvessel perimeter and microvessel number 
measured by CIAS.
The apparent disadvantage of interactive computer-aided IMD measurements is the time- 
consuming nature of the method. Automated hot-spot selection would solve both this 
problem and the problem related to the subjectivity associated with manual IMD 
assessment, Fox et al [1995] were unsuccessful in their attempt to perform completely 
automatic quantification, due to the extremely low level of interference of non-microvessel 
structures allowed by CIAS. Highly specific endothelial cell markers are needed and 
variations in staining intensity have to be eliminated or compensated for, for example, by
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automatic background subtraction. The use of reference slides and adjustment of fixation 
techniques in multicentre studies have to be considered.
In conclusion, CIAS seems to provide additional information on the morphology of the 
tumour vasculature. Most studies seem to indicate that MVA, EA, and MVP are a 
quantitative reflection of the degree of pathophysiological involvement of tumour 
angiogenesis in tumour progression. Integration of IMD. MVA, EA, and MVP with 
information of the activity status of the tumour-related endothelium might provide a more 
dynamic picture of the vascular component of a tumour. CIAS might be introduced as a 
more objective method of microvessel quantification and eventually to perform automated 
hotspot selection. The high signal-to-noise ratio of the immunostaining required for CIAS 
IMD assessment might result in a considerable number of tumour sections unsuitable for 
evaluation. Aitificial intelligence-based pattern recognition systems with a learning 
capability might have to be developed to counter the inherent degree of irreproducibility 
related to immunohistochemical techniques.
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Complemeiitaiw methods of assessing angiogenesis
These methods are complementary to the histological quantification of angiogenesis. 
Generally, they provide non-invasive analysis of the whole tumour as well as allowing 
repetitive sampling throughout the treatment of the tumours, including during the follow- 
up sessions.
Doppler ultrasound scan
It has been proposed that colour Doppler ultrasound may have a role in the non-invasive 
differential diagnosis of breast lesions [Cosgrove et al 1990]; where malignant lesions to 
be colour Doppler positive (moderate to high flow signals) and benign lesions negative (no 
flow signals). A study showed that although the colour Doppler mapping is useful in 
distinguishing benign from malignant breast lesions, the intensity of signal and velocity of 
flow had no correlation with the extent of angiogenesis of breast cancer [Lee et al 1995]. 
They did, however, find that the presence of a high-flow tumour signal in early breast 
cancer is significantly associated with the presence of axillary lymph node métastasés.
Serum and tissue sampling of angiogenic peptides
In colorectal carcinomas, more than 80% of pre-operative patients were found to have 
elevated serum levels of bFGF and /or VEGF. This was reduced to 33% post-operatively. 
Yamamoto et al [1996] reported significant elevated serum VEGF in patients with 
advanced primary breast cancer compared with those at an early stage. The pre-operative 
VEGF serum levels were elevated in association with an increase in MVD. The levels 
dropped in the majority of the patients after surgery.
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Increased serum levels of bFGF and VEGF were obseiwed in patients with metastatic 
colorectal, breast, ovarian and renal carcinoma [Dirix et al 1997]. Furthermore, levels of 
bFGF have been reported to be elevated in the urine of patients with a variety of cancers 
[Nguyen et al 1994].
Contrast-enhanced MRI scan
Hulka et al [1995] and Esserman et al [1996] reported that the kinetic profiles of contrast 
uptake and washout in contrast enhanced MRI appeared to correlate with tumour grade 
and MVD in breast cancer. In an animal model, MRI derived tumour tissue plasma volume 
increased exponentially with increasing histological vascular density [Van Dijke et al 
1996].
In DCIS, it was suggested that angiogenesis might play a role in the contrast enhancement 
on MR angiogram of this pre-invasive tumour [Giles et al 1995]. Contrast-enhanced MRI 
is considered to be inferior to mammography in the detection of DCIS because the 
induced angiogenesis is relatively faint and difficult to be detected by the scan [Friedrich et 
al 1998]. Bone et al [1998] showed that there was a significant correlation between 
contrast enhancement at MR scan of breast cancer and both tumour angiogenesis and 
proliferative cellular activity as shown by PCNA immunoreactivity. There was also a 
correlation between contrast enhancement and both tumour grade and invasiveness. The 
authors suggested that MR scan could turn out to be a valuable prognostic tool in breast 
cancers.
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Parameters measured by both techniques (serum and tissue sampling of angiogenic 
peptides/contrast-enhanced MRI scan) seem to be related to tumour progression or grade 
rather than simply to tumour volume. This aspect offers promising perspectives for their 
use in monitoring tumour response during treatment or in predicting tumour relapse. 
However, it will be necessary to determine the net balance between angiogenic growth 
factors and natural angiogenesis inhibitors.
Assay Quality Control
It would seem to be a reasonable objective that results produced by a given laboratory for 
each assay are consistent over time and that results produced by different laboratories 
from the same samples are comparable. At least one published study has investigated 
within- and between-laboratory variation in Elisa results in the USA (Kreider 1991b). 
Results varied significantly and substantially among different laboratories (the greater 
source of variation) and among different days in the same laboratory. This suggests that 
single determinations on individual serum samples are not likely to give a reliable estimate 
of antibody titre. The large variability within laboratories further indicates the need for 
standard reference pools of positive serum to be included in assays in order to substantiate 
assay results.
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Murray et al [1993] have discussed in some detail the sources of variability of assay 
results. While these authors concentrated on biochemical assays the same basic principles 
apply equally well to serology. Each assay must be validated to identify and quantify 
sources of variation in results. We must also keep in mind that there are non-assay sources 
of variation. These can be grouped into those factors which precede the assay (how and 
when a sample is taken, how it is manipulated, stored, transported, and identified) and 
those which come after (for example transcription errors in report generation). In 
validating an assay the following areas need to be addressed :
1. Specificity - A highly specific assay will have a low tendency to show "false positive" 
reactions in animals exposed to a closely related pathogen. This can be tested by 
obtaining mono-specific sera raised against a range of other pathogens and including 
them in the test.
2. Sensitivity - This is a measure of the ability to detect clinically important but very low 
levels of antibody. There will sometimes be a trade-off in that the higher the sensitivity 
of an assay the lower its specificity. In poultry production it is common practice to 
apply a highly sensitive technique as a screening test in order to identify problem 
flocks or individuals, then apply more specific tests only to these or on repeat sampling 
of the flock. The sensitivity of a test can be evaluated by diluting known positive 
samples sequentially and determining the dilution at which the reaction is lost.
3. Accuracy - This is a measure of the ability of the test to measure purified amounts of 
the substance sought when it is added in measured amounts to a typical test sample. 
Rarely will we have purified antibody available for this type of study but neither is this
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required in that we will not be reporting results in "milligrams of antibody". If known 
positive field sera are available then they can be used as a pool in repeated assays. This 
will be most valuable if this pool is also submitted to a reference laboratory for testing 
using a recognized and already validated procedure. The alternative is to take purified 
mono-specific antiserum and use this to "spike" sero-negative field serum at different 
concentrations then use the spiked samples to establish a measure of the variability of 
the assay results within a given sample.
4, Precision - This is the ability of the assay to consistently reproduce a result when sub­
samples are taken from the same specimen. Within-assay and inter-as say precision are 
two distinct measures of this can be made as part of the validation procedure. The 
formulae used for the calculation of CV% are slightly different from the conventional 
formula (Standard Deviation divided by the mean and multiplied by 100).
Within-assay precision
Assay 10 duplicated samples on the same plate (a total of 20 assays) and calculate an
intra-assay coefficient of variation as follows:
Mean o f the Standard Deviations o f the Duplicates
—  —  —  -  %  100
Grand, mean o f the duplicates
A figure of 10% or less is considered satisfactory [Murray et al 1993]
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Inter-assay Precision
In this case the 10 mns on duplicate samples are run on different days. For each mn the 
mean, the deviation, and the % C.E. are calculated. The interassay coefficient of variation 
is calculated from the formula:
Standard Deviation o f the means o f the duplicates
------------------------------------ --------------------------------------------------- X 100
Grand Mean o f the Duplicates
Much of the validation work described here will, in the case of commercially available 
antigens and test kits, be carried out by the manufacturer. A good first step in setting up a 
serological quality assurance system will be to request the manufacturer to provide data on 
with-run and between-assay precision. The laboratory can then quickly validate the assay 
using known positive and negative sera. Once an assay has been validated the continued 
satisfactory performance should be monitored by the use of a Quality control system.
This system should include a definition of criteria for assay acceptability, along with a 
means for identifying sources of variation and implementing corrective procedures. One 
component of such a system might be to repeat an Inter-assay Precision test. Alternatively, 
simply calculate the %CV for all assays of each standard control serum each month and 
plot the results over time. A reasonable target for %CV in routine testing is 10-15%.
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The prime aim of in-house quality assessment is to confirm that the results generated are 
consistent over time. Laboratories may also participate in inter-laboratory quality 
assurance schemes with a view to ensuring uniformity of results between different 
laboratories. Accreditation schemes take this a step further by independently checking 
procedures and standards, often with a periodic inspection. The only scheme currently 
operated in the UK which has a component specific to avian serology is the accreditation 
scheme îov Mycoplasma gallisepticum mid M.meleagridis testing operated by the Ministry 
for Agriculture Fisheries and Food. For a detailed discussion of the concepts behind 
quality assessment and accreditation schemes the reader is referred to Manser et al [1994]. 
At every point in the validation and QA of assays it is important that staff be educated and 
motivated. It is equally important for those interpreting the results to understand the 
inherent variability of the results and to be able to express an opinion by comparing them 
with "population means". This may lead to a decision which will take into account 
information from a variety of sources.
115
Section 3
Chapter 4 
Merseyside DCIS Review
Introduction
I carried out this study to demonstrate that recurrence in DCIS and transformation from 
in-situ to invasive ductal carcinoma is important clinically. In other words, angiogenesis in 
DCIS is a useful question to study and my hypothesis has clinical relevance. Another 
reason for this study was to recruit DCIS cases detected in Merseyside for my subsequent 
laboratory work in angiogenesis in DCIS.
The NHS Breast Screening Programme is set up to save lives by detecting breast cancer 
early. DCIS is a non fatal disease, however, if it progresses to the development of 
invasion, a significant morbidity and mortality are associated. Furthermore, the majority of 
DCIS cases detected are those of high nuclear grade and if progression occurs then these 
patients are more likely to develop high grade invasive carcinomas. The majority of studies 
that have been published to date on DCIS and its recurrence rate have not been in the 
screened population. It is therefore difficult to know whether these results can be 
extrapolated to the NHS breast screening population.
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DCIS is a heterogeneous disorder varying in cytology and architecture. Some histological 
features, particularly nuclear grade and necrosis, are associated with an increased risk of 
local recurrence [Badve et al 1998, Lagios et al 1995, Silver stein et al 1995a]. Lesion size 
and excision margin status are also important histological features that predict for 
recurrence. These histological parameters have been combined into the Van Nuys 
Prognostic index (size, excision margin, necrosis and nuclear grade) [Table 4 J \  and have 
been shown to predict for the risk of recurrence in DCIS that has been treated with breast 
conservation in North America better than the individual parameters [Silverstein et al 
1996]. However, the pathological classification of DCIS used in this index is not 
standardly used in the National Health Service Breast Screening Programme (NHS BSP). 
It is therefore important to determine if the VNPI is valid in DCIS detected in the NHS 
BSP, and if VNPI can be modified to use the pathological data routinely detected in the 
National Screening Programme.
Score 1 2 3
Size (mm) < or =15 16 to 40 > or =41
Margin width 
(mm)
> or =10 1 to 9 <1
Pathologic Non high grade Non high grade High grade with
classification without necrosis with necrosis or without 
necrosis
Table 4.1, Van Nuys Prognostic Index
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Patients and methods
With assistance from North-west Breast Screening Quality Assurance Co-ordinators, I 
obtained a list of DCIS patients in Mersey region. At the same time, I scanned the 
Pathology database in RLUH for symptomatic patients. I reviewed the case sheets of these 
355 patients and recorded relevant details as follows:
• Family history, menstrual status
• Detection: date, method, presentation, side affected, examination findings. X-ray 
findings
• Treatment: date, operation, adjuvant therapy
• Histology data
• Most recent follow-up: date, alive?, recurrence(s)?
Cases of DCIS with microinvasion were excluded. I also applied the VNPI and 
modified VNPI (using only grade) to those with pure DCIS treated by breast 
conservation with or without adjuvant therapy.
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Results
Data from 355 patients with DCIS was assessed. The patients had a mean age of 57 years 
(range 35-83) and mean follow up of 51 months (range 1-252). 80% of the cases were 
screen-detected. 97% of patients were still alive and only one patient had died of breast 
cancer. The patients had undergone a number of different treatment modalities and these 
included mastectomy or wide local excision with and without adjuvant hormonal treatment or 
radiotherapy. The recurrence rates and types of recurrence following individual treatment 
combinations is summarised in Table 4.2 and Figs. 4.1 &4. 2. The majority of patients 
underwent a wide local excision rather than a mastectomy and most of the patients received 
adjuvant tamoxifen but no radiotherapy. The overall five-year recurrence rate was 13%. The 
recurrence rate was highest (28%) in those patients treated with wide local excision alone 
and lowest in those patients that had adjuvant radiotherapy or had a mastectomy with 
adjuvant tamoxifen.
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WLE WLE/T WLE/Rx WLE/Tam/Rx Mx Mx/Tam Total
Number 57 115 8 26 68 82 355
In-situ
recurrence:
number
(%)
10
(17.5)
10
(&7)
— — 0
(0)
— 20
Invasive
recurrence:
number
(%)
6
(10.5)
4
(3 3)
- - — 2
(3)
“ “ 12
Total
recurrence:
number
(%)
16
(28)
14
(12)
0
(0)
0
(0)
2
(3)
0
(0)
32
Table 4.2. Comparison of outcome among different treatment modalities in DCIS. 
Abbreviation: wide local excision (WLE), tamoxifen (Tam), radiation (Rx), 
mastectomy (Mx)
2 15
ra <o
Figure 4.1. Treatment: number on top of each column shows percentage of patients in 
each type of treatment, number in bracket under the column shows number of patients 
in that treatment.
Abbreviation: wide local excision (WLE), Tamoxifen (Tam), radiation (Rx), 
mastectomy (Mx)
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Figure 4.2. Treatment and outcome: number on top of first column shows number of 
patients in each type of treatment, number on top of second column shows number of 
recurrence, number in bracket under both columns shows percentage of recurrence in 
each type of treatment.
Abbreviation: wide local excision (WLF), Tamoxifen (Tam), radiation (Rx), 
mastectomy (Mx)
O f the 32 recurrences, 12 (37.5%) were invasive o f which 3 had regional nodal 
involvement and 1 had bone marrow involvement. The patient with bone marrow 
metastasis eventually died o f breast cancer. The break-down o f  recurrences are shown in 
Table 4.3.
Treatment DCIS Invasive Local
Invasive
Regional Nodes Metastatic
WLE 10 6 5 1 0
WLE/Tam 10 4 3 1 0
Mx 0 2 0 1 1
Table 4.3. Break down of recurrences in the study.
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In addition, there were 8 cases o f contralateral breast cancers o f  which half were invasive. 
None o f  those patients given adjuvant Tamoxifen treatment developed contralateral [Fig. 
4 .3 1
60
A,
Figure 4.3. Treatment and contralateral event: number on top of first column shows 
number of patients in each type of treatment, number on top of second column shows 
number of contralateral event.
Abbreviation: wide local excision (WLE), Tamoxifen (Tam), radiation (Rx), 
mastectomy (Mx)
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The VNPI and modified VNPI (NHS breast screening program nuclear grade substituted 
for the Van Nuys histopathological grade) were applied to 104 patients with pure DCIS 
treated by breast conservation with or without adjuvant therapy that had undergone 
histopathological review. The whole series could not be assessed as a size measurement 
was not available for all. The findings are shown in Table 4.4.
VNPI Modified VNPI
High Intermediate Low High Intermediate Low
Number 9 16 19 9 15 20
Recurrence:
number 2 4 2 2 4 2
(%) (22.2) (5.2) (10.5) (22.2) (5.3) (10)
Table 4.4. Comparison beUveen conventional and modified VNPI on patients with 
breast conservation treatment.
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The results with both the VNPI and the modified VNPI were very similar. Both a high 
VNPI and high modified VNPI predicted for an increased likelihood o f  recurrence. Taking 
treatment into account, the highest recurrence rate was in those with a high VNPI and 
wide local excision only 1/3 (33.3%), this recurrence rate was reduced by Tamoxifen 1/5 
(20%) and abolished by radiation 0/1, however, the numbers in each group are very small 
[Fig. 4.4].
35 r
30 -
g 25 -
0)uc 20 -
0)fc 15 -3u
0) 10 icc 5 -
0 4 -
33.3
16.7
3 to 4 5 to 7 8 to 9
WLE
WLE/Tam
WLE/Rx
WLE/Tam/Rx
VNPI
Figure 4.4. Breast conser\^ation treatment in patients with different VNPI and 
outcome. None of those patients who had adjuvant radiotherapy recurred 
Abbreviation: wide local excision (Ex), Tamoxifen (Tam), radiation (Rx)
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Discussion
The local recurrence rate for DCIS ranges from 10-40%, and is dependant on tumour 
histology, type of treatment, and length of follow-up [Silverstein et al I995a&b,
Silverstein et al 1996, Solin et al 1993, Bellamy et al 1993, Fisher ER et al 1995, Fisher B 
et al 1998]. Silverstein [Silverstein et al 1992] showed that the local recurrence rates 8 
years after treatment for DCIS patients who had mastectomy, excision with adjuvant 
radiotherapy and excision alone were 0.5%, 16% and 21% respectively. The NSABP-06 
was a randomised trial to compare local excision alone, breast-conservation treatment, 
and mastectomy in patients with early invasive breast cancer [Fisher et al 1989]. A subset 
of 76 patients was found to have DCIS on subsequent pathologic review [Fisher et al 
1991]. 7% (2/27) of these patients who had wide local excision with adjuvant radiotherapy 
and 43% (9/21) who had wide local excision alone developed ipsilateral recurrence. No 
tumour recurrence was reported in the mastectomy group (n=28). In this series, wide local 
excision alone was associated with a high rate of local recurrence (28%) as compared with 
those of wide local excision with radiotherapy (0%) or mastectomy alone (3%).
Local recurrence after conservative treatment is demoralising and it causes marked patient 
morbidity. It is associated with invasive carcinoma in up to 50% of cases [Silverstein et al 
1995a&b and 96, Solin et al 1993&94&96]. In this study, 37.5% (12/32) of the 
recurrences were invasive. An invasive recurrence in a patient previously treated for DCIS 
upstages that patient from stage 0 disease to at least stage I breast cancer. This does have
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profound implications as invasive recurrence is a potential threat to life. One patient in this 
series died of breast cancer which recurred as invasive carcinoma with distant métastasés.
Nuclear grade, the presence of comedo-type necrosis, tumour size, and the excision 
margin are important factors which are able to predict local recurrence in patients with 
DCIS [Silverstein et al 1992&95a&95b&96&97c, Fisher B et al 1998, Lagios et al 1989]. 
However, the index uses the Van Nuys pathological classification and this is not 
standardly used in the NHS Breast Screening Programme. The screening programme 
instead stratifies DCIS according to nuclear grade. I therefore substituted nuclear grade 
for the Van Nuys pathological classification and found that stratification of patients into 
the Van Nuys Prognostic Index were similar and correlated with the risk of recurrence. It 
therefore appears that the index is still a useflil tool when data from the NHS Breast 
Screening Programme is used.
To sum up this clinical data, the treatment for DCIS varies widely and so do the 
recurrence rates. These recurrences have huge impact on the patients as well as resource 
implications. However, the patients’ concern at diagnosis is always for long term survival 
and therefore to avoid the risk of invasive recurrence. As shown in my previous literature 
review, present methods of histological assessment are inadequate to predict the clinical 
outcome and to provide the patients with the best possible, and most reliably informed 
treatment choice. This clinical data shows the importance of studying angiogenesis in 
DCIS.
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Chapter 5
Literature review & pilot study conclusions
After the literature review and pilot study, I conclude that;
• current histological classifications are inadequate to predict the development of 
invasive disease,
• no pathological or molecular features have been identified to predict the risk of 
recurrence or malignant transformation in DCIS,
• the best treatment of DCIS remains controversial,
• little is known of angiogenesis in DCIS; especially those with increased periductal 
vascularity,
• there is a need to study angiogenesis in DCIS and its prognostic value.
• assessments of angiogenesis in breast carcinoma have been mainly of stromal 
vascularity, and little work has been done on periductal vascularity
• highest microvessel counts (hotspots) have been used to assess stromal vascularity, 
which has been associated with inconsistent findings due to selection bias of hotspots 
at low power field
• most studies have employed a single anti-endothelial marker, and therefore have 
overlooked potential phenotypic changes of the microvessel
• no work has been done to correlate the stromal and periductal vascularity in DCIS
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Hypothesis
I hypothesize that:
• changes in vasculature are related to the progression of in situ to invasive carcinoma,
• the pattern and extent of periductal vascularity is related to the risk or potential for in 
situ or invasive recurrence in DCIS,
• the two vascular patterns in DCIS are related to one and another.
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Aim of the study
The aim of my study is to determine whether changes in vasculature (vascularity and 
phenotype) are related to the progression of in situ to invasive carcinoma and those factors 
that may predict for recurrences. The feature studied included periductal and stromal 
vascular density and phenotype in DCIS with and without invasive cancer and how this 
relates to the histological features, proliferative activity, and Thymidine Phosphorylase 
expression of the tumour. The relationship between the two vascular patterns is also 
examined.
Clinical releyance
While the majority of patients are cured by the treatment of their DCIS a small proportion 
go on to develop invasive breast cancer, and therefore have their life threatened by what, 
at initial presentation, was a curable disease. It may be that measurable changes in 
microvessel density and angiogenesis at diagnosis may predict these who will subsequently 
develop invasive cancer or recurrence, and therefore need more aggressive treatment 
following initial diagnosis,
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Section 2
Chapter 6 
Methodology
If angiogenesis is important in malignant transformation from in situ to invasive cancer, it 
is likely that MVD or vessel phenotype will be different around DCIS with invasive 
carcinoma compared with pure DCIS, Periductal vessels are likely to be most important in 
transformation from in-situ to invasive carcinoma as incipient invasion is most likely to be 
associated with changes in vessels in the immediate vicinity of the tumour cells.
Chapter 9
Periductal angiogenesis in pure DCIS and DCIS associated with invasive cancer 
My first experiment in chapter 9 was to compare the periductal angiogenesis in pure 
DCIS and DCIS associated with invasive cancer. Studies of breast cancer angiogenesis in 
the past have been associated with inconsistent findings, I therefore used rigorous 
morphometric methodology to compare vascularity in DCIS with normal breast and 
employed a panel of anti-endothelial antibodies to take account of potential phenotypic as 
well as numerical changes. As part of this study I also determined if vascular density and 
phenotype have any relationship to the histological features, of nuclear grade, necrosis and 
duct size. The correlation between MVD and endothelial density was also examined. 20 
consecutive cases of DCIS were examined in each group.
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Chapter 10
Proliferation in DCIS
MVD increased from low intermediate nuclear grade but decreased in high grade lesions, I 
therefore went on to measure proliferation in DCIS using Ki-67 and correlate this with 
MVD in chapter 10,
Chapter 11
Microvessel density and recurrence & dual staining immunofluorescene o f periductal 
blood vessels
MVD would be expected to be increased at diagnosis in those who subsequently 
developed a recurrence compared to those that did not. Periductal vessel density from a 
group of women with pure DCIS (no known development of recurrent disease) was 
compared with a group that subsequently developed recurrence either as in situ or 
invasive carcinoma. Out of 355 DCIS cases recruited in Merseyside with mean follow-up 
of 51 months, there were 20 cases of in situ and 12 cases of invasive recurrences 
respectively, and the MVD at diagnosis was measured in these cases and compared to 
those with no recurrence.
The results in chapter 9 suggest a phenotypic changes in the periductal vessels from 
normal lobules to DCIS, to DCIS with invasion. To confirm the above findings, I carried 
out dual staining immunofluoresence to determine the phenotype of individual periductal 
blood vessels.
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Chavter 12
Correlation between periductal and stromal vascularity & Thymidine Phosphorylase, 
periductal vascularity and recurrence
Having demonstrated that changes in periductal vascularity are associated with the 
presence of an invasive carcinoma and recurrence, I investigated the relationship between 
periductal and stromal vascular patterns and investigated which as a better prognostic 
marker in DCIS.
In addition, I investigated the association of Thymidine phosphorylase with the increased 
periductal vascularity previously identified and with disease recurrence. Thymidine 
phosphorylase is thought to have a role in endothelial cell migration [Risau et al 1992] and 
has been shown to be present within DCIS [Engels et al 1997b, Lee et al 1999].
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Chapter 7 
Materials
Sections
• Original haematoxylin and eosin (H&E) sections
• Formalin-fixed paraffin-embedded sections
• Slides
• Coverslips
Basic hardware and software
• Pressure cooker
• Microwave
• Microscope
• Image analysis (Zeis Axiohome with software version 3.0, Germany)
• Computer with SPSS package (Version 10.0 for Window 97/NT)
Primary antibodies
• Monoclonal anti-CD31 (JC/70A, DAKO, Denmark, Code No. M823)
• Anti"CD34 (Qbend/10, DAKO, Denmark, Code No. M7165)
• Anti-CD 141 (Anti-Thrombomodulin, DAKO, USA, Code No. M0617)
• Polyclonal anti-human von Willebrand factor, vWF (DAKO, Denmark, Code No. 
A082).
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• Polyclonal anti-Ki 67 antibodies (Novocastra Laboratories Ltd, Newcastle upon Tyne, 
UK)
• Monoclonal Thymidine Phosphorylase (Clone P-GF.44C, NeoMarkers, USA) 
Secondaiw antibodies
• Biotinylated sheep anti-mouse antibody (Amersham Pharmacia Biotech, Essex UK)
» Swine anti-rabbit TRITC Conjugated antibody (DAKO, Cambridge, UK)
• Swine a  Anti-Rabbit Immunoglobulin TRITC
Chemical solutions
Xylene
Industrial methylated spirits
Mixture of H202/methanol [12ml H2 O2 (30%) in 400 ml methanol]
0.2g of trypsin 
0.4g of calcium chloride
Tris Buffered Saline, TBS [50mM Tris-HCL, 150mMNaCl, pH 7,4]
Mixture of 5% BSA/TBS [Ig Bovine Semm Albumen in 20 ml TBS] 
Ethylenediamine-Tetraacetic Acid (ED2SS; Sigma Chemical, St Louis USA) 
Phosphate buffered solution
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Chromogen
• Envision Labeled Polymer (mouse or rabbit as appropriate)
• 33’ diaminobenzidine, DAB (chromogen)
• Commercial kit [DAKO EnVisionTM + System, Peroxidase (DAB), USA, Code No. 
K4010 (rabbit) and K4006 (mouse) ]
• Haematoxylin solution
• Flourescein Avidin DCS (A-2011; Vector Labs, Peterborough UK)
• 4’,6-diamidino-2-phenylindole (Sigma)
Mountant
• Resinous mountant (DPX, BDH Laboratory supplies, England)
• Anti-fading medium (Vectashield, Vector Laboratories, Peterborough UK)
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Chapter 8 
Methods
Patients and tumours
Formalin-fixed paraffin-embedded breast samples of patients with ductal carcinoma in situ 
were collected from the archives of the Pathology Department of the Royal Liverpool 
University Hospital and peripheral hospitals.
The original haematoxylin and eosin (H&E) stained sections from the primary tumour 
were reviewed by 2 pathologists (BS & IPS) for classification by architecture and nuclear 
grade following the guidelines of the European Commission and UK National Breast 
Screening Programme [National coordinating group for breast screening pathology 1997, 
The consensus conference committee 1997]. A representative block for each patient was 
selected for subsequent immunostaining.
Immunohistochemistrv
Sections were stained using monoclonal antLCD31 (JC/70A, DAKO, Denmark, Code No. 
M823), anti-CD34 (Qbend/10, DAKO, Denmark, Code No. M7165), anti-CD 141 (Anti- 
Thrombomodulin, DAKO, USA, Code No. M0617), polyclonal anti-human von 
Willebrand factor, vWF (DAKO, Denmark, Code No. AO82), polyclonal anti-Ki 67 
antibodies (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) and monoclonal 
Thymidine Phosphorylase (Clone P-GF.44C, NeoMarkers, USA).
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Sections were dewaxed through two changes of xylene and industrial methylated spirits. 
Endogenous peroxidase activity was blocked with a mixture of H202/methanol [12ml 
H2O2 (30%) in 400 ml methanol] for 12 minutes. Antigen retrieval was performed by 
treating the sections with 0.2g of trypsin and 0.4g of calcium chloride in 440 ml Tris 
Buffered Saline, TBS [50mM Tris-HCL, 150mM NaCl, pH 7.4] at 37°Cfor 20 minutes.
No pre-treatment was needed for the staining with Thymidine Phosphorylase antibodies. 
For staining with anti-Ki 67 antibodies, the sections were treated with 2000ml of 
Ethylenediamine-Tetraacetic Acid (ED2SS; Sigma Chemical, St Louis USA) in a pressure 
cooker for 8 minutes.
Prior to staining with the polyclonal antiserum, sections were treated with a mixture of 5% 
BSA/TBS [Ig Bovine Serum Albumen in 20 ml TBS] for 10 minutes. The antibodies were 
diluted 1:5 for anti-CD31, 1:10 for anti-CD 141, 1:20 for anti-CD34, 1:1000 for anti­
human vWF, 1:1000 for anti-Ki 67 and 1:100 for Thymidine Phosphorylase antibodies in 
5% BSA/TBS.
The sections were incubated with primaiy antibodies at room temperature for 40 minutes. 
Secondary antibodies were incubated for 40 minutes using EnVision Labeled Polymer 
(mouse or rabbit as appropriate). Sections were washed with TBS between incubation 
steps. 33’ diaminobenzidine, DAB was used as a chromogen. The last two steps were 
carried out using a commercial kit [DAKO EnVisionTM + System, Peroxidase (DAB), 
USA, Code No. K4010 (rabbit) and K4006 (mouse) ].
137
The cellular nuclei were counter-stained blue with Haematoxylin solution. The sections 
were dehydrated through four changes of IMS and three changes of xylene before being 
mounted in resinous mountant (DPX, BDH Laboratoiy supplies, England). Omission of 
the primary antibody was used as a negative control and the microvessels of the normal 
adjacent breast tissue served as internal positive controls.
Assessment of tumour periductal vascularity
Vascular density was determined without knowing how the architecture or nuclear grade 
had been classified. No scanning of stained microvessels or endothelial cells to identify 
‘hot-spots’ at low magnification was undertaken. The assessment of completely transected 
involved ducts started from the upper right of all stained sections, moving downwards and 
to the left. All or the first 50 foci (duct cross sections) encountered were assessed on each 
section, thus eliminating selection bias. Up to three representative histological sections for 
each patient were chosen by two pathologists. These sections on average have 30 foci of 
DCIS for each patient.
In the assessment of DCIS accompanied by invasive carcinoma, only those foci that were 
at least 2 mm away from the invasive component were assessed to minimize the detection 
of direct local effects of the invasive disease.
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Evaluation the area of DCIS
I measured the area rather the circumference because I intended to evaluate the vascular 
density using the formula under the heading of'Countingperiductal microvessels and 
endothelial cells ’ below. In addition, I planned to assess the relationship between 
periductal vascular density and the core size of DCIS.
Two areas were measured: a) the area of each DCIS focus (core area) and, b) the core 
area plus the area around the DCIS focus to a width of 100 micrometer from the edge of 
the individual focus of DCIS (total area). I chose to assess those vessels lying within 100 
micrometers from the edge of the tumour (each focus) because I believe these vessels are 
least likely to be affected by factors secreted by adjacent tumour (either invasive or 
DCIS). These areas were measured at x200 magnification using image analysis (Zeis 
Axiohome with software version 3.0, Germany). The peripheral area, where the 
microvessels or endothelial cells were counted, was obtained by subtraction of core area 
from total area [Fig. 8.1],
Peripheral area ^  Total area -  Core area
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Figure 8.1, Sin^lified diagram o f an individual focus o f ductal carcinoma in situ 
(DCIS) and peripheral area where the periductal microvessels were counted
edge of DCIS 
focus
peripheral area where 
microvesseis w ere counted
100 pm
core area of DCIS focus
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Counting periductal microvessels and endothelial cells
The microvessels and endothelial cells within the peripheral area were counted at high 
magnification (x400) for each focus. Eligible microvessels included any immunostained 
endothelial cell or cluster of cells around a visible lumen clearly separated from adjacent 
microvessels, tumour cells and other connective tissue components [Fig. 8.2-8.5], The 
presence of red blood cells was not required. It was not possible to distinguish blood and 
lymphatic vessels. Where vessels were in clusters, each was counted as separate if it met 
the above criteria. Endothelial cells were counted at the same time. Microvessel and 
endothelial density for each individual focus was calculated using the following formula:
Microvessel or endothelial density = Number o f microvessels or endothelial cells
Peripheral area
The assessment of microvessels and endothelial cells were carried solely by myself. I 
underwent three-month-training with two pathologists. The study only began once we 
reached an agreement ratio of at least 70%.
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Figure 8.2. Periductal microvessels stained with anti-vWF antibody (high power field).
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Figure 8.3. Periductal microvessels stained with anti-CD3l antibody (high power
field).
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Figure 8.4. Periductal microvessels stained with anti-CD141 antibody (high power 
field).
m
Figure 8.5. Periductal microvessels stained with anti-CD34 antibody (high power
field).
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Assessment of stromal tumour vascularity
Microvessel count was determined as described by Weidner et al [ Weidner N et al 1991]. 
Microvessels were assessed in the areas o f stroma containing the most capillaries 
(hotspots). Areas with high vascularisation were identified by scanning the sections at low 
power fields (x40 and xlOO) \Fig. 8.6\. Only those stromal areas at least 2 mm fi-om the 
edge o f the nearest tumour were assessed. Up to 30 individual highly vascularised areas 
were then examined at high power field (magnification: x200; field size: 0.32 mm^). The 5 
highest counts were recorded to give the data for hotspots (highest microvessel density), 
mean stromal M(5)VD (average o f 5 highest microvessel densities) and mean stromal 
M(3)VD ( average of 3 highest microvessel densities).
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Figure 8.6. Stromal microvessels stained with anti-CD34 antiho^ (low power field).
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Controls
Five normal lobules in the surrounding breast were used for internal controls and were 
assessed for microvessel and endothelial density in the same manner, The normal lobules 
were assessed only if they were situated more than 2 mm from the nearest tumour.
Evaluation of degree of necrosis
As part of the histological assessment, the degree of necrosis was semi-quantitatively 
assessed in sections of high grade DCIS from patients with and without invasive disease. 
There were three categories:
Area of necrosis Score
None 1
1- 50% 2
>50% 3
Quantification of Ki-67 staining
a) KU67 density (KD)
All or the first 50 foci of DCIS encountered were assessed on each section, thus 
eliminating selection bias. The core areas of DCIS foci were measured at the x200 
magnification using image analysis (Zeis Axiohome with software version 3.0, Germany). 
The Ki-67density for each individual focus was calculated by dividing the number of Ki-67 
positive cells in the focus with the corresponding core area of the tumour [Fig. 8.7 & 8.8], 
The mean Ki-67 density (MKD) was also calculated for each section.
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Figure 8.7. //<^A density o f  parenchymal cells (DCIS) positively-stained with anti-Ki67 
antibody (high power field).
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Figure 8.8. Low density o f parenchymal cells (DCIS) positively-stained with anti-Ki67 
antibody (high power field),
b) Ki-67 fraction/percentage (KP)
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On each section, the first 1000 tumour cells were counted randomly. The number of Ki- 
67 positive cells was expressed in percentage.
Assessment of Thymidine Phosphorvlase expression
Sections were examined at low power field (x40 and xlOO) [Fig. 8.9\. TP expression in 
carcinoma cells was both cytoplasmic and nuclear, with the former predominating. The 
nuclear and cytoplasmic staining was not separated, scoring was given to overall staining. 
The expression in cancer cells was evaluated both for intensity (0, negative; 1, weak; 2, 
intermediate; 3, strong) and percentage o f cell staining [Fig. 8. JO & 8.11]. The product of 
multiplication o f intensity and percentage o f cell staining were then added to produce a 
‘H-score’ with a range from 0 to 300.
Figure 8.9, Thymidine Phosphorylase expression in DCIS parenchymal cells (low 
power field).
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Figure 8.10. High intensity o f Thymidine Phosphorylase expression in DCIS 
parenchymal cells (high power field).
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Figure 8.11. Low intensity o f Thymidine Phosphorylase expression in DCIS 
parenchymal cells (high power field).
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Immiinocvtocheniistrv for dual immuiiostainiiig (vWF and CD341
Sections were dewaxed through two changes of xylene and IMS respectively. The sections 
were treated with 500 ml of Ethylenediamine-Tetraacetic Acid (ED2SS; Sigma Chemical, 
St Louis USA) in the microwave for 20 minutes. Prior to incubation with primary 
antibodies, sections were treated with a mixture of 5% BSA/TBS for 10 minutes. The 
antibodies were diluted 1:10 for anti-CD34 and 1:1000 for anti-human vWF in 5% 
BSA/TBS. The sections were incubated with primary antibodies at room temperature for 
40 minutes. Secondaiy antibodies were applied for 30 minutes using a biotinylated sheep 
anti-mouse antibody (Amersham Pharmacia Biotech, Essex UK) diluted 1:100 and a swine 
anti-rabbit TRITC Conjugated antibody (DAKO, Cambridge, UK) diluted 1:50. Sections 
were then incubated for 30 minutes using Flourescein Avidin DCS (A-2011; Vector Labs, 
Peterborough UK) diluted 1:100 and Swine a  Anti-Rabbit Immunoglobulin TRITC 
diluted 1:50. Sections were washed with TBS between incubation steps.
DNA was stained by immersion in a solution of 4’,6-diamidino-2-phenylindole (Sigma) at 
a concentration of 250 ng/ml in phosphate buffered saline for 10 min and coverslips were 
mounted onto the tissue sections in an antifading medium (Vectashield, Vector 
Laboratories, Peterborough UK). Control slides were included in each analysis by 
performing the same procedures and substituting non-immune serum for primary 
antibodies and secondary antibodies individually.
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Assessment of slides in dual immunostaining
Quantification of the fluorochrome-labeled vessels was performed as above. Each vessel 
was examined under a high power lens for the red (TRITC), green (fluorescein) and blue 
(4’,6-diamidino-2-phenylindole) fluorochromes using the appropriate filters in succession 
to assess the presence or absence o f double-labeled vessels. A triple band filter in which all 
three fluorochromes could be seen simultaneously was used for confirmation of dual 
staining. In my study, CD34- and vWF-positive endothelial cells stained green and red in 
colour respectively [Fig. 8.12 & 8.13].
Figure 8.12. High power field: CD34-, vWF-, and dual positive (in the middle) 
microvessels were present
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Figure 8.13. High power field: only CD34- and vWF-positive microvessels were 
present
Statistics
The differences of parameters were analysed using the Kruskal-Wallis method and Mann- 
Whitney U-test. The relationship between microvessels or endothelial density and a variety 
of histological features was assessed by means o f 2-tailed Spearman's or Pearson's 
Correlation test as indicated A p-value below 0.05 was considered statistically significant. 
All analyses were undertaken using the SPSS package (Version 10.0 for Window 97/NT).
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Section 4
Chapter 9
Periductal Vascularity in Ductal Carcinoma in situ of the Breast 
Results
Nuclear grade of DCIS
In each group of 20 patients with and without invasive breast cancer, 7 lesions were low,
6 intermediate and 7 high nuclear grade.
Microvessel density in DCIS without invasive carcinoma
Normal lobules
The highest values of periductal MVD were obtained using the anti-vWF antiserum, 
followed by monoclonal antibodies CD34, CD141 and CD31. These differences were 
significant apart from those between CD141 and CD34. \Fig.9J^.
DCIS
The highest periductal MVD was obtained using the antibody to CD34, followed by 
CD141, vWF and CD31. This reflected increases in CD34, 141 and 31 positive vessels but 
a decrease in those immunopositive for vWF. Changes in periductal MVD detected by the 
CD34, CD31 and vWF antibodies were statistically significant compared to those around 
normal lobules [Fig.9.2'\. Periductal MVD around DCIS using CD34 was less than that 
around normal lobules using anti-vWF. However, the difference was not statistically 
significant.
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per 20 
mm^
vW F CD31 CD141 CD34
Comparison p Value Comparison p Value Comparison p Value
vWF vs 
CD31
<0.001 vWF vs 
CD34
0.010 CD31 vs 
CD34
<0.001
vWF vs 
CD141
0,003 CD31 vs 
CD141
<0.001 CD141 vs 
CD34
0.279
Figure 9,1. MVD around normal lobules in cases o f DCIS without in vasive carcinoma.
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Vesse s
per 50. 
mm
vWF CD31 CD141 CD34
Comparison p Value Comparison p Value Comparison p Value
vWF vs 
CD31
<0.001 vWF vs 
CD34
<0.001 CD31 vs 
CD34
<0.001
vWF vs 
CD141
0.244 CD31 vs 
CD141
<0.001 CD141 vs 
CD34
<0.001
Figure 9.2. MVD around DCIS without invasive carcinoma.
Comparison of values between Fig. 1 and ]Fig. 2
Comparison p Value Comparison p Value
vWF 0.001 CD141 0.054
CD31 0.015 CD34 0.004
Table 9.1. Comparison between MVD around normal lobules and DCIS without 
invasive carcinoma.
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Microvessel density in DCIS with invasive carcinoma
Normal lobules
In contrast to cases of pure DCIS, normal lobules associated with DCIS with invasive 
carcinoma exhibited the greatest periductal MVD using the CD34 antibody, followed by 
CD 141, vWF and CD31. CD31 gave significantly different values to the other 3 
antibodies. There was no significant difference between the periductal MVD as measured 
by CD34, CD141, and vWF [Fig.9.5\ The periductal MVD obtained with vWF was 
significantly lower than in normal lobules from cases of pure DCIS whereas those obtained 
with CD31, CD34 and CD141 showed no significant difference.
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120
mm 20
vWF CD31 CD141 CD34
Comparison p Value Comparison p Value Comparison p Value
vWF vs 
CD31
<0.001 vWF vs 
CD34
0.348 CD31 vs 
CD34
<0.001
vWF vs 
CD141
0.813 CD31 vs 
CD141
<0.001 CD141 vs 
CD34
0.093
Figure 9.3. MVD around normal lobules in cases o f DCIS with invasive carcinoma.
Comparison of values between Fig. 1 and 'Fig. 3
Comparison p Value Comparison p Value
vWF 0.014 CD141 0J63
CD31 0.513 CD34 0.209
Table 9.2. Comparison between MVD around normal lobules in cases o f DCIS with 
and without invasive carcinoma.
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DCIS
The highest periductal MVD was obtained using the CD34 antibody, followed by CD 141, 
vWF and CD31. There were significant differences between all 4 antibodies apart from 
between CD34 and CD 141 [Fig.9.4]. In common with cases of pure DCIS, there were 
increases above normal in CD31, CD34 and CD 141 but a decrease in vWF 
immunopositive vessels. All these changes were statistically significant.
When compared with pure DCIS, there were increases in periductal MVD as determined 
by CD34 and 141 and decreases as determined by CD31 and vWF. Except for CD31, 
these findings were statistically significant.
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CD34vWF CD31 CD141
Comparison p Value Comparison p Value Comparison p Value
vWF vs 
CD31
<0.001 vWF vs 
CD34
<0.001 CD31 vs 
CD34
<0.001
vWF vs 
CD141
<0.001 CD31 vs 
CD141
<0.001 CD141 vs 
CD34
0.034
Figure 9,4, MVD around DCIS with invasive carcinoma.
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Comparison of values between Fig. 3 and Fig. 4
Comparison p Value Comparison p Value
vWF 0.030 CD141 0.004
CD31 <0.001 CD34 0.003
Table 9.3. Comparison betyveen MVD around normal lobules and DCIS with invasive 
carcinoma.
Comparison of values between Fig. 2 and !Fig. 4
Comparison p Value Comparison p Value
vWF <0.001 CD141 0.001
CD31 0.305 CD34 0.001
Table 9.4. Comparison between MVD around DCIS with and without invasive 
carcinoma.
Relationship between MVD and nuclear grade
Periductal MVD increased from low to intermediate nuclear grade but decreased in high 
grade DCIS usually to a level below that of low grade. The difference between low and 
intermediate grade DCIS was statistically significant for pure DCIS and those associated 
with invasive carcinoma using all antibodies (except for pure DCIS using vWF). The 
difference between intermediate and high grade was significant for both pure DCIS and 
those associated with invasive carcinoma with all antibodies (except for invasive cases 
using CD31). The difference between low and high grade, however, was significant only 
for pure DCIS using CD141, CD31 and vWF antibodies and for invasive cases using 
CD31 [Figs. 9.5 & 9.6].
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vWF
MVD'
HNGINGLNG
CD
MVD
HNGINGLNG
CD
141
MVD
HNGINGLNG
CD
MVD
HNGINGLNG
vWF CD31 CD14t CD34
Comparison PValue
Comparison PValue
Comparison PValue
Comparison PValue
LNG vs ING 0.071 LNG vs ING <0.001 LNG vs ING <0.001 LNG vs ING <0.001
LNG vs HNG <0.001 LNG vs HNG 0.047 LNG vs HNG <0.001 LNG vs HNG 0.843
ING vs HNG <0.001 ING vs HNG <0.001 ING vs HNG <0.001 ING vs HNG <0.001
Figure 9.5. Relationship betiveen periductal MVD and nuclear grade in DCIS without
invasive carcinoma. (LNG = low nuclear grade, ING = intermediate nuclear grade,
HNG  = high nuclear grade)
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vWF " 
MVD
LNG ING HNG
CD
MVD «.
ING HNGLNG
141
MVD"
LNG ING HNG
CD
34
MVD
LNG ING HNG
vWF CD31 CD141 CD34
Comparison P
Value
Comparison PValue
Comparison P
Value
Comparison P
Value
LNG vs ING <0.001 LNG vs ING <0.001 LNG vs ING 0.007 LNG vs ING <0.001
LNG vs HNG 0.800 LNG vs HNG 0.001 LNG vs HNG 0.064 LNG vs HNG 0.136
ING vs HNG <0.001 ING vs HNG 0.473 ING vs HNG <0.001 ING vs HNG <0.001
Figure 9,6, Relationship bet^veen periductal MVD and nuclear grade in DCIS with
invasive carcinoma, (LNG ~ low nuclear grade, ING = intermediate nuclear grade,
HNG  = high nuclear grade)
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Relationship between MVD and core area
A significant negative correlation was noted between the core area of individual foci and 
MVD as determined with all four antibodies except when CD31 was used on cases of 
DCIS associated with invasion (Figs. 9.7 & 9.8) : as the area of the DCIS focus increased 
so the periductal MVD decreased.
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Doilines show Means
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Core Art’
'S
titjody
Antibody Correlation
vWF p <0.001
CD31 p <0.001
CD141 p <0,001
CD34 p <0.001
Figure 9.7. Relationship between periductal MVD (vessels per l ( f  pm )^ and core area 
(l(f pm )^ in DCIS without invasive carcinoma, (antibody 1-vWF, 2=CD31, 3=CD141, 
4=CD34)
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vWF p <0.001
CD31 p =0.288
CD141 p <0.001
CD34 p <0.001
Figure 9.8. Relationship between MVD (vesselsper l( f  pm )^ and core area (l(f pm )^ 
in DCIS with invasive carcinoma, (antibody 1-vWF, 2~CD31, 3=CD141, 4=CD34)
164
Relationship between MVD, core area and necrosis
As these analyses were restricted to high nuclear grade DCIS, cases with and without 
invasive carcinoma were pooled.
A significant negative correlation was observed between necrosis scores and MVD using 
all four antibodies: the more necrosis there was, the less vascularity there was. Using 
CD141 antibody, there was a significant difference in MVD from necrosis score 1 to 2 as 
well as between 2 and 3. Using anti-vWF and anti-CD34 antibodies, a significant 
difference was only seen between necrosis score of either 1 or 2 and 3 [Fig. 9 .9 \
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1G0i
140'
120-
Degree100"
necrosis80'
MVD
60'
Vessels
P efz  4Cmm
2 0 *
2
vWF CD31 CD141 CD34
vWF CD31 CD141 CD34
Comparison 1>Value
Comparison PValue
Comparison PValue
Comparison PValue
N 1 vs N 2 0.18 N 1 vs N 2 0.176 N 1 vs N 2 0.033 N 1 vs N 2 0.620
N 1 vs N 3 <0.001 N 1 vs N 3 0.057 N 1 vs N 3 <0.001 N 1 vs N 3 0.004
N 2 vs N 3 <0.001 N 2 v s N  3 <0.001 N 2 v s N  3 <0.001 N 2 v s N  3 <0.001
Figure 9,9. Relationship between periductal MVD and degree of necrosis in DCIS M’ith 
and without invasive carcinoma, ( N  in table represents the degree of necrosis)
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A significant positive correlation was observed between necrosis scoring and core area of 
the foci for both pure DCIS and DCIS associated with invasion; the larger the area of 
DCIS, the more necrosis was present [Fig. 9.10].
1000r
800
600
400
Core 200 
Area
10^ 
l^ tm^
Degree of necrosis
Comparison p Value
Degree of necrosis 1 vs 2 <0.001
Degree of necrosis 1 vs 3 <0.001
Degree of necrosis 2 vs 3 <0.001
Figure 9.10. Relationship between the degree o f necrosis and core area in DCIS yvith 
and without invasive carcinoma, (samples stained with CD34 were used fo r  this 
assessment)
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Relationship between MVP and ED
In this series, there was a significant and positive correlation between MVD and ED in 
both groups of patients ( all p <0.001): as MVD increases, so does ED {Fig.9. l la -d  & 
9.12a-d\.
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CD34VD
Regression
Figure 9.1 la. DCIS without invasive lesions: correlation between vascular density, 
VD (microvessels per 10  ^jum )^ and endothelial density, ED (endothelial cells per 
1 (f jum )^ around DCIS stained with CD34 antibody.
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Figure 9.11b. DCIS without invasive lesions: correlation between vascular density, VD 
(microvessels per l ( f  pm^) and endothelial density, ED (endothelial cells per l ( f  pm^) 
around DCIS stained with CD141 antibody.
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Figure 9.11c. DCIS without invasive lesions: correlation between vascular density, 
VD (microvessels per l ( f  jum )^ and endothelial density, ED (endothelial cells per 
l ( f  jum )^ around DCIS stained with CD31 antibody.
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Figure 9.12a, DCIS with invasive lesions: correlation between vascular density, VD 
(microvessels per l ( f  jum )^ and endothelial density, ED (endothelial cells per l ( f  
pm^) around DCIS stained with CD34 antibody.
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Figure 9.12b. DCIS with invasive lesions: correlation between vascular density, VD 
(microvessels per l ( f  jum )^ and endothelial density, ED (endothelial cells per l ( f  
pm^) around DCIS stained yvith CD141 antibody.
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Figure 9.12c. DCIS with invasive lesions: correlation between vascular density, VD 
(microvessels per l ( f  pm^) and endothelial density, ED (endothelial cells per l ( f  
jum )^ around DCIS stained with CD31 antibody.
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Figure 9.12d. DCIS with invasive lesions: correlation between vascular density, VD 
(microvessels per l ( f  pm^) and endothelial density, ED (endothelial cells per l ( f  
pm^) around DCIS stained with vWF antibody.
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Discussion
Several groups have previously investigated vascularisation of DCIS but none, to my 
knowledge, has compared vascular density around involved ducts and normal structures in 
cases with and without invasive carcinoma using morphometry and a panel of anti- 
endothelial antibodies. I am thus unaware of any previous reports of changes in MVD and 
vascular phenotype immediately surrounding DCIS and of their relationship with the 
presence of invasive carcinoma, the degree of necrosis and duct size.
For a tumour to grow beyond 1-2 mm3, it requires the formation of new blood vessels to 
supply oxygen and nutrients, and to excrete catabolites. There have been many studies of 
the process of angiogenesis in breast carcinoma but most have focused on invasive 
disease. Some have investigated DCIS and other precursor lesions [Lee AHS et al 
1997&99, Guidi et al 1994&97, Engles et al 1997a&b, Sales et al 1999, Valtola et al 
1999, Brown et al 1995] where 2 patterns of vascularity have been described: difluse 
stromal vascularity and a vascular rim around the involved ducts. Several studies have 
shown that pre-malignant lesions of the breast can induce angiogenesis in animal 
experimental systems and in the human breast [Lichtenbeld et al 1998, Gimbrone et al 
1976, Brem et al 1977, Maiorana et al 1978, Strum et al 1983, Heffelfinger et al 1996]. It 
thus seems possible that the pattern or extent of vascularisation around DCIS may be an 
important factor in determining the transformation from in situ to invasive carcinoma. It is 
likely that the periductal vessels are most important in this respect as incipient invasion is
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most likely to be associated with changes in vessels in the immediate vicinity of the tumour 
cells.
The different antibodies gave different values for MVD both in normal lobules and DCIS 
indicating that they identified different sub-populations of small vessels. In pure DCIS, 
there was a significant increase above normal in CD34+ and CD31+ vessels but a 
reduction in those staining for vWT. These findings are in keeping with a change in 
phenotype as well as a change in vascular density although significant vascular 
proliferation must have taken place in order to maintain roughly normal density around 
greatly enlarged structures.
DCIS associated with invasive carcinoma showed a similar profile of vascular 
immunostaining but there were significantly greater numbers of CD34+ and CD 141+ 
vessels and fewer staining for vWF. It is not clear at present whether this higher periductal 
MVD reflects a greater predisposition to invade or whether the effect is due to the 
proximity of invasive carcinoma which induces angiogenesis. The latter possibility of the 
latter was minimised by evaluating DCIS at least 2mm from the nearest focus of invasive 
carcinoma but this would not exclude any effect of factors released by the tumour into the 
blood or lymphatic system. It is of interest in this context that the normal lobules from 
cases of DCIS with invasive carcinoma exhibited significantly lower numbers of vWF+ 
vessels than those from cases of pure DCIS. This finding is in apparent conflict with the 
work of Heffelfinger et al [1996] who found the vascularity of histopathologically normal 
epithelium to be greater in breast containing invasive carcinoma using an antibody to vWF.
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The breasts without invasive disease in this study, however, included those with benign 
proliferative change as well as DCIS.
The different antibodies used gave different values for MVD in normal breast and showed 
dissimilar changes in DCIS. For patients with and without invasive disease, vWF+ vessels 
were at lower density in DCIS than in the normal breast. This is in keeping with 
observations on invasive tumours (colorectal carcinoma) where vWF immunostaining has 
been found to be absent from some of the capillaries in the tumour [Vermeulen et al 
1995]. It has been shown that anti-vWF stains large vessels more strongly than small ones 
[Vermeulen et al 1996] and consequently our findings could reflect the immaturity of 
newly formed tumour-associated vessels. The density of CD34+/vWF- or CD141+/vWF- 
vessels could thus reflect the rate of tumour angiogenesis.
CD31 gave consistently lower values for MVD than the other antibodies. The molecule 
has a role in platelet adhesion in inflammation and wound healing [Parums et al 1990]and 
is expressed on large and small vessels in either normal or tumour tissue [Vermeulen et al 
1996, Horak et al 1992, Toi et al 1993]. In contrast to vWF it appears not to be expressed 
on lymphatic vessels [Burgdorf et al 1981] and this could at least partially explain why 
determinations of MVD with the CD31 antibody were consistently lower in both normal 
lobules and DCIS. The possible contribution of lymphatics to neo-vascularisation in 
tumours has been largely ignored.
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Values for MVD as determined using CD34 and 141 antibodies were roughly comparable 
both in normal lobules and DCIS. Both showed a significant increase in DCIS, with 
greater values in cases associated with invasive carcinoma.
CD34 is a cell surface adhesion glycoprotein expressed on human haemopoietic stem and 
progenitor cells and blood vessels. It has roles in leucocyte adhesion and endothelial cell 
migration [Fina et al 1990]. The antigen is a 105-120IcDa single chain transmembrane 
protein which is expressed on most haematopoietic colony-forming cells from human bone 
marrow, including unipotent and multipotent progenitors [Civin et al 1984&89&90].
CD34 appears to be expressed at highest levels on the earliest progenitors, and to decrease 
progressively with maturation [Civin et al 1989]. Anti-CD34 antibodies are sensitive 
endothelial markers that stain small and large vessels in normal and tumour tissue equally 
[Vermeulen et al 1996]. Perivascular stromal cells and a proportion of lymphatic vessels 
are also stained [Vermeulen et al 1996]. My findings confirm those of Martin et al [1997], 
that CD34 antibodies give consistently higher vessel counts in breast carcinomas than 
antibodies against vWF or CD31.
CD141 antibodies bind thrombomodulin (TM), an endothelial cell-surface receptor that 
functions as a potent natural anticoagulant through its cofactor role in the thrombin- 
catalysed activation of human protein C [Bourin et al 1988, Preissner et al 1990]. It is 
widely distributed in normal human tissues, such as endothelial cells of blood vessels, 
lymph vessels and syncytiotrophoblast [Maruyama et al 1985]. It was recently reported by 
Calnek et al [1998] that the TM-dependent anticoagulant activity is regulated by VEGF,
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an angiogenic factor. It has been reported that decreased TM expression could be 
associated with métastasés of tumour cells [Tesuka et al 1995, Suehiro et al 1995, Collins 
et al 1992], something I was able neither to confirm nor refute in the present study.
I found an unexpected relationship between MVD and nuclear grade of DCIS. It might 
have been expected that MVD would simply increase with grade but in those with and 
without invasive disease, the MVD was significantly higher in intermediate than either low 
or high-grades. MVD was generally less in high than low grade DCIS but this often did 
not achieve statistical significance. There was also a significant negative correlation 
between vascular density and both the cross-sectional areas of the ducts involved and the 
extent of the necrosis of the tumour they contained. The last finding is in apparent conflict 
with the study of Guidi et al [1994]., who found that comedo-type lesions were more 
likely to be associated with higher microvessel density. In their study, however, vessels up 
to 500|_im from the involved structures were included and only those from the 5 most 
vascular fields were recorded. Vessels forming cuffs around ducts were not studied 
quantitatively as they were found only in a minority of cases. These authors, however, 
identified vessels using an antibody to vWF only, which in my study stained significantly 
' fewer vessels than the CD34 and CD 141 antibodies. A likely explanation for my findings is 
that angiogenesis increases with growth rate but is unable to keep pace with the most 
rapidly growing lesions.
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In this series, there was a significant positive correlation between MVD and ED in both 
groups of patients. It implies that it is sufficient to assess the MVD of the in-situ breast 
tumour as the results suggest that MVD represents the ED profile of the tumours 
examined. There were a few studies which examined the endothelial cell kinetics [Tannock 
et al 1970, Hirst et al 1982, Hobson et al 1984, Fox et al 1993, Vartanian et al 1994] in 
solid tumour angiogenesis. None had found any significant correlation between 
intratumoral endothelial cell proliferation with MVD [Vartanian et al 1994] even though it 
has become generally accepted that endothelial cell proliferate 30 - 40 fold faster in solid 
tumour blood vessels than in the vasculature of normal tissue [Fox et al 1993]. On the 
other hand, Simpson et al [1996] measured the total endothelial area (EA) of CD34 
positive microvessels in invasive breast carcinoma using Samba 4000 image analyzer. 
Endothelial area was prognostically significant in univariate analysis of disease-free 
survival (DFS) and overall survival (OS). In multivariate analysis, EA remained as an 
independent predictor for OS in lymph node negative patients and for DFS in lymph node 
positive patients. Likewise, endothelial density would be a useful prognostic indicator if 
the study of this in-situ breast cancer is to be extended to a larger number of patients.
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Chapter 10
Microvessel Density and Proliferating Activity in 
Ductal Carcinoma in situ of the Breast
Results 
Relationship between either KD or MKD and KP
The mean value of Ki-67 density was 752 mm‘^ . Ki-67 fraction ranged from 2 to 30.5% 
with a mean value of 12.5%. As part of the assessment of the validity of the second 
method of quantification of Ki-67 staining and whether this was representative of the 
proliferative activity of the tumour assessed, a significant positive correlation between KP 
and KD (p<0.001) [Fig. 10.1} as well as MKD (p<0.001) was demonstrated.
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Figure 10.1. Correlation between Ki-67 percentage and Ki-67 density in DCIS.
Relationship between angiogenesis and proliferative activity
Mean microvessel density in each section of DCIS stained with a panel of endothelial 
markers (vWF, CD31, CD141 and CD34) from previous work were used for this 
assessment. There was no significant correlation between neither MKD nor KP and mean 
MVD using four endothelial markers.
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Relationship between proliferative activity and histological features 
Core area
The mean value core area of DIGS was 171x 10  ^jam The individual core areas of DCIS 
were significantly and inversely correlated with the corresponding KD (p<0.001): as area 
of DCIS increased, the proliferation activity decreased.
Nuclear grade
There was a significant positive correlation between the nuclear grade and the 
corresponding KD (p<0.001). The proliferative activity increased from low to 
intermediate grade but decreased in high grade DCIS. There was a significant difference in 
KD between low grade and either intermediate (p=0.003) or high grade (p<0.001) lesions. 
However, there was no significant difference in KD between intermediate and high grade 
tumours [Fig. 10.2].
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Figure 10.2. Relationship between nuclear grade and Ki-67 density in DCIS
Nevertheless, the nuclear grade was also significantly and positively correlated with KP 
(p=0.0I6). KP in high grade tumours was significantly higher than those in low grade 
lesions (p=0.005) whereas the difference in KP between intermediate grade and either low 
or high grade DCIS did not achieve statistical significance [Fig. 10.3].
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Figure 10.3. Relationship between nuclear grade and Ki67percentage in DCIS.
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Discussion
There have been some interests in the proliferation activity in DCIS as measured by anti- 
Ki67 antibodies [Zafrani et al 1994, Mack et al 1997, Gandhi et al 1998]. However, little 
is known of its significance in relation to angiogenesis in DCIS. Zolota et al [1999] 
investigated the relationship between periductal MVD (using anti-vWF antibodies)and 
proliferation activity (using anti-Ki-67 antibodies) semi-quantitatively. The rim of 
microvessels adjacent to the basement membrane was scored as an average of the 
percentage of the circumference occupied. Periductal MVD was scored as low when < 
25% of the duct circumference was occupied by vessels, intermediate when it was 25% to 
50% and high when it was > 50%. The percentage of neoplastic cells showing nuclear 
staining with Ki-67 was estimated with 10% taken as the cut-off level between low and 
high proliferating activity. An association was found between angiogenesis and over­
expression of Ki-67.
In the previous chapter, I showed the microvessel density (MVD) in DCIS from patients 
with or without invasive carcinoma increased from low to intermediate grade but 
decreased in high grade DCIS. I also found a significant negative correlation between 
MVD and degree of necrosis as well as core areas in high grade DCIS. This suggests that 
the angiogenesis increases with the tumour growth rate but is unable to keep pace with the 
most rapidly growing lesions. To confirm this, I examined periductal vascularity in relation 
to proliferation activity using Ki-67 antibody in DCIS.
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In this study, the proliferative activity was assessed quantitatively because I believed it 
represented a truer picture than semi-quantitative methods. As part of our quality 
assessment between two different methods of quantification of Ki-67 positive cells, I 
managed to show a positive and significant correlation between the two methods. This 
suggests KP does represent reasonable true picture of proliferation activity and its 
assessment is less time consuming compared with the one of KD.
KP ranged from 2% to 30.5% with a mean value of 12.5%. The mean percentage by other 
studies ranged from 7.2% to 22%. These differences can be partially secondary to 
different methods adopted. McGurrin et al [1987], who counted 1000 tumour cells in the 
section areas with the most dense labelling, found the highest mean percentage (22%). On 
the other hand, Wrba et al [1989] reported the lowest mean value of 7.2% by counting 
1000 cells randomly. My results fell within the range from various groups and this 
confirmed the validity of my methodology.
I found a significant and positive correlation between nuclear grade and KD as well as KP. 
KP increased significantly and steadily from low to high grade DCIS. On the other hand, 
KD increased from low to intermediate grade but decreased in high grade DCIS at a level 
significantly higher than those in low grade lesions. I also showed that individual core 
areas of DCIS was significantly and inversely correlated with KD. These findings appeared 
to agree with my suggestion in previous chapter that angiogenesis around affected ducts in 
DCIS increases with the growth of the tumour but is unable to cope with most aggressive 
lesions, which contributes to the decreased proliferation activity in high grade lesions with
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larger core areas. Previous studies showed the proliferation activity is related to tumour 
grade in breast cancer [Zafrani et al 1994, McGurrin et al 1987, Wrba et al 1989, Lell’e et 
al 1987, Barnard et al 1987, Walker et al 1988, Bouzubar et al 1989], so did our study.
Proliferation was also assessed within the microvessels around foci of DCIS as if there is 
any angiogenesis, this may be detected using the Ki-67 antibody. Also it has been shown 
that endothelial cells proliferate 30 - 40 fold faster in solid tumour blood vessels than in 
the vasculature of normal tissue [Fox et al 1993]. Thus if proliferation could be detected 
within these blood vessels, Ki-67 expression could possibly represent a quick method of 
assessing angiogenesis. Unfortunately, despite the reported increased proliferation rate 
within tumour associated blood vessels the rate remained too low to detect proliferating 
blood vessels in significant numbers.
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Chapter 11
Vascular Density and Phenotype around Ductal carcinoma in situ 
of the Breast: relationship to Recurrences
Results
DCIS with no 
recurrence
DCIS with in situ 
recurrence
DCIS with invasive 
recurrence
Number of cases 20 20 12
Age (years)
Range 48-87 45-78 43-82
Mean 66.2 65.6 63.3
Follow up after treatment of
DCIS (months)
Range 29-138 9-98 7-52
Mean 94 43 48
Death 2 (both not related to 0 1 (died of breast
breast cancer) cancer)
Operation
Wide local excision 18 20 10
Mastectomy 2 0 2
Adjuvant Therapy
None 9 9 5
Hormone 11 11 7
Radiotherapy 0 0 0
Others 0 0 0
Nuclear Grade
Low 4 3 4
Intermediate 4 6 2
High 12 11 6
Van Nuys pathological grade
1 2 3 3
2 6 6 3
3 12 11 6
Size (mm)
Range 1-65 5-20 1-22
Mean 16.6 13.5 11.7
No of cases not assessable 0 9 3
Excision margin (mm)
<1 7 4 3
1< to 10> 4 4 0
>10 5 4 3
No of cases not assessable 4 8 6
Table 11,1. Clinical and pathological data from  the three groups o f DCIS patients.
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Normal breast
The mean MVD around normal lobules was 79 vessels/mm^ for CD 34 and 91 
vessels/mm^ for vWF. There was no significant difference in MVD for CD34 when normal 
lobules were compared in cases of DCIS with and without recurrence (Mann Whitney, 
P=O.S). In contrast, staining with vWF was more variable, the normal lobules of patients 
with DCIS that subsequently developed recurrent disease had a lower MVD than those 
that did not (Mann Whitney, P=0.024). In addition, MVD stained with anti-vWF antibody 
in cases with invasive recurrence was significantly lower than those that developed 
recurrence as in situ carcinoma (Mann Whitney, P<0.001).
DCIS
The MVD for the three groups of DCIS is summarised in Table 11.2.
CD34 Mean MVD 
(vessel s/mm^)
vWF Mean MVD 
(vessels/mm^)
Normal Lobules 79 91
(sd=60) (sd=72)
DCIS 95 80
(Non Recurrence) (sd=49) (sd=65)
DCIS 119 89
(In-situ Recurrence) (sd=66) (sd=65)
DCIS 126 77
(Invasive Recurrence) (sd=59) (sd=53)
Table 11.2, Microvessel density fo r  CD34 and vWF for normal lobules and DCIS.
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CD34
The highest MVD for CD34 was seen in cases of DCIS that subsequently developed an 
invasive recurrence and the lowest in cases of DCIS that were not known to have 
developed recurrent disease [Fig. 11.1], The mean MVD was significantly higher around 
cases of DCIS that subsequently developed recurrent disease than those that did not 
(Mann Whitney P<0.001). The MVD was significantly higher in cases that developed an 
invasive recurrence than those that developed recurrent DCIS. However, the confidence 
intervals between these two groups largely overlaps. In addition, all three groups of DCIS 
had a higher MVD than that seen in normal breast ( highest P 0.001).
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Figure 11.1. Comparison o f CD34 microvessel density (MVD) among normal lobules 
and three groups o f ductal carcinoma in situ (DCIS) [no recurrence (No R), 
recurrence with ductal carcinoma in situ (In situ R), recurrence with invasive 
carcinoma (Invasive R)]. The squares represent the mean values and the bars 
represent the 95% confidence intervals o f the mean.
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vWF
The data for vWF positive vessels was less dear cut. Normal lobules had the highest value 
of MVD, and DCIS with subsequent invasive recurrence the lowest [Fig, 11.2],
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Figure 11,2. Comparison o f vWF microvessel density (MVD) among normal lobules 
and three groups o f  ductal carcinoma in situ (DCIS) [no recurrence (No R), 
recurrence with ductal carcinoma in situ (In situ R), recurrence with invasive 
carcinoma (Invasive R)J. The squares represent the mean values and the bars 
represent the 95% confidence intervals o f the mean.
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Dual immunofluoresence for CD34 and vWF
On the 12 cases of DCIS on which dual immunofluoresence was performed three different 
immuophenotypes of blood vessels were identified around normal breast and DCIS: 
CD34+/F8-, CD34+/F8+ and CD34-/F8+.
Normal lobules
The mean MVD for CD34 positive vessels was 83 vessels/mm^ , of these 45% 
coexpressed vWF. The mean MVD for vWF positive vessels was 56 vessels/mm^ and of 
these 68% coexpressed CD34.
DCIS
The mean MVD for CD34 positive vessels around DCIS was 87 vessels/mm^ , and of 
these 34% coexpressed F8. The mean MVD for vWF positive vessels around DCIS was 
42 vessels/mm^ and of these 72% coexpressed CD34. The MVD of CD34+/F8- vessels 
was significantly higher around DCIS than normal lobules (Mann Whitney f<0,001) [Fig. 
1L3]. In contrast there was no difference between CD34+/F8+ or CD34-/F8+ vessels 
between normal breast and DCIS (Mann Whitney, lowest P=0.4).
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Figure 11,3. Comparison o f microvessel density (MVD) fo r  CD34+/vWF~ vessels 
around ductal carcinoma in situ (DCIS) and normal lobules. The squares represent 
the mean values and the bars represent the 95% confidence intervals o f the mean.
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Discussion
In chapter 9 ,1 have shown that there are differences in micro vessel density between pure 
DCIS and DCIS associated with invasive cancer suggesting that increases in angiogenesis 
occur in cases that develop invasion. The aim of this study was to determine if the 
vascularity of DCIS at diagnosis was different in those who subsequently developed 
recurrent cancer compared to those who did not and thus whether angiogenesis could 
predict which women are likely to develop a recurrence, I have also shown in chapter 9 
that in comparison to normal lobules, DCIS shows an increase in CD34 positive MVD and 
a decrease in vWF MVD. In this study, I carried out dual staining immunofluoresence to 
determine the phenotype of individual periductal blood vessel. This more precise method 
of determining the phenotype of vessels involved in angiogenesis may be able to give 
further insight into the role of angiogenesis in progression to malignancy.
This study demonstrates different populations of microvessels in DCIS and normal lobules 
using dual immunostaining. In DCIS, there was a significant increase above normal in 
CD34+ vessels, however for vWF the changes were less clear cut and overall were more 
in keeping with a drop in MVD rather than an increase. This agrees with my suggestion in 
previous chapter that there is a change in phenotype as well as vascular density from the 
transition from normal breast to DCIS, although significant vascular proliferation must 
have taken place in order to maintain roughly normal density around greatly enlarged 
structures.
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The groups of DCIS that subsequently recurred had higher mean values for CD34+ MVD 
than those that did not. Increases in CD34 MVD thus not only correlated with the 
progression from normal to in situ neoplasia but also appeared to be able to detect cases 
that are likely to recur. Furthermore MVD was independent of the size, nuclear grade, and 
excision margin status as these were appropriately matched between the groups, however, 
the small numbers in each of these groups precludes flirther comment. In contrast the 
findings for vWF were more difficult to interpret. Differences were seen between normal 
lobules from the three different DCIS groups. It is not certain whether the changes in vWF 
MVD is due to the proximity of the DCIS, however, I attempted to minimise this by 
evaluating normal lobules at least 2mm from the nearest focus of DCIS. Furthermore, no 
such change was seen for CD34. Alternatively, staining with vWF may be more sensitive 
to the effects of tissue fixation and processing, the differences in staining reflecting these 
rather than definite changes in microvessel phenotype. DCIS also showed differences in 
MVD for vWF between the three groups. However, unlike that seen for CD34 a clear 
step-wise increase was not seen and instead there was a trend towards a decrease in 
MVD. When dual immunofluoresence was used the values for CD34 were comparable to 
those obtained by standard immunohistochemistry. However, far fewer vWF positive 
vessels were detected, again suggesting that this antibody may be affected by the 
methodology.
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The dual immunofluoresence staining did, however, give further insight into the change in 
MVD. There was no difference between normal lobules and DCIS when vessels showing a 
CD34+/vWF+ or a CD34-/vWF+ phenotype were compared. In contrast, vessels with a 
CD34+/vWF- phenotype showed a significant increase between normal lobules and DCIS. 
This suggests that the increased vasculature around DCIS is primarily due to an increase in 
CD34+/vWF- vessels. This is in keeping with observations on colorectal carcinoma where 
vWF immuno staining has been found to be absent from some of the capillaries in the 
tumour [Vermeulen et al 1995]. It has been shown that anti-vWF stains large vessels more 
strongly than small ones [Vermeulen et al 1996]. In contrast, anti-CD34 antibodies are 
sensitive endothelial markers that stain small and large vessels in normal and tumour tissue 
equally [Vermeulen et al 1996]. Perivascular stromal cells and a proportion of lymphatic 
vessels are also stained [Vermeulen et al 1996], the former were excluded from my study 
by using a rigid definition for a vessel. The role of the latter in neoangiogenesis is 
unknown. Consequently my findings could reflect the immaturity of newly formed tumour- 
associated vessels. The density of CD34+/vWT- vessels could thus be related to the rate of 
tumour angiogenesis and the consequences it has for the biological behaviour of DCIS. It 
would therefore be interesting to know the phenotype of the blood vessels in the 
subsequent recurrences.
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Solid tumours express genes which code for angiogenic stimulators [Klagsburn et al 1991, 
Leek et al 1994, Bicknell et al 1996, Bouck (b) et al 1996, Folkman (c) et al 1996], 
suggesting that the ability to form new vessels is part of the malignant phenotype. There is 
little doubt that an angiogenic phenotype develops during tumour progression, and that 
the development of a blood supply is vital in the escape from dormancy. Vessel density 
increases gradually with growth in some tumours, such as cervical squamous cell 
carcinoma [Smith-McClune et al 1994], whereas it may increase dramatically in others 
such as breast carcinoma [Stellmach et al 1996]. Oncogenes influence angiogenesis by 
coding for proteins and enzymes vital to the angiogenic process [Bouck (b) et al 1996, 
Bouck et al 1996, Volpert et al 1997]. Suppressor gene loss may, however, have a more 
profound effect [Stellmach et al 1996]. Increased production of pro angiogenic factors 
appears to be necessary, but not sufficient, for the development of the angiogenic 
phenotype [Folkman (b) et al 1995], a decrease in inhibiting factors must also occur 
[Folkman (c) et al 1995, Dameron et al 1994]. Some neoplastic cells switch from an 
angiogenesis inhibiting to an angiogenesis stimulating phenotype upon transformation, as 
has been observed in cultured fibroblasts in patients with Li-Fraumeni syndrome [Dameron 
et al 1994]. Although the sequential events of vessel formation are similar, tumour vessels 
differ from those of normal tissue, in terms of permeability, cellular composition, stability 
and regulation of growth [Folkman et al 1976]. This suggests that antigenic differences 
may exist which may be exploited in specifically targeting tumour vasculature [Denekamp 
et al 1993, Fan et al 1995]. A number of antigens preferentially expressed in tumour 
vasculature have now been identified, includingEN 7/11 antigen, E9 antigen, TP-1, TP-3,
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VEGF, Tie receptor kinase, Endosialin, BC-1 antigen, Integrins, and Endoglin. Gasparini 
and Chereah et al [2001] assessed the expression of intergin alphaVbeta3 in a cohort of 
primary breast cancers and in normal breast tissue as control. They found that LM 609 
antibody preferentially immuno stained proliferating vessels of small caliber within the 
tumour, whereas only weak expression of integrin alphaVbeta3 was observed on vessels 
of non-cancerous tissue.
A number of other studies have also looked at angiogenesis around pre-invasive disease. 
Ottinette et al [1988] examined vascular number and size within a 100 micrometer 
perimeter of proliferative breast disease and DCIS. They found an increased mean vascular 
size in proliferative breast disease and DCIS relative to normal epithelium but unlike the 
present study no increase in vessel numbers. Guidi et al [1994] used both a 1-3+ estimate 
of vascularity and quantitative counts of microvessels within 500 micrometer of DCIS.
The vascularity was greater in comedo than non-comedo DCIS, was proportional to 
nuclear grade, and correlated with Her2/neu. Heffelfinger et al [1996] estimated 
angiogenic grade (0 to 4) according to the proportion of basement membrane of involved 
ducts touched by vessels and found that the vascularity of normal epithelium was higher in 
breasts containing invasive disease than in breasts lacking invasive disease; simple 
proliferative breast disease had a higher count than normal breast epithelium and, 
vascularity increased in proportion to epithelial lesion progression and relative risk of 
invasion. Interestingly, Guinebretiere et al [1994] showed that periductal vascularity in 
fibrocystic disease was a predictor of progression to invasive disease. In this study, I 
concentrated our investigations on periductal vascularity as I hypothesised that risk of
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recurrence is likely to be associated with vascular changes in the immediate vicinity of the 
tumour foci.
In conclusion, this study shows that the blood vessels surrounding DCIS appear to have a 
different immunophenotype when compared with blood vessels surrounding normal breast 
lobules. Furthermore increases in vascular density, as detected with the CD34 antibody, 
correlates with recurrence and the development of invasive carcinoma.
201
Chapter 12
Stromal Vascularity and Thymidine Phospliorvlase expression in Ductal 
Carcinoma in-situ of the Breast
Results
Comparison of stromal and periductal MVD 
vWF
The mean stromal MVD and the mean periductal MVD when measured using anti-vWF 
antibody were both 160 vessels/mm^ . A strong positive correlation was identified 
between stromal and periductal density regardless of how measured (eg. hotspot, mean of 
3 highest stromal counts, mean of 5 highest stromal counts, highest periductal density, 
mean periductal density) [Figs. 12.1-12.6]. The weakest correlation was between hotspot 
and mean periductal MVD (Pearson: lowest 1-0.464, highest P<0,001).
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Figure 12.1. Relationship het\s>een hotspot and mean periductal MVD in all cases 
stained with vWF antibody
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Figure 12.2. Relationship between hotspot and highest periductal MVD in all cases 
stained with vWF antibody
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Figure 12.3. Relationship betypeen mean stromal M(5)VD and mean periductal 
MVD in all cases stained with vWF antibody
204
400
300-
200
Mean 
Stromal 
MVD 
(5) 1 0 0 .
(micro­
vessel
per
mm) Q
0 100 200 
Highest periductal MVD (microvessel per mm^)
300 400
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Figure 12.5. Relationship between mean stromal M(3)VD and mean periductal 
MVD in all cases stained with vWF antibody
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Figure 12.6. Relationship between mean stromal M(3)VD and highest periductal 
MVD in all cases stained with vWF antibody
There was no significant correlation between nuclear grade and stromal MVD in the entire 
group of DCIS (Spearman: lowest P=0.292). No significant difference was identified in 
stromal vascularity between DCIS cases which did and did not recur eventually (Mann- 
Whitney: lowest P=0,932).
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CD34
The mean stromal MVD when measured using anti-CD34 antibody was 182 vessels/mm^ 
and was higher than that seen with vWF (Mann-Whitney: P=0.037) [Figs. 12.7-12.9], The 
mean periductal density was 210 vessels/mm^ and was again higher than that seen with 
vWF (Mann-Whitney: P<0.001) {Figs. 12.10-12.11], Furthermore, in contrast to that seen 
with vWF, the periductal MVD was higher than the stromal MVD regardless of how 
measured (Mann-Whitney: highest P=0.037). Unlike staining with vWF antibody, there 
was no significant correlation noted between stromal and periductal vascularity stained 
with CD34 antibody (Pearson: lowest P=0,101).
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Figure 12.7. Hotspot in sections stained with vWF and CD34 antibodies (p=0.037)
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Figure 12,8. Mean stromal M(5)VD in sections stained with vWF and CD34 
antibodies (p=0.019)
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Figure 12.9. Mean stromal M(3)VD in sections stained with vWF and CD34 
antibodies (p=0.025)
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Figure 12.10. Mean periductal MVD in sections stained with vWF and CD34 
antibodies (p<0.001)
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Likewise as staining with vWP, no significant correlation was noted between nuclear 
grade and stromal vascularity (Spearman: lowest P=0.379). There was no significant 
difference in stromal vascularity between DCIS which did and did not recur after initial 
treatment (Mann-Whitney: lowest P=0.509).
Thymidine PhosphoiTlase staining in DCIS
No difference was identified when H-scores for TP staining were compared between 
cases of DCIS that subsequently recurred or did not recur (Mann-Whitney: P^O. 181)
[Fig. 12.12\ A negative correlation was seen between the TP H-score and DCIS nuclear 
grade (Spearman: r=0.292, P=0.049), However, no significant difference in the TP H~ 
score was identified between nuclear grade (Mann-Whitney: lowest P=0.061) [Fig. 12.13], 
The TP H-score also correlated with stromal (Pearson: highest P=0.035) but not 
periductal (Pearson: lowest P=0.091) vWF MVD. In contrast, for CD34, no significant 
correlation was identified between TP H-score and both types of vascularity (Pearson: 
lowest P=0.598).
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Figure 12.12. Relationship between TP expression and clinical outcome 
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Figure 12.13. Relationship between TP expression and nuclear grade in all cases of
DCIS (LNG=Lower nuclear grade, ING=intermediate nuclear grade, HNG=high
nuclear grade; TP=Thymidine Phosphorylase)
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Discussion
Angiogenesis is thought to play an important role in the progression of invasive cancer 
[Weidner et al 1991, Bosari et al 1992, Horak et al 1992, Weidner et al 1992, Karaiossifidi 
et al 1996, Heimann et al 1996]. It also appears to have a role in the development of 
hyperplastic and other precancerous lesions [Brem et al 1977, Gimbrone et al 1976, 
Guinebretiere et al 1994, Lichtenbeld et al 1998, Maiorana et al 1978, Strum et al 1983].
In DCIS two vascular patterns are described [Guidi et al 1994, Engels et al 1997a, 
Heffelfinger et al 1996], a diffuse stromal increase and an increase in periductal blood 
vessels (Pattern I and II). An increase in periductal MVD (Pattern II) is seen in 23-62% of 
DCIS cases [Guidi et al 1994, Engels et al 1997a, Heffelfinger et al 1996]. In my previous 
studies, I have shown that an increase in periductal MVD (Pattern II) around DCIS 
predicts for the development of a recurrence, particularly an invasive recurrence. An 
increase in vessels picked up by the antibody CD34 appear to be particularly important. It 
has also been proposed that the increased periductal MVD (Pattern II) may result from 
angiogenic factors secreted by tumour cells [Engels et al 1997a].
Although two patterns of vascularity (Pattern I and II) have been described in DCIS, the 
relationship between these two patterns is unclear. Guidi et al [1994] found increased 
stromal vascularity (Pattern I) in 25% of cases and the presence of a periductal vascular 
cuff (Pattern II) in 35%. However, they could not show an association between stromal 
(Pattern I) and perivascular (Pattern II) density. In contrast, I found with vWF a strong 
correlation between stromal (Pattern I) and periductal (Pattern II) vascularity with similar
213
values in each. CD34 on the other hand showed higher values than that seen for vWF . 
There was also a difference between stromal (Pattern I) and periductal (Pattern II) 
vascularity with the highest values being seen in the latter. The difference between the 
stromal (Pattern I) and periductal (Pattern II) counts is probably due to an increase in 
CD34/vWF -  blood vessels as shown in our previous study. It thus appears that detection 
of periductal MVD (Pattern II) using the CD34 antibody is a sensitive predictive marker 
of DCIS recurrence and the development of invasion.
TP is thought to have a role in endothelial cell migration [Risau et al 1992] and 
differentiation [Klagsburn et al 1991] and has been shown to be associated with increased 
periductal MVD (Pattern II) in DCIS [Engels et al 1997b]. I therefore proposed that the 
increased periductal MVD (Pattern II) in those cases of DCIS that subsequently recurred 
was a result of TP expression. However, I found that TP expression in DCIS correlated 
with vWF stromal but not CD34 periductal MVD. It thus appears that TP may play a role 
in increased stromal vascularity (Pattern I) of vWF positive vessels, however, other factors 
may also be important and these may have a more important role. It would be interesting 
to see if other factors stimulated by TP, such as VEGF show a similar correlation.
TP in invasive breast cancer correlates with MVD and has prognostic value [Fajardo et al 
1992, Folkman et al 1996,Fox et al 1996,Toi et al 1995]. It has also been shown to 
correlate with the relapse rate in DCIS although the same study did not show a significant 
correlation between relapse free survival and TP expression [Engels et al 1997b]. In the 
present study, when H-scores for TP expression were compared between patients that did
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or did not subsequently develop recurrence, a difference was not seen. Although TP may 
have a role in vWF stromal MVD, its influence in the development of recurrence is 
probably less.
TP can also be induced by hypoxia and low pH [Shweiki et al 1992]. High grade DCIS 
with comedo necrosis may therefore be thought to be more likely to show TP expression. 
Surprisingly in our study we found that the TP H-score showed a negative correlation 
with grade even though most of our high grade DCIS cases showed at least focal comedo 
necrosis. Interestingly Lee et al [1999] also found no relationship between TP expression 
and recurrence. Possibly the hypoxia present in DCIS is not a strong enough stimulus to 
induce TP expression or the cells in high grade DCIS are so genetically deranged that they 
are unable to respond to the hypoxia by upregulation of TP.
In conclusion, stromal and periductal MVD measured by anti-vWF antibody correlates, 
but does not predict for recurrence. Stromal and periductal MVD measured by anti-CD34 
antibody does not correlate, and the periductal MVD correlates with recurrence. This is 
important and supports my previous studies strongly: it is CD34+ periductal new 
micro vessels that are important with regard to the risk of recurrence in DCIS after 
conservation treatment.
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Chapter 13 
Summary of results and Conclusions
Over 20% of screen-detected breast cancers are in-situ, the majority of those are treated 
by wide local excision, but as yet no molecular marker has been identified to predict for 
recurrences. I hypothesized that angiogenesis was important in the transformation of in- 
situ to invasive cancer and may predict an increased chance of recurrence.
The importance of angiogenesis has been demonstrated in that DCIS had a higher level of 
CD34 positive vessels compared to normal, interestingly not only on the number of vessels 
increased but also their phenotype. The vessels around DCIS tend to be positive for CD34 
and negative for vWF, a finding not previously described.
The MVD continues to increase in DCIS associated with invasive cancer and once again 
these vessels are more likely to stain positively for CD34 and not vWT, suggesting that the 
vessels that are important in malignant transformation and growth are different from those 
found in normal breast lobules.
A correlation was noted between MVD (CD34) and nuclear grade with an increase in 
MVD in intermediate grade DCIS compared to low grade. It might have been expected 
that the MVD would continue to increase in high grade DCIS but this was found to be 
lower than intermediate grade DCIS. In an attempt to explain this, I measured MVD in 
relation to the area of the focus of DCIS and the degree of necrosis present. In both cases
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MVD decreased. This provides a possible explanation for decreased MVD in high grade 
DCIS in that the vessel density increases with grade, but in high grade DCIS with high 
proliferation activity the new vessel growth fails to keep pace so the MVD decreases, and 
tumour necrosis occurs within the DCIS.
Increased CD34 positive vessel formation is important in malignant transformation as 
demonstrated above. It is not unreasonable to hypothesize that it may also act as a marker 
for recurrence in those who have had wide local excision. This proved to be the case with 
significantly increased periductal MVD in DCIS at diagnosis in those patients who 
subsequently developed a recurrence compared to those who did not.
Stromal (Pattern I) and periductal (Pattern II) vascularity had been described in DCIS and 
yet no one has identified the relationship between the two vascular patterns. I 
hypothesized that the relationship does exist and had also shown that both types of 
vascular network do correlate to one and another in sections stained with anti-vWF but 
not anti-CD34 antibody. The latter observation could be partly due to more immature new 
vessels (which stained better with anti-CD34 antibody ) around DCIS compared to the 
distant stroma. Once again, these periductal vessels (which stained better with anti-CD34 
antibody ) had been shown to be reasonably related to the likeliness of recurrence as I 
could not show the relationship between the stromal vascularity and the risk of 
recurrence.
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In conclusion, blood vessels surrounding DCIS appear to have a different 
immunophenotype when compared with blood vessels surrounding normal breast lobules. 
Increases in vascular density, as detected with the CD34 antibody, correlates with 
recurrence and the development of invasive carcinoma. Recurrent disease does not appear 
to be related to TP expression by DCIS. Periductal MVD appears to be more important 
than stromal MVD in predicting for recurrence in DCIS.
My work suggests that angiogenesis does play an important role in DCIS and periductal 
vascularity does have a potential value as a prognostic marker. The strength of my study is 
(1) the robustness of the methods, (2) the length of follow up of those patients who were 
treated for DCIS, and (3) usage of multiple endothelial markers to evaluate the 
microvessel density as well as vascular phenotype.
I was the only assessor of periductal and stromal vascularity after basic training with two 
consultant histopathologists in assessing microvessels for three months. I only started the 
project once our assessment of microvessels reached an agreement ratio of at least 70%. 
My study is transferable to another laboratoiy because;
1. The representative histological sections were selected by two consultant 
histopathologists,
2. The immunostaining was carried out with the standard method using the standard 
antibodies,
3. Adjacent non-cancerous lobules were used as internal controls,
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4. During the assessment of micro vessels, the histological sections were scanned in a 
systematic manner to avoid selection bias,
5. Strict criteria was adopted for assessment of microvessels,
6. The sole assessor was trained with two consultant histopathologists for three months, 
when the agreement ratio among three observers of microvessels reached at least 70%,
7. Overall, the methodology was robust
There are several weak points in my study. First of all, it is a retrospective study which 
involves a small number of DCIS cases with recurrence. Secondly, histological data for a 
few patients were not available during the study either due to inadequate histological 
assessment at diagnosis or poor record keeping. As for future work, a prospective study 
involving larger number of DCIS cases would be sensible. In addition, it would be 
interesting to compare the periductal vessel density between pure DCIS and DCIS with 
microinvasion. It would also be interesting to evaluate the phenotype of the blood vessels 
in the subsequent recurrences.
219
Chapters 14 
Prognostic value of markers of angiogenesis
Before we look into the future, it is appropriate to review the values of current markers of 
angiogenesis as a prognotic indicator from recent literatures.
Breast cancer 
Tumoural vascularisation
Up to mid 2000 [Gasparini et al 1998], studies had been published in peer-reviewed 
journal, on the association between tumoural vascularisation and clinical outcome (Table
14,1). All the studies were retrospective and used mainly the Weidner or Chalkley 
methods to determine and evaluate microvessel counts; 28 and 22 studies for relapse-free 
and overall survival, respectively, including multivariate analysis.
For relapse-free survival 31/41 studies and for overall survival 23/30 studies that evaluated 
the prognostic value of vascularity found a statistically significant association between 
microvessel counts and prognosis. In multivariate analysis, 23/29 and 20/23 showed that 
tumoral vascularistion is a significant an independent prognostic indicator relapse-free 
survival or overall survival, respectively. Among the studies with multivariate analysis that 
used antibodies to CD31 or CD34, most gave positive results on relapse-free survival 
(13/14) and all on overall survival (12/12) gave better results than with factor VIII-RA 
(relapse-free 8/13 and overall survival 7/10). Therefore, CD31 emerges as the 
panendothelial marker of choice for prognostic purposes (Table 14.1).
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Tumour type Number of 
studies
Number of 
patients
Stage Median of 
follow-up 
(years)
Male urogenital 
tract
Prostate 4 516 Tl-2 Nx Mo (3), 
Gleason 6-7 (1)
3, 5-15
Bladder 3 314 Invasive stages 2.1-6.6
Renal 3 204 Invasive stages 1.9-3.0
Testicular germ­
cell tumour
2 145 A-B 3.0-4.3
Female genital 
tract
Cervix 9 684 FIGO lA-IVA 1.5-7,1
Endometrium 6 603 FIGO I-IV 2.6-11.5
Ovarian 7 323 FIGO I-IV (3), 
FIGO III-IV (4)
1,7-9.8
Gastrointestinal
tract
Oesophagus 5 393 Invasive stages 2.6-5.0
Gastric 5 723 Invasive stages 2.5-5.5
Colorectal 10 1247 Dukes A-C 1.3-6.3
Pancreas 1 40 Invasive 2.1
Other
Head and neck 6 384 I-IV (5), 1-11(1) L2-6.0
Lung 14 2450 I-IV (3), I-III 
(7), I-II (4), I (1)
2.0-8.5
Malignant
melanoma
9 695 Invasive stages 3.1-10.0
Brain 4 238 Invasive stages 1.8-4.5
Breast 46 7345 I-II 2.1-16.0
Table 14,1, Studies on the prognostic value o f intratumoral vascularisation.
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The prognostic value of vascularity was first shown by two groups in 1992 [Horak et al 
1992, Weidner et al 1992]. Others have since shown that the degree of vascularisation of 
the primary tumour correlates directly with presence of bone marrow micrometastases at 
diagnosis [Fox et al 1997], and that the presence of vascular ‘hot spots’ in axillary lymph 
nodes is associated with outcome [Guidi et al 2000]. Finally, the prognostic value of 
integrin alphaVbetaS was investigated using the monoclonal antibody LM609 and 
immunohistochemisty [Gasparini et al 1998]. Determination of microvessel density by 
LM609 antibody was the single most significantly prognostic indicator for relapse-free 
survival in both node-negative and node-positive patients.
Angiogenic factors in breast tumours
Among proangiogenic factors, VEGF is the most extensively studied. 12 published 
retrospective studies, involving 3688 cases, have assessed the association between VEGF 
and clinical outcome in breast cancer. Among those using univariate analysis, 9/10 and 6/6 
found a significant association between VEGF expression and relapse-free or overall 
survival. Among those with multivariate analysis, 7/9 and 6/6 found that VEGF is a 
significant and independent prognostic indicator for relapse-free or overall survival.
In a recent study by Linderholm et al [Linderholm et al 2000], of 363 consecutive node­
positive patients, not only was the tumoral VEGF content of prognostic value, but also it 
predicted the anatomical site of first recurrence; the patients who developed brain, 
visceral, or soft-tissue métastasés had a significantly higher VEGF content in the primary 
tumour than those with bone recurrences.
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8 retrospective studies, of 1649 cases, evaluated the association between Thymidine 
Phosphorylase (TP) and prognosis; 4/7 studies and 4/5 found TP of significant prognostic 
value for relapse-free or overall survival, respectively, in univariate analysis [Toi et al
1999]. Most of the studies found that TP is a prognostic factor in the subgroups of 
patients treated with CMF adjuvant chemotherapy (cyclophosphamide, methotrexate, 
fluorouracil).
In the only published study on naturally occurring antiangiogenic factors [Gasparini et al
2000] there was no correlation of thro mho spondins 1 and 2 with prognosis in 168 node­
negative patients (Table 14.1).
Other tumours 
Tumoral vascularisation
The prognostic value of vascularisation in non-small-cell lung cancer (NSCLC) has been 
evaluated in 2334 patients from 14 studies. In terms of overall survival, 10/14 studies were 
positive, including 7/8 with multivariate analysis (Table 14.1). Pastorino et al [Pastorino et 
al 1997] studied 515 cases of pathological stage 1 NSCLC, with median follow-up of 102 
months. Several biological markers of angiogenesis were tested, including anti-CD31, and 
immunohistochemistry with Chalkley score. None of the biological markers emerged as 
independent prognostic factors, but in the subgroup of 137 patients with stage TINOMO, 
both microvessel counts and EGFR expression were associated with relapse-free and 
overall survival in multivariate analysis. Fontanini et al [Fontanini et al 1997] examined
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407 patients with stage S1-S3 NSCLC, with a median follow-up of 29 months. Tumour 
microvessel count stained with anti-CD34 antibody showed a significant and independent 
prognostic value for overall survival in multivariate analysis.
The largest study on melanoma [Massi et al 1999, Makitie et al 1999] showed that 
osteonectin, a glycoprotein involved in tissue mineralisation, regulation of endothelial cell 
shape, and proliferation during angiogenesis, was significantly correlated with clinical 
outcome in a series of 188 patients with thin cutaneous disease (<0.76mm).
In patients with choroidal and ciliaiy body melanoma, microvascular loops and altered 
networks were significantly and independent prognostic factors for overall survival. The 
majority of studies on cancers of the female genital tract revealed positive correlations 
between micro vessel count and prognosis. However, owing to the heterogeneity of FIGO 
(Federation of International Gynaecological Oncology) stages included, the short follow- 
up time in some studies, and the scarcity of multivariate analysis, no definitive data can be 
obtained from these studies.
Most published studies on male urogenital-tract tumours reported positive correlations of 
microvessel count with prognosis in prostate cancer, with another six showing statistically 
significant correlations between highly vascularised cancers and the presence of métastasés 
or extraprostatic spread at diagnosis. All three studies of the prognostic value of 
vascularisation in bladder invasive cancer reported positive associations with outcome, just 
as for renal cancer (Table 14.1).
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Not all the studies showed that microvessel counts give independent prognostic 
information. Possible explanations for these discrepancies may be related to the small 
number of cases studied in certain tumour types and to potential methodological pitfalls, 
including criteria for selection of patients, heterogeneous therapy, inadequate follow-up, 
the choice of antibody used to stain endothelium, the vascular variable quantified and the 
area of tumour section assessed, the experience of the observer, and the appropriateness 
of statistical analysis. A consensus among experts has recently been proposed [Vermeulen 
(a) et al 1996],
Angiogenic factors
VEGF expression in oesophageal and gastric cancers has been shown to be an independent 
prognostic indicator in various multivariate analysis on overall survival (Table 14.2). A 
few studies with inconclusive results have been carried out on VEGF in other tumour 
types (Table 14.2).
2 studies examined TP expression in 330 cases of NSCLC both reported negative results 
on overall suiwival in multivariate analysis. Another 3 studies on patients with ovarian, 
head and neck, and endometrial cancers evaluated TP expression using multivariate 
analysis, and only those looking at head and neck cancer reported positive results (Table
14.2). Only 2 studies assessed the prognostic value of thrombospondin.
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Tumour type Number of 
studies
Number of 
patients
Stage Median of 
follow-up 
(years)
VEGF
Breast 12 3688 LII 3.0-5.0
Bladder 2 116 Invasive ND
Prostate 1 221 Invasive 3.5
Brain 1 27 Invasive 4.3
Head and neck 2 142 Invasive 6.1
Endometrium 2 107 FIGO I-IV 2.2-11.0
Ovary 2 126 FIGO I-II (1), I- 
11(1)
3.0-6.0
Melanoma 1 70 Invasive 3.3
Lung 4 493 I-IV 3.2-5.0
Colorectal 2 ? Dukes A-D (1), 
B ( l )
3.0-4.4
Oesophagus 3 257 Invasive 2.6-5.0
Gastric 5 736 Invasive 3.0-5.5
Pancreas 1 40 Invasive 2.1
Testicular 1 80 I-II 4.3
TT
Oesophagus 1 93 Invasive 3.0
Colorectal 3 156 A-C 1.6-4.5
Gastric 1 126 Invasive 3.0
Pancreas 1 40 Invasive 2.1
Breast 8 1649 I-II 3.0-9.8
Bladder 1 58 Invasive 2.0
Ovary 1 56 I-IV 3.0
Brain 1 27 Invasive 2.5
Head and neck 2 152 I-IV 3.0-4.0
Endometrium 1 109 I-IV 3
Cervix 2 146 Ib-II 3.6
FGFs
Breast 4 658 I-II 3.0-3.9
Brain 1 26 Invasive 2.5
Head and neck 1 282 I-IV 2.3
Table 14.2. Studies on the prognostic value o f angiogenic factors.
226
Chapter 15 
The Future
To date, most studies examining therapeutic inhibition of angiogenesis have concentrated 
on advanced disease rather than prevention. Recently, there has been an increase in studies 
using genetically engineered mouse models, which themselves provide a general 
prototype of the pathways, parameters, and molecular mechanisms of multistage 
tumorigenesis. Such models provide opportunities for both the development of anti­
cancer therapies as well as preventive measures that block the progression of pre- 
malignant lesions into tumours.
In general, antiangiogenic agents inhibit proliferation or invasion of blood vessels and may 
take days or weeks to produce an effect. Tumours may shrink proportionally to vessel 
regression, so there may be no reduction in vascular density and an increase in apoptosis 
[Bergers et al 1999]. Bergers et al [1999] studied the effects of four different angiogenesis 
inhibitors on RIPl-Tag2 mice at three distinct stages of pancreatic islet carcinogenesis.
The experimental design included firstly, a prevention trial for the hyperplastic stage; 
secondly, an intervention trial for the early small asymptomatic cancers; and thirdly, a 
regression trial for advanced cancers. The four inhibitors examined were AGM-1470 
(TNP470), BB-94 (batimastat), angiostatin, endostatin, and a combination of the latter 
two inhibitors. In the prevention trial, BB94, endostatin and the combination of 
endostatin/angiostatin reduced angiogenic switching by 50%, 61% and 63% respectively.
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In the intervention trial, angiostatin, AGM-1470, BB-94 and endostatin reduced tumour 
burden by 60%, 82%, 83% and 88% respectively. Interestingly, histological analyses 
including vessel density didn’t show a significant difference between the treatment and 
control groups.
On the other hand, drugs that affect the cytoskeleton of endothelial cells [Tozer et al 
1999], or cause acute cell death, such as intra-arterial TNFa, produce effects within a few 
hours - rapid shutdown of blood flow and necrosis of large areas of tumour. Targeting 
coagulation factors to tumour vessels via upregulated specifically antigens, such as 
endoglin, also causes acute shutdown. Preclinical models indicate that antiangiogenic 
approaches work better on smaller tumours, as do synergies with conventional treatments 
[Teicher et al 1994]. The new agents are therefore likely to be used in combination 
therapy, which provides a rationale for early assessment of this approach.
The development of specific surrogate predictive marker for activity of inhibitors of 
angiogenesis is presently a major challenge of translational oncological research, taking 
into account that more than 40 antiangiogenic compounds are already under clinical 
evaluation [Gasparini et al 1997]. To rationalize the indications, monitoring of activity and 
to select the patients to be treated with inhibitors of angiogenesis, the availability of 
reliable, standardized and useful predictive markers of angiogenesis represents one of the 
major areas of research in the years to come.
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